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High throughput measurement of antibody and complement mediated
immunity in meningococcal disease
PhD Thesis Charlotte Brookes
The accepted correlate of protection for meningococcal disease is serum
bactericidal activity. The importance of bactericidal activity was established by
Goldschneider et a/. (1969) who demonstrated an inverse relationship between
disease incidence and bactericidal titres of ~1:4. The importance of antibody and
complement mediated immune mechanisms is also emphasised by the increased
susceptibility of complement deficient individuals to meningococcal disease.
However, the absence of bactericidal activity does not necessarily indicate
susceptibility and protection has been demonstrated in the absence of bactericidal
activity. This has indicated the importance of other protection mechanisms such as
opsonophagocytosis.
In this study a high throughput antibody-mediated complement deposition assay
has been developed to measure the deposition of both C3b/iC3b and C5b-9 onto
Neisseria meningitidis. Antibody mediated C5b-9 deposition measured in this
assay has been shown to correlate highly with bactericidal activity for several
strains and C3b/iC3b deposition has been shown to correlate with
opsonophagocytosis. This assay has also been shown to be reproducible.
Measurement of antibody mediated C5b-9 and C3b/iC3b deposition will not be a
replacement for opsonic killing assays or the accepted correlate SBA, but could be
used as a tool to evaluate large panels of sera against multiple strains due to the
very low serum volumes required.
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A respiratory burst assay has also been developed to measure both the uptake of
fluorescently-stained bacteria and the induction of a respiratory burst response.
This assay was optimised with respect to the reagents used to measure the
respiratory burst response, bacterial stain and the assay buffers.
Complement is an important reagent used in immunoassays to evaluate antibody
mediated immunity to N. meningitidis. Due to the high levels of nasopharyngeal
carriage in adults it is difficult to obtain a complement source without cross-
reactive bactericidal activity, often resulting in the requirement for a source from a
different individual for each strain. An IgG-depleted complement source has been
developed for use in immunoassays. The method developed has been shown to
be reproducible and effective at removing the IgG whilst retaining functional
complement and will be a valuable tool for assessing immunity to N. meningitidis.
For Mum, Dad and my husband Stuart
5
6
Acknowledgements
I would like to thank my supervisors, Andrew Gorringe, Stephen Taylor and Robert
Heyderman and all the members of the meningococcal vaccines group, without
their help and support this thesis would not have been possible.
Above all, I would like to thank my husband Stuart for his encouragement and
great patience at all times; and my parents, gran and brothers who have given me,
as always, their unequivocal support throughout. In addition to this I would also
like to thank all my family and friends for their continued support.
I would like to acknowledge all the support staff who ensure that work is always
able to continue, especially the Media department, Librarians, Gordon and also the
research secretaries.
I would like to thank the HPA for funding this project.
7
Contents
Chapter 1: Introduction 23
Meningococcal disease 23
1.1.1 Neisseria meningitidis 23
1.1.2 Carriage 24
1.1.3 Pathogenesis 26
1.1.4 Clinical aspects of disease 28
1.2.1 Global epidemiology of meningococcal disease 30
1.2.2 England and Wales 31
1.2.3 United States 32
1.2.4 Sub-Saharan Africa 33
1.2.5 Age-related incidence 33
1.2.6 Seasonal Occurrence 34
1.3 Immune defence against N. meningitidis 35
1.3.1 Complement. 35
1.4 Complement in meningococcal disease 39
1.4.1 Serum bactericidal activity (SBA) 39
1.4.2 Opsonophagocytosis (OPA) 41
1.4.3 Evasion of the complement system 42
1.4.4 Immunological activity of different antibody subclasses and isotypes 43
1.5 Genetic polymorphisms and disease susceptibility .45
1.5.1 Disease susceptibility in complement deficient individuals 45
1.5.2 Disease susceptibility and FcyR polymorphisms .46
1.6 Meningococcal vaccines 47
1.6.1 Polysaccharide vaccines .47
1.6.2 Conjugate vaccines .48
1.6.3 Outer membrane vesicle vaccines (OMV) 49
1.6.4 Factor H binding protein containing vaccines 53
1.7 Current assays for measurement of immunity to meningococcal disease 54
1.7.1 Serum bactericidal assay (SBA) 55
1.7.2 Opsonophagocytosis assay (OPA) 56
1.7.3 Whole Blood Assay 59
1.7.4 T cell assays 60
1.7.5 Meningococcal Antigen Typing System (MATS) assay 61
1.7.6 MeASure assay 61
1.7.7 ELISA 62
1.7.8 Animal models 63
1.8 Project aims 66
1.9 Hypothesis 67
8
Chapter 2: Materials and Methods 71
2.1 Laboratory reagents 71
2.1.1 List of Chemicals 71
2.1.2 Laboratory stock solutions 73
2.2 Neisseria meningitidis 77
2.2.1 Bacterial strains used 77
2.3 Preparation of bacteria for use in immunoassays 78
2.3.1 Growth of unstained N. meningitidis 78
2.3.2 Cryopreservation of N. meningitidis 78
2.3.3 Gram staining 79
2.4 Staining of N. meningitidis 80
2.4.1 BCECF-AM fluorescent staining of live N. meningitidis 80
2.4.2 Bacterial staining using various nucleic acid stains (PI, 7AAD and SYTO
59) 80
2.4.3 Staining of N. meningitidis using 5-(and-6)-carboxy SNARF®-1,
acetoxymethyl ester (SNARF-AM) and dihydrocalcein, AM 81
2.4.4 Staining of N. meningitidis using 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindodicarbocyanine-5,5'-disulfonic acid (DiIC1s(5)-DS) and PKH-26
lipid anchoring stains 81
2.5 Cell culture 82
2.5.1 Preparation of cell culture medium 82
2.5.2 Cell line maintenance 82
2.5.3 Cell counting and viability 82
2.5.4 Differentiation of HL60 cells 84
2.5.5 Leukocyte extraction from fresh blood 84
2.5.6 Cryopreservation and revival of HL60s 85
2.5.6.1 Crypopreservation 85
2.5.6.2 Revival of cryopreserved cells 85
2.6 OMV preparation 86
2.7 Generation of Immune sera 87
2.7.1 Animals 87
2.7.2 Vaccine preparation 87
2.8 Labelling of monoclonal antibody 88
2.8.1 Zenon labelling of monoclonal antibody 88
2.8.2 Alexa fluor 647 monoclonal antibody labeling 89
2.9 Immunoassay methods 90
2.9.1 Surface binding assay (SLA) 90
2.9.2 Complement deposition assay (CDA) original method 90
2.9.3 CDA using a secondary antibody 91
2.9.4 Duplexed complement deposition assay (dCDA), final method 91
9
2.9.5 Total haemolytic complement activity radial immunodiffusion assay .....92
2.9.6 Measurement of the alternative complement cascade using a radial
immunodiffusion assay 92
2.9.7 OPA- original method 93
2.9.8 Duplexed respiratory burst assay (dRBA) final method 93
2.9.10 SBA 95
2.9.11 Antibody (lgG, IgM, or IgA) ELISA 95
2.9.12 IgG subclass ELISA 96
2.9.13 C1q ELISA 97
2.10 Complement 97
2.10.1 Collection of plasma or serum 97
2.10.3 Antibody depletion of human plasma method during development 98
2.11 Flow cytometry 99
2.11.1 Data Analysis using MXP software (Beckman Coulter): Gating 100
2.11.2 Data Analysis using MXP software (Beckman Coulter): Compensation
..................................................................................................................... 101
2.11.3 Data analysis used in the surface labeling assay (SLA) 102
2.11.4 Complement deposition assay (CDA) 104
2.11.5 Opsonophagocytosis Assay (OPA) 105
2.11.6 Respiratory burst assay 107
2.12 Statistics 108
2.12.1 Z test 108
2.12.3 T-test 108
2.12.4 Pearson's correlation coefficient 108
Chapter 3 Development of a Duplexed C3b/iC3b and C5b-9 Antibody-mediated
Complement Deposition Assay 111
3.1 Introduction 111
3.2 Development of the assay 113
3.2.1 Measurement of C5b-9 antibody-mediated MAC deposition on
meningococci 113
3.2.2 Correlation of C5b-9 CDA with the SBA. 117
3.2.3 Conjugation of monoclonal antibody C5b-9 120
3.2.4 Titration of monoclonal antibody C5b-9 124
3.2.5 Correlation of antibody surface binding on killed or live N. meningitidis .
..................................................................................................................... 125
3.2.6 Duplexing the measurement of C3b/iC3b and C5b-9 127
3.3 Optimisation 129
3.3.1 Optimisation of duplexed complement deposition assay - effect of
incubation time and temperature 129
3.3.2 Comparison of antibody-mediated complement deposition at 25°C and
3rC and correlation with SBA. 136
10
3.3.3 Optimisation of incubation time for anti C3b/iC3b and C5b-9 conjugates
in the antibody-mediated complement deposition assay 141
3.4 Precision of duplexed complement deposition assay measuring both
deposition of C3b/iC3b and C5b-9 144
3.5 Correlation of C5b-9 deposition with N. meningtidis H44176 and
M01240185 147
b 148
3.6 Application of duplexed antibody-mediated complement deposition assay
to evaluate a candidate meningococcal vaccine enriched in heat shock
proteins 149
3.7 Application of duplexed antibody-mediated complement deposition assay to
evaluate immunity induced by purified outer membrane protein complexes .... 154
3.8 Application of duplexed antibody-mediated complement deposition assay
to evaluate NHBA-GNA1030 stability 156
3.9 Discussion and further work 157
Chapter 4: Development of a respiratory burst opsonophagocytosis assay 167
4.1 Introduction 167
4.2 Results 171
4.2.1 Investigation of different reagents to detect respiratory burst response in
differentiated HL60 cells 171
4.2.2 Optimisation of DHR123 application during the assay- Comparison of
three different methods 175
4.2.3 Optimisation of DHR 123 concentration and preloading incubation with
the HL60 cells 176
4.2.4 Comparison of HL60 cells and fresh human polymorphonuclear cells 178
4.3 Optimisation of respiratory burst opsonophagocytosis assay (RBA) 180
4.3.1 Use of a priming agent.. 180
4.3.2 Effect of sodium azide in the assay buffer 185
4.3.3 Effect of glucose addition to the assay buffer 187
4.4 Bacterial stains 188
4.4.1 Investigation of alternative bacterial stains 188
4.4.2 The use of Intracellular stains 189
4.4.3 DNA bacterial stains 191
4.4.4 Lipid stains 194
4.5 Duplexing the assay 197
4.5.1 Correlation of duplexed assay responses with single assay responses .
..................................................................................................................... 197
4.5.2 Staining of killed bacteria with 1,1'-dioctadecyl-3,3,3' ,3'-
tetramethylindodicarbocyanine-5,5'-disulfonic acid (DiIC1s(5)-DS) 200
4.5.3 Comparison of total antibody binding to DiIC1s(5)-DS stained or
unstained bacteria 202
4.5.4 Correlation of duplexed assay with single plex assay 204
4.6 Assay precision 207
11
4.6.1 Precision of duplexed respiratory burst assay measuring both opsonic
uptake of N. meningitidis and the respiratory burst response 207
4.6.2 Effect of formaldehyde fixation of RBA 212
Chapter 5: Development of a human complement source for use in immunoassays
............................................................................................................................ 227
5.1 Introduction 227
5.2 Results 229
5.2.1 Optimisation of complement source used- Plasma or Serum? 229
5.2.2 Comparison of total haemolytic complement activity comparison of
complement sources 236
5.3 Optimisation of antibody depletion of plasma - ELISA assessment of
efficiency and reproducibility of antibody depletion 239
5.4 Optimisation of antibody depletion of plasma - Assessment of complement
function using radial immunodiffusion assays 243
5.5 Effect of addition of C1q on complement activity 248
5.6 Large scale antibody depletion from plasma 252
5.7 Discussion 260
6.1 General discussion 269
12
ACDP
BB
BCECF-AM
BSA
CC
CDA
CSF
CoV
dCDA
dRBA
DHR
DHE
DMF
DMSO
DPBS
EDDHA
EDTA
FcyR
FFI
fH
fHbp
FM 1-43
FI
FI- C'
FITC
FRET
GNA
HBSS
HL60
H202
hSBA
IgG
IgA
Abbreviations
Advisory committee for dangerous pathogens
Blocking buffer
2' I7'-bis-(2 -carboxyethyl)-5-( and-6)-carboxyfluorescein I
acetoxymethyl ester
Bovine serum albumin
Clonal complex
Complement deposition assay
Cerebral spinal fluid
Coefficient of variance
Duplexed complement deposition assay
Duplexed respiratory burst assay
Dihydrorodamine
Dihydroethidium
Dimethylformamide
Dimethyl sulfoxide
Dulbecco's phosphate buffered saline
Ethylenediaminedi (O-hydroxyphenylacetic) acid
Ethylenediamine tetraacetic acid
Fc gamma receptor
Flexible film isolator
Factor H
Factor H binding protein
N-(3-triethylammoniumpropyl)-4-(4-
(dibutylamino)styryl)pyridinium dibromide
Fluorescence index
Fluorescence index minus the complement only control
Fluorescein isothiocyanate
Fluorescence resonance energy transfer
Genome neisserial antigen
Hanks buffered saline solution
Promylocytic suspension cell line
Hydrogen peroxide
Serum bactericidal activity using human complement
Immunoglobulin class G
Immunoglobulin class A
13
IFN-y
IL-4
IP
LCCD
LOS
mAb
MAC
MLST
NHBA
NIBSC
OMP
OMV
OP
OPA
OPKA
pAb
PBS
PBT
PCR
PI
PMNs
PMSF
RBA
ROS
RP
rSBA
se
SBA
SLA
SNARF-AM
ST
TLR
TeC
WBA
WT
7-AAD
Interferon gamma
Interleukin 4
Intraperitoneal
Late complement component deficiency
Lipooligosaccharide
Monoclonal antibody
Membrane attack complex
Multilocus sequence type
Neisserial heparin binding antigen
National Institute of Biological Standards and Controls
Outer membrane protein
Outer membrane vesicle
Opsonophagocytosis
Opsonophagocytosis assay
Opsonophagocytosis killing assay
Polyclonal antibody
Phosphate buffer solution
Positive bactericidal threshold
Polymerase chain reaction
Propidium Iodide
Polymorphonuclear leukocytes
Phenylmethylsulphonyl fluoride
Respiratory burst assay
Reactive oxygen species
Relative potency
Serum bactericidal activity using rabbit complement
Subcutaneously
Serum bactericidal activity
Surface labeling assay
SNARF -4F 5-(and-6)-carboxylic acid, acetoxymethyl ester
Sequence type
Toll like receptor
Terminal complement component
Whole blood assay
Wild type
7 aminoactinomycin 0
14
15
List of figures
Figure Title Page
Figure 1.2.1 Global distribution of meningococcal disease by serogroup. 31
Figure 1.2.2 Meningococcal disease incidence in England and Wales 1998- 32
2009.
Figure 1.3.1 Complement cascade 38
Figure 2.5.3 Haemocytometer grid used for cell counting. 83
Figure 2.8.1 Zenon labelling method 88
Figure 2.11.1 Histogram to illustrate gating strategy used for flow cytometry 100
data analysis.
Figure 2.11.2 Method of Compensation when using two fluorochromes within 102
the same assay.
Figure 2.11.3.1 Gating strategy used in data analysis of a surface labeling 103
assay.
Figure 2.11.3.2 Overlay plot of SLA data. 103
Figure 2.11.4.1 Figure 2.11.4.1 Gating strategy used in data analysis of a 104
dCOA.
Figure 2.11.4.2 Overlay plot of COA data. 105
Figure 2.11.5.1 Gating strategy used in data analysis of a dCDA. 106
Figure 2.11.5.2 Overlay plot of OPA data. 107
Figure 3.2.1.1 Antibody mediated C3b/iC3b deposition on N.meningitidis. 115
Figure 3.2.1.2 Antibody mediated C5b-9 deposition on N. meningitidis with 115
Quidel mAb.
Figure 3.2.1.3 Antibody mediated C5b-9 deposition on N. meningitidis with 116
Oako mAb.
Figure 3.2.2.1 Correlation between log10 bactericidal titre and the log10 FI-C' 119
antibody-mediated deposition of C5b-9 measured using the
Oako mAb.
Figure 3.2.2.2 Correlation between log10 bactericidal titre and the log10 FI-C' 119
antibody-mediated deposition of C5b-9 measured using the
Quidel mAb.
Figure 3.2.3.1 Overlay plot of C5b-9 deposition measured by Zenon labelled 122
C5b-9 mAb.
Figure 3.2.3.2 Overlay plot of C5b-9 deposition measured by Alexa fluor 647 122
labelled mAb.
Figure 3.2.3.3 Excitation and emission spectra for FITC and Alexa fluor 647. 123
Figure 3.2.4.1 Optimisation of antibody dilution for detection of C5b-9 124
deposition.
Figure 3.2.5.1 Correlation of total antibody binding between live and killed N. 126
meninqitidis.
Figure 3.2.6.1 Correlation of duplexed antibody-mediated C3b/iC3b and C5b- 128
9 deposition on N. meningitidis M01240149 in comparison with
C3b/iC3b measured separately and C5b-9 measured
separately.
Figure 3.3.1.1 Optimisation of incubation temperature for C3b/iC3b deposition 131
in the first assay incubation.
Figure 3.3.1.2 Optimisation of incubation temperature for C5b-9 deposition in 132
the first assay incubation.
Figure 3.3.1.3 Optimisation of first assay incubation time on C3b/iC3b and 133
C5b-9 deposition.
Figure 3.3.1.4 Overlay plot of antibody-mediated deposition of C3b/iC3b 134
following incubation at 37°C.
Figure 3.3.1.5 Overlay plot of antibody-mediated deposition of C3b/iC3b 134
following incubation at 25°C.
Figure 3.3.1.6 Overlay plot of antibody-mediated deposition of C5b-9 135
16
following incubation at 37°C.
Figure 3.3.1.7 Overlay plot of antibody-mediated deposition of C5b-9 135
following incubation at 25°C.
Figure 3.3.2.1 Correlation between OPA and C3b/iC3b deposition performed 137
at 3rc.
Figure 3.3.2.2 Correlation between OPA and C3b/iC3b deposition performed 138
at 25°C.
Figure 3.3.2.3 Correlation between SBA and C5b-9 deposition performed at 139
37°C.
Figure 3.3.2.4 Correlation between SBA and C5b-9 deposition performed at 140
25°C.
Figure 3.3.3.1 Effect of conjugate incubation time on antibody-mediated C5b- 142
9 (a) and C3b/iC3b (b) deposition on N. meningitidis
M01240149.
Figure 3.3.3.2 Effect of incubation with or without shaking on antibody- 143
mediated C5b-9 (a) or C3b/iC3b (b) deposition on N.
meningitidis M01240149.
Figure 3.4.1 Correlation of SSA with C5b-9 deposition in optimised assay 146
conditions.
Figure 3.5.1 Correlation of antibody-mediated C5b-9 deposition and 148
bactericidal titre with H44/76 and M01240185.
Figure 3.6.1 Antibody-mediated C5b-9 deposition mediated by mouse sera 151
raised against different Hsp vaccine preparations, against a
panel of circulating N. meningitidis strains.
Figure 3.6.2 Comparison of antibody-mediated C5b-9 deposition and 152
bactericidal titre with mouse sera raised against Hsp enriched
vaccines.
Figure 3.6.3 Antibody-mediated C3b/iC3b deposition of sera raised against 153
different Hsp vaccine preparations, against a panel of
circulating N. meningitidis strains.
Figure 3.7.1 Evaluation of immunity induced by purified outer membrane 155
protein complexes by SLA, dCDA and OPA.
Figure 3.8.1 Antibody mediated C3b/iC3b and C5b-9 deposition assay with 156
mouse sera raised against anti- NHBA fusion protein before
and after heat stress against N. meningitidis M01-240101.
Figure 4.2.1.2 Comparison of four respiratory burst detection reagents in 173
HL60 cells.
Figure 4.2.1.3 Investigation into the use of dihydrorodamine 6G (DHR6G) as 173
a respiratory burst detection reagent in HL60 cells.
Figure 4.2.1.4 Investigation into the use of dihydroethidium (DHE) as a 174
respiratory burst detection reagent in HL60 cells.
Figure 4.2.2.1 Comparison of different methods of DHR123 addition into the 175
RBA using N. meningtidis NZ98/254.
Figure 4.2.3.1 Optimisation of DHR123 concentration in RSA. 177
Figure 4.2.3.2 Optimisation of DHR123 preloading incubation time. 177
Figure 4.2.4.1 Correlation of respiratory burst observed with either HL60 cells 179
or PMN cells.
Figure 4.3.1.1 Comparison of cell primers in the RSA. 182
Figure 4.3.1.2 Optimisation of IFN- y concentration for priming the cells in an 182
RBA.
Figure 4.3.1.3 Correlation between unstimulated and stimulated (100 ng/ml) 183
samples in an RSA against N. meningitidis M01240149.
Figure 4.3.1.4 Effect of increasing incubation time with IFN-y (100 ng/ml) 183
stimulation in an RSA against N. meningitidis NZ98/254.
Figure 4.3.1.5 Overlay plots illustrating the effect of increasing incubation time 185
with IFN-y on the response observed in the complement only
control and positive control sera.
17
Figure 4.3.2.1 Investigation into the effect of sodium azide in RSA assay 186
buffer.
Figure 4.3.2.2 Investigation into the effect of sodium azide on HL60 cell 186
viability following 2 hours incubation.
Figure 4.3.3.1 Effect of glucose addition to the RSA assay buffer. 187
Figure 4.4.1.1 Fluorescent spectra for SCECF-AM and DHR 123. 188
Figure 4.4.2.1 Flow cytometric analysis of N. meningitidis H44/76 staining 189
using internal bacterial stain SCECF-AM.
Figure 4.4.2.2 Flow cytometric analysis of N. meningitidis H44/76 staining 190
using internal bacterial stain SNARF-AM.
Figure 4.4.2.3 Opsonophagocytosis assay using SNARF-stained bacteria 190
against N. meningitidis H44176.
Figure 4.4.3.1 N. meningitidis H44/76 staining using Syto 63 nucleic acid 192
stain.
Figure 4.4.3.2 Opsonophagocytosis assay performed using Syto 63 stained 193
N. meningitidis H44/76.
Figure 4.4.4.1 Staining of N. meningitis 44/76 using PKH-26 lipophillic 195
stain.
Figure 4.4.4.2 Use of PKH-26 in an OPA. 196
Figure 4.5.1.1 Correlation of opsonic response for PKH-26 stained bacteria in 198
a duplexed assay vs the opsonic response of PKH-26 stained
bacteria only.
Figure 4.5.1.2 Correlation of opsonic response for PKH-26 stained bacteria in 198
a vs the opsonic re~onse of SCECF-AM stained bacteria only.
Figure 4.5.1.3 Correlation of respiratory burst response measured with 199
DHR123 in a duplexed assay vs the respiratory burst response
measured with DHR123 only.
Figure 4.5.2.1 Overlay plot of increasing concentrations DiIC1s(5)-DSstaining 201
of N. meningitidis H44/76.
Figure 4.5.3.1 Correlation of DiIC1s(5)-DS stained bacteria with unstained 203
bacteria in a total antibody surface labelling assay against
M01240149.
Figure 4.5.3.2 Correlation of SCECF stained bacteria with unstained bacteria 203
in a total antibody surface labelling assay against M01240149.
Figure 4.5.4.1 Correlation of opsonic response DilC1s(5)-DSlabelled bacteria 205
in a duplexed RSA with the opsonic response for internalised
DiIC1s(5)-DSlabelled bacteria only.
Figure 4.5.4.2 Correlation of opsonic response for DiIC,s(5)-DS labelled 205
bacteria in a duplexed assay with the opsonic response of
SCECF-AM labelled bacteria only.
Figure 4.5.4.3 Correlation of respiratory burst response measured with 206
DHR123 in a duplexed assay compared with the respiratory
burst response measured with DHR123 only.
Figure 4.6.1.1 Percentage change between duplicate assays run as part of 210
the precision testing.
Figure 4.6.2.1 OPA response measured over 120 min following completion of 213
assay, with or without formaldehyde fixation.
Figure 4.6.2.2 Respiratory burst response measured over 120 min following 213
completion of the assay with or without formaldehyde fixation.
Figure 5.2.1.1 Comparison of different anti-coagulated complement sources 233
in the dCDA..
Figure 5.2.1.2 Comparison of different anti-coagulated complement sources 234
in the OPA.
Figure 5.2.1.3 Comparison of baby rabbit and human complement in an OPA. 235
Figure 5.2.2.1 Total haemolytic complement activity in different complement 237
sources.
Figure 5.4.1 Comparison of total haemolytic function following depletion 245
18
methods using either protein A, protein L or protein G
Sepharose.
Figure 5.4.2 Comparison of alternative complement cascade haemolytic 245
function following depletion methods using either protein A,
protein L or protein G Sepharose.
Figure 5.4.3 Overlay plot illustrating the difference in C3b/iC3b deposition 246
achieved with either protein A, protein L, protein G depleted
complement or native complement.
Figure 5.4.4 Overlay plot illustrating the difference in C5b-9 deposition 247
achieved with either protein A, protein L, protein G depleted
complement or native complement.
Figure 5.5.1 C1q ELISA comparing C1q concentration before and after IgG 249
depletion of complement.
Figure 5.5.2 Addition of increasing concentrations of C1q to dCDA. 250
Figure 5.5.3 Total haemolytic complement activity of complement anti- 251
coagulated with lepirudin before and after IgG depletion, or
after IgG depletion with addition of 40 !-Ig/ml purified C1q
_(_Quidel).
Figure 5.6.1 Chromatogram illustrating IgG depletion of lepirudin-treated 254
plasma using protein G.
Figure 5.6.2 Comparison of total haemolytic activity of two batches of 256
plasma following depletion with protein Gadding 40 !-Ig/mlof
C1q.
Figure 5.6.3 Comparison of alternative complement pathway of two batches 256
of plasma following depletion with protein Gadding 40 !-Ig/mlof
C1q.
Figure 5.6.4 Overlay plot illustrating consistency between depleted plasma 257
batches in a dCDA.
Figure 5.6.5 Antibody-mediated C3b/iC3b deposition on N. meningitidis 258
NZ98/254 comparing antibody-depleted plasma from batch 1
and batch 2.
Figure 5.6.6 Antibody-mediated C5b-9 deposition on N. meningitidis 258
NZ98/254 comparing antibody-depleted plasma from batch 1
and batch 2.
Figure 5.6.7 Opsonophagocytosis assay using N. meningitidis M01240013 259
comparing antibody-depleted plasma from batch 1 and batch
2.
19
List of tables
Table Title Page
Table 2.1.1.1 List of chemicals 71
Table2.1.1.2 List of Suppliers Address 72
Table 2.2.1 N. meningitidis strains used in immunoassays. 77
Table 3.3.2.1 Summary of the CoY for the antibody-mediated C3b/iC3b 137
deposition at 25°C and 3rC.
Table 3.3.2.2 Summary of the CoY for the antibody-mediated C5b-9 139
deposition for 25°C and 3rc.
Table 3.4.1 Assay precision for antibody mediated C3b/iC3b deposition. 145
Table 3.4.2 Assay precision for antibody mediated C5b-9 deposition. 146
Table 4.2.1.1 Summary of the respiratory burst detection reagents. 172
Table 4.6.1.1 Summary of duplexed RSA %CoV for 21 low, medium and high 209
responding human sera.
Table 4.6.1.2 Summary of opsonic response only, %CoV for 21 low, medium 211
and high responding human sera.
Table 4.6.1.3 Summary of respiratory burst response only, %CoV for 21 low, 211
medium and high responding human sera.
Table 5.3.1 Antibody ELiSAs comparing antibody depletion methods. 242
Table 5.6.1 Comparison of antibody depletion between batches of protein 255
depleted plasma.
20
Chapter 1
21
22
Chapter 1: Introduction
Meningococcal disease
1.1.1Neisseria meningitidis
Neisseria meningitidis is a Gram negative encapsulated diplococcus of between
0.6-1.9 urn in diameter. Of the Neisseria genus, only N. meningitidis and N.
gonorrhoeae are able to cause disease, and other Neisseria strains including N.
lactamica, N. flavascens, N. cinerea and N. subflava are regarded as
commensals. The human nasopharynx is the only known reservoir for N.
meningitidis, with colonisation rarely resulting in disease. Thirteen serogroups of
N. meningitidis have been described based on differences in capsular
polysaccharide, and of these only sergroups A, S, C, W135, Y and X are
responsible for the majority of invasive disease. Non-serogroupable strains are
often isolated from the nasopharynx. It is thought that a lack of capsule may be
preferable for carriage (Claus et al. 2002). Classification of N. meningitidis is
based on capsule type (serogroup) and then subcapsular antigens PorS
(serotype) and PorA (serosubtype) and lipooligosaccharide (immunotype).
Strain variation has been measured using panels of monoclonal antibodies
(Frasch et al. 1985; Abdillahi and Poolman 1988), as well as sequencing of the
genes encoding these antigens (Maiden et al. 1991). Multilocus enzyme
electrophoresis (MLEE) has been used to characterise the electrophoretic mobility
of cellular enzymes and allows meningococci to be characterised by an
electromorph type (ET) (Selander et al. 1986). ET-5 and ET-37 were associated
with hyperinvasive N. meningitidis, with ET-5 causing a large proportion of
serogroup S meningococcal disease in the 1980s (Caugant et al. 1986). MLEE
has disadvantages, including difficulty of comparing results between laboratories.
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MLEE has therefore been replaced by multilocus sequence typing (MLST), a
measurement of variation in DNA sequence in eight housekeeping genes, araE,
pgm, adk, abcZ, pdhC, porA, fumC and gdh (Maiden et al. 1998; Holmes et al.
1999; Birtles et al. 2005). This method has been shown to be reproducible, cost
effective and high throughput. Based on MLST, meningococci are allocated a
sequence type (ST) and a group of STs which have 4 or more of the eight loci in
common are known as a clonal complex (cc). The most prevalent cc types in the
UK are 41/44, 213, 269 and 32 and across Europe these same cc represent the
majority disease causing isolates (Lucidarme et al. 2009). In fact the majority of
disease-causing strains globally are caused by a few hypervirulent lineages,
whereas nasopharyngeal carriage strains are much more diverse in ST type. This
observation indicates these strains may be genetically predisposed to cause
disease.
1.1.2 Carriage
Understanding meningococcal carriage is important in understanding the
epidemiology and transmission of disease. Carriage of meningococci is generally
described at 10% in a population, but the carriage rate varies highly between age
groups. Duration of carriage has been shown to be up to 6 months, and could
extend past this period, although studies have not yet assessed this (Glitza et al.
2008). Nasopharyngeal colonisation of N. meningitidis induces bactericidal
antibodies effective against homologous and heterologous strains, and thus
carriage is important in the development of natural immunity, but also maintenance
of antibody levels (Goldschneider et al. 1969; Reller et al. 1973). The relationship
between carriage and disease incidence is unclear, where some studies have
demonstrated an increase in disease with an increase in carriage others have
found the opposite (Olsen et al. 1991; Fernandez et al. 1999). Some of the
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differences observed in these studies could be attributable to differences in the
sampling site used, swab handling and also the selection of the population to be
swabbed (i.e. were they randomly selected?). A recent meta-analysis of 89
carriage studies from European countries with predominantly serogroup Band C
disease, predicted the carriage rate in infants to be 4.5%, 7.7% in 10year olds,
peaking at 23.7% in 19 year olds, and decreasing in the older adult age groups to
7.8 % in those over 50 years old (Christensen et al. 2010).
Carriage of N. lactamica has been shown to be high in young infants whilst
meningococcal carriage is relatively low, and as levels of N. lactamica carriage
decline increasing meningococcal carriage is observed (Gold et al. 1978;
Cartwright et al. 1987). Nasopharyngeal carriage with N. lactamica has been
shown to restrict carriage of N. meningitidis and induce opsonophagocytic
antibodies cross reactive with meningococci (Evans et al. 2011). This study did not
observe the induction of cross reactive bactericidal antibodies, while a previous
study demonstrated children carrying N. lactamica have higher titres of bactericidal
antibodies which are cross reactive with meningococci, in comparison with non
carriers (Gold et al. 1978).
Carriage of meningococci can be elevated in certain populations, including military
recruits, and university students, resulting from living in confined areas. In addition,
smoking has also been shown to increase the carriage rate (Cartwright 1995;
Bakir et al. 2001). An increase in meningococcal carriage has also been described
in children who were also colonised with Streptococcus pneumoniae, and
Haemophilus influenzae (Bakir et al. 2001).
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1.1.3 Pathogenesis
The human nasopharynx is the only known reservoir for N. meningitidis, and
colonisation of the nasopharynx occurs via respiratory droplets and secretions.
Colonisation is most frequently asymptomatic, and only rarely progresses to
invasion of the mucosal surfaces and bloodstream resulting in sepsis and/or
meningitis.
Following colonisation, N. meningitidis adheres to the mucosal surface initially
through the expression of type IV pili which bind with human CD46 (Kallstrom et
a/. 1998). Attachment is followed by down-regulation of capsule (Deghmane et a/.
2002) allowing for closer adhesion of the bacteria via interactions such as Ope and
Opa with CEACAMs/CD66. Following adhesion, meningococci are able to invade
epithelial and endothelial cells. It has been observed that some
lipooligosaccharide (LOS) mutants are unable to invade efficiently, and it has been
suggested that the toxicity of LOS may be important in invasion (Dunn et a/. 1995).
The exact mechanism of how meningococci cross the epithelial and endothelial
layer is unknown, but it has been suggested that meningococci cross these cell
layers by transcytosis, or an alternative hypothesis is that they are transported
within a vacuole inside the cells. It is possible that meningococci invade the
epithelial cells in order to evade an immune response. Evasion of host immunity is
critical, with capsule and LOS important in resistance to complement mediated
immunity (Geoffroy et al. 2003). Following colonisation IgA1 protease is produced
by the bacteria which neutralises IgA1 by cleavage on the hinge region. N.
meningitidis also expresses lactoferrin binding protein (Lbp) enabling the
acquisition of iron from human lactoferrin in the mucosa (Gray-Owen et al. 1997).
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Following penetration of the epithelial and endothelial layers some bacteria
occasionally cross into the circulation, where bacteria can multiply rapidly causing
bacteriaemia. During bacteriaemia meningococci shed outer membrane vesicles
(OMVs) in the circulation, which has the effect of amplifying inflammation and
immune activity and overwhelming the host immune system. Meningococci
express LOS and capsular polysaccharide which are important in resistance to
complement-mediated killing and are key virulence factors, and without which the
bacteria are unable to survive within the circulation (Geoffroy et al. 2003). In
addition, meningococci express transferrin binding proteins (TbpA and Tbp8)
which enable the bacteria to acquire iron from the human iron transport protein
transferrin. N. meningtidis has evolved mechanisms to vary surface proteins in
order to evade host immunity. Phase variation, a process of on/off gene
expression is utilised and occurs by slipped strand mispairing; a process where a
repetitive DNA sequence upstream of a gene or within an open reading frame,
gains or losses a nucleotide, which leads to a change in the protein expression
levels. Alternatively, DNA can be taken up from the environment via horizontal
transfer, which can result in, for example, capsule switching. Antigenic variation
can occur via intragenomic recombination and results in variation of the expressed
surface proteins (Hill et al. 2010).
After invasion of the circulation, bacteria are able to cross the blood brain barrier
(BBB). The BBB consists of the choroid plexus, consisting of cuboidal epithelial
cells and capillary endothelia both with tight junctions. It is thought that adhesion
occurs once again via pili, although the exact method used to cross the BBB is
unknown. There are several possible theories: attached meningococci are
transcytosed and are able to enter the meninges, signalling to endothelial cells
results in disruption of the tight junctions and bacteria are then able to cross the
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BBB (Carbonnelle et al. 2009) or through direct damage of the endothelia by LOS
(Dunn et al. 1995). Once meningococci have crossed the BBB, this leads to the
inflammation of the meninges (meningitis).
1.1.4 Clinical aspects of disease
Clinical presentation of disease ranges from asymptomatic carriage of
meningococci to fulminant septicaemia and meningitis. Fulminant meningococcal
septicaemia includes patients with sepsis, or a combination of septicaemia and
meningitis. Some patients present with meningitis only and there are also milder
forms of systemic infection which do not develop into persistent septicaemia or
meningitis. Case fatality rates vary between different clinical presentations of
disease. Individuals with fulminant septicaemia have a case fatality rate of
between 15-30% which can reach 50% in developing countries, patients with
septicaemia and meningitis have a case fatality rate of 10-25%, and patients
presenting with meningitis have a fatality rate of <5%. The overall case fatality rate
is 5-10%. In addition, there are also a number of more unusual presentations
including for example pneumonia, conjunctivitis, myocarditis and septic arthritis
(Cartwright and Ala'Aldeen 1997).
Meningococcal disease can develop rapidly and normally develops over 2-48
hours. Patients present with general flu-like symptoms initially, which makes early
diagnosis very difficult to distinguish from other milder viral infections. Patients
demonstrate fever, loss of appetite, headache and seizures (meningitis), and upto
50% of patients also have neck pain. Several types of haemorrhagic rash are
associated with fulminant septicaemia, these include macropapular rashes which
fade when pressure is applied, and petechial rash which will not fade when
pressure is applied. The formation of haemorrhagic rashes results from ruptured
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blood vessels, which occur following the inflammatory response and the release of
high concentrations of LOS and OMVs in the circulation.
Diagnosis of meningococcal disease is difficult due to the common symptoms
during the initial stages of disease. Benzylpenicillin is given to patients prior to
referral by general practitioners in suspected cases of meningococcal disease.
Children presenting with petechial rash and symptoms of meningococcal disease
are immediately given intravenous ceftriaxone on arrival at hospital (NICE 2010).
Chemoprophylactic treatment is used in most European countries to remove
nasopharyngeal carriage of N. meningitidis. Treatment with rifampicin or
ciprofloxacin is recommended prior to hospital discharge for patients recovering
from meningococcal disease in the UK. The carriage rate is only 3% in patients
who have received benzylpenicillin to treat meningococcal disease prior to
chemoprophylactic treatment, but this method has been evaluated and shown to
reduce disease in close household contact by 89% (Purcell et al. 2004). The
protection afforded by chemoprophylactic treatment is short lived and disease in
contacts has been reported following chemoprophylactic treatment, so in addition
to this it is also thought that vaccination of patient family and friends, may further
reduce disease in patient contacts (Hoek et al. 2008).
10-20% of patients who recover from meningococcal disease suffer long term
sequelae. This can range from headaches, skin scarring to limb amputation
deafness and in some cases learning disabilities.
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1.2Epidemiology
1.2.1 Global epidemiology of meningococcal disease
Meningococcal disease occurs as sporadic case outbreaks and epidemics, with
epidemiology varying with geographic location (figure 1.2.1.). Surveillance of
meningococcal disease is important to investigate epidemiology. Various
surveillance mechanisms are used. Laboratory culture confirmation from either
cerebrospinal fluid (CSF) or blood can be used to identify the bacterial strain from
a patient with invasive meningococcal disease. Culture confirmation is not always
successful, and therefore other mechanisms have been developed. Polymerase
chain reaction (PCR) is also used for diagnosis of meningococcal disease,
however the disadvantage of this method is that an isolate is not then available for
further characterisation. However genotypic characterisation can be carried out ,
and serogroup specific PCR can be used to determine the serogroup. Multilocus
sequence typing (MLST) is also utilised to characterise disease-causing
meningococcal isolates.
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Figure 1.2.1 Global distribution of meningococcal disease by serogroup
(Harrison et al. 2009).
1.2.2 England and Wales
In England and Wales in 2010 a total of 896 cases of meningococcal disease were
reported, 88% of which were serogroup B (Gray et al. 2011). 8T269 accounted for
31% of disease, and 8T41/44, 8T213 and 8T32 also represented a large
proportion of disease. 8erogroup C disease in 1999 represented 35% of invasive
meningococcal disease. This has reduced to 2% of disease in 2010 as a result of
the successful introduction of the serogroup C conjugate vaccine in 1999 and the
herd protection this has induced (www.HPA.org.uk 2011)(figure 1.2.2). 8erogroup
Y represents a small proportion of invasive meningococcal disease, but an
increase in disease has recently been reported. 7% of disease was reported as
serogroup Y in 2010, which is more than double that reported in 2004. This small
but detectable trend has also been reported in many other European countries
(Jacobsson et al. 2011; Parent du Chatelet and Taha 2011; Toropainen et al.
2011).
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Figure 1.2.2 Meningococcal disease incidence in England and Wales 1998-
2009 (www.HPA.org.uk 2011).
Serogroups B, C and Yare responsible for the majority of meningococcal disease
in the United States, with disease levels varying between 0.5 and 1.7 per 100000
population for the last 50 years. Serogroup Y represents 33% of meningococcal
disease in the United States, and has increased gradually from very low levels
reported in 1991. The tetravalent conjugate polysaccharide A,C,Y,W135 vaccine is
recommended for adolescents, however the uptake of vaccine remains poor
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1.2.4 Sub-Saharan Africa
A region stretching from Senegal to Ethiopia is termed the meningitis belt of sub-
Saharan Africa, and has the largest burden of meningococcal disease in the world.
Serogroup A meningococci has been the predominant epidemic-causing
serogroup, however infections with W135, Y, C and X are also present. Serogroup
X disease is unusual globally but has caused epidemics in Niger and North Ghana
(Leimkugel et al. 2007) and serogroup W135 disease has caused disease in Niger
and Burkina Faso (Fonkoua 2002; Taha et al. 2002). Serogroup A meningococcal
disease can exceed 1000 cases per 100000 population. This is a much higher rate
of disease than experienced elsewhere. Meningococcal epidemics tend to occur in
cycles and in sub-Saharan Africa these coincide with the dry season (Harrison et
al. 2009). It has been shown however that carriage rates, which range from 3 -
30%, are not variable by season (Trotter et al. 2007).
1.2.5 Age-related incidence
Invasive meningococcal disease is most prevalent in infants. Children under 6
months of age show some immunity as a result of maternal antibodies
(Goldschneider et al. 1969), but as maternal antibodies wane incidence of disease
increases peaking at 6 months of age at 75 incidences per 100,000 per year.
Disease levels continue to fall until 8 years of age where low levels of disease are
observed «3 incidence per 100000). This low level is maintained until a further
smaller peak of disease is observed in young adults 16-24 years old
(www.HPA.org.uk 2011). This pattern of disease is altered during epidemics of
disease, where increased numbers of older children present with invasive disease
who have low levels of antibodies against the epidemic strain (Peltola et al. 1982).
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1.2.6 Seasonal Occurrence
Meningococcal disease occurs in seasonal epidemics, in temperate climates the
infection numbers are greatest in winter months. This is thought to result from
close contact during the colder weather and also an increase in viral disease,
which can cause nasopharyngeal mucosal damage, thus increasing the risk of
contracting meningococcal disease (Cartwright 1995). In sub-Saharan Africa,
epidemics mainly occur during the dry season between December and June. Dust
storms, low humidity and upper respiratory tract infections may play a role in
compromising the mucosal barrier (Moore 1992). In addition to this it is thought
that overcrowded housing and pilgrimages also playa role in increasing the risk of
nasopharyngeal carriage.
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1.3 Immune defence against N. meningitidis
1.3.1 Complement
The complement system has three pathways: the classical pathway, the
alternative pathway, and the lectin pathway (figure 1.3.1), and is composed of at
least 35 proteins which are both fluid phase and membrane bound. Complement
plays an important role in protective immunity to meningococcal disease. It is
important in the inflammatory response, opsonisation, chemotaxis, serum
bactericidal response and also plays an important role in the development of an
antibody response and can augment the immunological memory (Walport 2001;
Dunkelberger and Song 2010).
The classical pathway is initiated by the binding of C1q to the Fc portion of clusters
of antibody (lgG or IgM) complexed with antigen. This activates C1r and C1s; the
two other components of the C1 complex. This then enables C4 and C2 to be
cleaved forming C4bC2a which is the classical pathway C3 convertase. This then
cleaves C3, producing C3b and C3a. C3a initiates local inflammatory responses
and C3b is able to coat the surface of the pathogen.
The lectin pathway has a starting point very similar in structure to the classical
pathway. Mannose binding lectin (MBL) or ficolins bind mannose residues, other
sugars and sialic acid, which activates MASP1 and MASP2; which are
homologous to C1r and C1s. This then leads to the cleavage of C4 and C2
forming a C3 convertase as in the classical pathway.
The alternative pathway relies on low levels of spontaneous hydrolysis of C3,
which directly binds to the surface of the bacteria. Factor B binds to C3b in the
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presence of Factor 0 leading to the production of C3b and Bb. C3bBb is then
stabilised by binding properdin, and then cleaves C3 to C3a and C3b by acting as
the alternative pathway C3 convertase. There are also other factors involved in the
alternative pathway which act as regulatory proteins, for example factor Hand
factor I. Factor H leads to the inactivation of the C3b component to iC3b, as a co-
factor to factor I (Schneider et al. 2007). In addition to properdin's role in stabilising
C3bBb, it has also been suggested that properdin can bind directly with the
bacterial surface and provide a platform where the alternative pathway
convertases can form and function (Spitzer et al. 2007).
The conversion of C3 to C3a and C3b is where the three complement pathways
converge. As part of the classical or lectin pathway, C3b binds C4b2a (C4b2a3b)
or as part of the alternative pathway C3b binds C3bBb (C3bBb3b), making a C5
convertase which cleaves C5 to C5a and C5b. This leads to the assembly of the
membrane attack complex (MAC) with complement components C5b,C6,C7,C8
and C9. This forms a multiprotein pore-like structure which inserts into the lipid
bilayers of the bacteria membrane resulting in membrane disruption and cell lysis.
C3b can also act by binding directly to the surface of bacteria acting as an opsonin
able to bind with complement receptors (CRs) present on the surface of
phagocytes inducing phagocytosis, whereas the cleaved C3a acts as an
anaphylatoxin by acting as a potent chemoattractant. Factor H acts by inactivating
C3b into iC3b which can also opsonise bacteria. C3b and iC3b are able to bind
with CR1, CR3, and CR4, which are present on the surface of phagocytes, and
mediate uptake via phagocytosis (Ehlenberger and Nussenzweig 1977).
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The complement system contains regulation factors to prevent inappropriate
activation and subsequent host cell damage. Soluble receptors (C4BP, factor H
and C1-inhibitor) are circulated in the bloodstream and at mucosal surfaces to
prevent inappropriate complement activation by downregulating the production of
C3 convertases. S protein (vitronectin) is an important fluid phase regulator of the
MAC, preventing insertion into the membrane. SC5b-9 is usually associated with
the fluid phase, but it is known that <O.4moles S protein per 1 mole of C5b-9 can
be found in membrane bound C5b-9, although membrane bound SC5b-9 may not
be lytic (Bhakdi et al. 1988). Host cell membranes also contain negative regulators
to prevent damage, these include decay-accelerating factor, CR1, and CD59.
CD59 inhibits the formation of C5b-9 on host cell surfaces.
Complement components also play an important role in the adaptive immune
response. B cells are able to bind C3 and its degraded components, which results
in a lowering of the activation threshold for bound antigen with B cells.
Complement also plays a role in the selection and maintenance of B1 cells, and
may also playa role in the differentiation of B cells into memory B cells and affinity
maturation. The observation that CD4 and CD8 T cell priming is reduced in C3
deficient mouse model also indicates a role for complement in T cell immunity,
although the mechanisms for this are still unknown (Kemper et al. 2008;
Dunkelberger and Song 2010).
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Figure 1.3.1 Complement cascade
Taken from Mollnes,T.E.et al. illustrating the classical, alternative and lectin
complement pathways (Mollnes et al. 2002).
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1.4 Complement in meningococcal disease
1.4.1 Serum bactericidal activity (SBA)
Goldschneider first described an inverse relationship between hSBA (SBA
performed with human complement) titres of ~1:4 and serogroup A, Band C
disease by age. Whilst maternal antibodies persist disease incidence is low, but
when these wane disease incidence increases, and then declines during childhood
peaking again in late teenagers. In addition 14744 military recruits were sampled
at the beginning of their training, and during the investigation period 54 cases of
serogroup C meningococcal disease were recorded. Only 3 out of 54 recruits who
developed disease had a detectable bactericidal titre, this was in contrast to 444 of
540 of healthy controls. This established an hSBA titre of ~1:4 as an appropriate
correlate of protection (Goldschneider et aJ. 1969).
This study led to SBA becoming a 'gold standard' for measuring vaccine-induced
immunity and is now a requirement for licensure of meningococcal vaccines. This
study (Goldschneider et aJ. 1969) was performed using human complement in the
bactericidal assay. However, baby rabbit complement has frequently been used to
evaluate the responses to meningococcal polysaccharide vaccines as it is easily
standardisable. rSBA (SBA performed with baby rabbit complement) has been
used to evaluate meningococcal serogroup C polysaccharide conjugate vaccines
in immunogenicity and safety studies and vaccines were introduced in the UK in
1999, without a phase III efficacy trial (Miller et aJ. 2001).
There is strong evidence for a role of SBA in protective immunity to meningococci,
but there is evidence that other mechanisms are also involved. Outer membrane
vesicle (OMV) vaccines have shown a correlation with vaccine efficacy and % of
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subjects with SBA titres 2:4, but the % of subjects with SBA titres 2:1:4 has also
been observed to underestimate vaccine efficacy. This trend was observed
following OMV vaccination in Chile, Brazil, Cuba and Norway (Granoff 2009).
Goldschneider first described an inverse relationship between hSBA titres of ~ 4
and serogroup A, Band C disease by age. A more recent serogroup C
seroprevalence study, performed with age-stratified sera collected from 1689 UK
subjects prior to the introduction of the serogroup C conjugate vaccine, showed
much lower levels of protection than observed in the Goldschneider study (Trotter
et al. 2003). A further seroprevalence study, performed with 2415 age stratified
sera, demonstrated a different relationship between serogroup B disease and
bactericidal titre. Data showed that in the 2-12 year old age range there was a low
disease rate whilst only low bactericidal antibody titres could be detected (Trotter
et al. 2007). This may indicate the involvement of additional mechanisms in
protection.
Whole blood from individuals with a SBA titre <4 has been shown to be able to kill
meningococci (Ison et al. 1999; Welsch and Granoff 2007), and passive protection
studies carried out in the infant rat model, have shown protection in the absence of
bactericidal activity (Toropainen et al. 2001; Welsch et al. 2003; Welsch and
Granoff 2004; Welsch and Granoff 2007), although caution must be used in
interpreting data from the infant rat model due to the specificity of fHbp for human
fH (Granoff 2009). Susceptibility of recurrent meningococcal infection is described
for individuals with late complement component deficiencies (LCCD), who are
unable to form MAC and induce SBA. However, it has been shown in this group of
individuals that vaccination with a tetravalent meningococcal polysaccharide
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vaccine is able to reduce the risk of developing meningococcal disease (Platonov
et a/. 2003).
1.4.2 Opsonophagocytosis (OPA)
As already described, there is evidence to suggest that there are additional
immune mechanisms that provide protection against meningococcal disease.
Opsonophagocytosis has been suggested as an alternate mechanism important in
natural and vaccine-induced immunity and has been shown to be effective at
killing meningococci (Ross et al. 1987; Schlesinger et al. 1994). Evidence supports
a role for opsonophagocytosis (reviewed in (Granoff 2009)) and it has been shown
that vaccination of LCCD patients with a tetravalent polysaccharide vaccine results
in a reduction in recurrent infections; most probably due to the induction of opsonic
antibodies (Andreoni et al. 1993; Platonov et al. 2003). In addition to this an
increase in opsonic activity is also observed in convalescent patients (Halstensen
et al. 1989) and also in response to OMV vaccination (Gorringe et al. 2009).
Whole blood from subjects with no detectable bactericidal activity is able to kill
meningococci (Welsch and Granoff 2007) and passive protection has been
achieved in the infant rat model in the absence of SBA (Welsch and Granoff 2004;
Toropainen et al. 2006).
An opsonic killing assay using polymorphonuclear leukocytes (PMNs) with a
complement source which was either C6-depleted, and therefore unable to
perform membrane attack complex (MAC) deposition, or native complement, has
been used to investigate anti-PorA mAb and its ability to kill meningococci. No
bactericidal activity was detected with the CB-depleted complement but with the
addition of PMNs, efficient killing was observed. In addition, adult serum with no
detectable bactericidal activity was able to induce killing in the presence of PMNs
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(Plested et al. 2009), indicating an important role for opsonophagocytosis in
immunity to meningococcal disease.
1.4.3 Evasion of the complement system
N. meningiditis has developed mechanisms for complement resistance. The most
important of which is the presence of polysaccharide capsule and sialyated LOS.
This was confirmed from a study aiming to isolate meningococcal genes involved
in complement resistance. 4500 mutants were studied and their susceptibility to
complement killing assessed and it was estimated that mutants were achieved in
between 80-90% of N. meningitidis non-essential genes. Of these 4500 mutants
37 mutants were susceptible to complement killing. The investigation identified
that all 37 mutants had disruption in 18 genes which had lost function for either
capsule biosynthesis or expression of truncated LOS (Geoffroy et al. 2003).
In addition to capsule and sialyated LOS, meningococci also express surface
exposed proteins factor H binding protein (fHbp) and ParA, which are able to bind
with factor Hand C4bp respectively (Schneider et al. 2007). In addition, NspA has
also recently been shown to bind fH (Lewis et al. 2010). The functional relevance
of C4bp binding has not yet been established. Binding of factor H has been
suggested as a mechanism of complement resistance, as bound fH is able to
interact with bound C3b, inactivating this to iC3b and thus limiting complement
activation. It is also thought that binding of fH by meningococci during
bacteriaemia may deplete the fH in the bloodstream, which may cause the host
tissue to become more susceptible to complement attack, and thus contribute to
the development of the haemorrhagic rash, which is common in fulminant
meningococcal disease (Serruto et al. 2010).
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1.4.4 Immunological activity of different antibody subclasses and isotypes
Antibody-driven immunity is very important for protection against meningococcal
disease (Flexner 1913). This is confirmed by the observation that
agammaglobulinaemic patients suffer recurrent life-threatening meningococcal
infections (Hobbs et al. 1967). Carriage of N. meningitidis strains or commensal
Neisseria species leads to the generation of natural immunity to meningococcal
infection, which consists of IgG, IgM and IgA (Goldschneider et al. 1969).
IgA is present in both the mucosa and serum, as either IgA1 or IgA2. These two
subclasses are found as either monomeric, dimeric, polymeric or a secretory form,
which consists as dimeric IgA with a J chain. IgA has been shown to be capable of
inducing phagocytosis albeit to a lesser degree than IgG, and to be unable to
induce bactericidal activity (Vidarsson et al. 2001). In addition an FcaR has been
identified and is expressed on macrophages and PMNs (Boross 2008). IgA is
unable to bind C1q and does not therefore activate the classical complement
cascade, but it has been shown that polymeric IgA is capable of activating the
lectin complement pathway by binding MBL (Roos et al. 2001). IgM is efficient at
complement activation due to its pentameric structure, but does not contribute to
phagocytosis, as the FCIJR is not located on the surface of PMNs and
macrophages (Boross 2008).
IgG exists as four main subclasses: IgG1, IgG2, IgG3 and IgG4. Serum
concentrations are IgG1 >lgG2 > IgG3 = IgG4, with IgG1 making up approximately
50% of IgG. Following vaccination with meningococcal capsular polysaccharide
conjugated to CRM197, a strong IgG2 response has been observed with lower
levels of IgG1 (Huo et al. 2005), whereas vaccination with OMVs induced a
predominantly IgG1 and IgG3 response with low levels of IgG2 and IgG4. IgG
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antibodies are able to activate the complement cascade, resulting in SBA and
binding with FcyRs to induce OPA (Naess et al. 1999). A comparison of chimeric
human IgG1,2,3,4 and IgA1, 2 with identical V genes against PorA showed that
the ability of subclasses to bind complement was IgG1=lgG3>lgG2>lgG4 and
IgG3>lgG1 >lgG2»lgG4 for phagocytic activity (Vidarsson et al. 2001).
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1.5 Genetic polymorph isms and disease susceptibility
One third of the risk of contracting meningococcal disease is thought to be due to
the host's genetic factors (Haralambous et a/. 2003).
1.5.1 Disease susceptibility in complement deficient individuals
The importance of complement is emphasised by the susceptibility of complement
deficient individuals to disease, resulting in approximately 10-20% of individuals
who develop meningococcal disease (Ellison et al. 1983) and 31% of individuals
who suffer recurrent meningococcal disease. Individuals with LCCD demonstrate
recurrent invasive disease, which is usually milder than disease in complement
sufficient patients possibly due to the reduction in release of bacterial products
following MAC-induced lysis. Disease caused by serogroups W135 and Y and
other rarer serogroups are more frequently seen in complement deficient
individuals although serogroups Band C are still the most commonly isolated
strains. Alternative pathway defects are also associated with recurrent
meningococcal infection. Individuals with the alternative pathway deficiency
demonstrate a higher mortality rate in comparison with complement sufficient
patients. Properdin deficient individuals with meningococcal disease demonstrate
a particularly poor prognosis possibly resulting from an inability to perform both
opsonophagocytosis and serum bactericidal activity (Schneider et al. 2007).
Individuals with polymorph isms which increase the amount of factor H,
demonstrate a higher incidence of meningococcal infection. This is because
binding of Factor H to Factor H binding protein (FHbp) enhances the survival of
the bacteria (Haralambous et a/. 2006; Kugelberg et a/. 2008). MBL
polymorph isms effect the amount of MBL in plasma and low levels of MBL have
been associated with an increased susceptibility to meningococcal disease,
polymorph isms in MBL gene are more common than LCCD and therefore
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potentially responsible for a larger number of cases of meningococcal disease
(Vermont and van den Dobbelsteen 2002).
1.5.2 Disease susceptibility and FcyR polymorph isms
Antibody is important in the initiation of complement-mediated killing of bacteria
through either MAC deposition and lysis, or opsonophagocytosis. Polymorph isms
in FcyRs have been associated with increased risk of developing meningococcal
disease. IgG bind with three main receptors: FcyRI (CD64), FcyRII (CD32) and
FcyR1l1 (CD16) present on the surface of the phagocyte, and polymorph isms in
FcyRlla and FcyRlllb are thought to be important in meningococcal disease
(Domingo et al. 2002).
FcyRlla occurs in two allelic forms resulting from a single amino acid difference at
position 131, FcyRlla-R131 (arginine) and FcyRlla-H131 (histidine). Homozygote's
for FcyRlla-R131 are poorer at binding IgG2, resulting in a reduced ability to
induce phagocytosis. It has been found that 44% of children who survive
meningococcal septicaemia are FcyRlla-R131 homozygote, compared to the 23%
occurrence of this FcyRlla type in the general population (Bredius et al. 1994;
Domingo et al. 2002). This suggests a role for FcyRlla in the protective response
in meningococcal disease.
FcyRlllb also has two allelic forms NA1 and NA2. FcyRlllb- NA1 binds IgG3 with
higher affinity than NA2, and IgG1 and IgG3 bound to NA 1 is more effective at
inducing phagocytosis than FcyRlllb - NA2 (Boross 2008).
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1.6 Meningococcal vaccines
There is currently no effective vaccine against all meningococcal disease.
However, vaccines have been developed to combat serogroups A, C, Y, W135
and strain-specific serogroup B OMV vaccines have been developed to combat
clonal epidemic disease. The main focus of recent vaccine research is the
development of a vaccine effective against all serogroup B disease.
1.6.1 Polysaccharide vaccines
Vaccines composed of high molecular weight capsular polysaccharide have been
available since the 1970s where this type of vaccine was shown to be
immunogenic in clinical trials conducted in military recruits, and was able to
prevent disease in adults (Gotschlich et al. 1969). Polysaccharide vaccines have
been widely utilised and have been shown to be very safe (Khatami and Pollard
2010). The immunogenicity and efficacy of these vaccines has been shown to be
age-related, with poor immunity demonstrated in infants with older children
producing more, higher avidity antibody. It has also been observed that immunity
wanes quickly in all age groups but particularly in infants (Kayhty et al. 1980).
Polysaccharide vaccines have been shown to induce a T cell-independent immune
response, and this is the reason why poor memory responses are observed with
this type of vaccine. Capsular polysaccharide is able to directly stimulate a B cell
response by cross linking B cell receptors, explaining the requirement for
polysaccharide to be high molecular weight to be immunogenic (Kabat and Bezer
1958). Cross linking of B cell receptors results in the formation of B plasma
antibody producing cells, which produce predominantly the IgM isotype. This is
because there is no T cell help for inducing class switching, affinity maturation or
production of B memory cells.
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1.6.2 Conjugate vaccines
Conjugation of capsular polysaccharide to a carrier protein like CRM'97 or tetanus
toxoid enables the induction of a T cell-dependent response. The capsular
polysaccharide and carrier protein are taken up by antigen presenting cells which
present peptides on MHC II molecules and are recognised by CD4 T cells. T
helper cells are then able to activate B cell proliferation and differentiation into
memory B cells, and induce isotype switching and affinity maturation.
Conjugate vaccines are more immunogenic in infants than polysaccharide
vaccines, and have been shown to induce herd protection by reducing
nasopharyngeal carriage. In 1999 the UK became the first country to introduce a
N. meningitidis serogroup C conjugate vaccine, with a three dose schedule at 2, 3
and 4 months, and was offered to everyone under 18 years in a phased catch up
campaign. This resulted in a 67% reduction in carriage in adolescents 1 year after
the introduction of the vaccine (Maiden and Stuart 2002), and this resulted in herd
protection in the unvaccinated population (Ramsay et a/. 2003; Maiden et al.
2008).
Tetravalent conjugate vaccines have been developed to target A, C, W135 and Y
disease, and have been shown to be immunogenic in all age groups. There is no
conjugate serogroup B polysaccharide vaccine due to similarities between
serogroup B capsular polysaccharide and host sialylated neuronal cell adhesion
molecules (Finne et al. 1987). Thus, there is a theoretical concern that vaccination
with this polysaccharide would induce auto-antibodies. Attempts have been made
to modify the polysaccharide to prevent the induction of autoantibodies. N-acetyl
groups were been replaced with N-propionyl groups, which was able to induce
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bactericidal responses in mice (Jennings et al. 1987) but was poorly immunogenic
in humans (Bruge et al. 2004). Work has therefore focused on developing an
effective serogroup B vaccine using noncapsular approaches including using outer
membrane vesicles and/or recombinant proteins.
1.6.3 Outer membrane vesicle vaccines (OMV)
Detergent-extracted OMV vaccines are made by separating OMVs from bacteria
and treating with detergents to remove LOS and thus reduce endotoxin activity.
OMVs are released from the bacteria whilst they are multiplying, and contain
immunogenic sub-capsular outer membrane proteins (OMPs), which when used
as a vaccine have been shown to be safe and efficacious. OMV vaccines have
been used against epidemic serogroup B strains in Cuba (Sierra et al. 1991),
Norway (Bjune et al. 1991), New Zealand (Hoist et al. 2005), and Brazil (de
Moraes et a/. 1992). OMV vaccines show poor cross-reactivity between strains.
The main immune response has been shown to be directed against PorA, a highly
immunodominant protein which demonstrates high levels of antigenic variability,
and thus these vaccines are only efficacious for clonal epidemics caused by
strains with a common PorA antigen. A broader immune response has been
demonstrated in adults than in infants, who show a particularly strain specific
response. A possible reason for this could be natural priming of the immune
system following nasopharyngeal carriage resulting in a boost of these responses
following vaccination with OMVs. This was demonstrated by an immunogenicity
trial held in Chile where OMV vaccines manufactured to combat the epidemics in
Cuba and Norway were used to vaccinate children (2-4 years) and infants (0-1
years) and adults (17-30 years). Neither vaccine was able to induce a significant
increase in SBA (4 fold increase in titre) response against a heterologous strain
(Chilean epidemic strain) in vaccinated infants, whereas 31-35% of children and
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37-60% of adults demonstrated a four-fold rise in bactericidal titre against the
heterologous Chilean epidemic strain. 90% of infants demonstrated a four-fold rise
in bactericidal titre against the homologous strain (Tappero et a/. 1999).
In order to broaden protection afforded by OMV vaccines, a vaccine consisting of
OMVs from two recombinant strains which have each been modified to express 3
ParA serosubtypes, has been developed in the Netherlands. This hexavalent OMV
vaccine (HexaMen), showed some ParA types to be less immunogenic than others
and that specific priming with monovalent OMVs was required to improve this
response (Luijkx et al. 2006). In order to broaden the protection afforded by the
HexaMen vaccine further, a nonavalent OMV vaccine (NonaMen) has been
produced. The Nonamen OMV vaccine has been used in a phase 1 clinical trial
and has been shown to be safe, however there is currently no immunogenicity
data available. The large diversity in ParA from serogroup B disease causing
strains makes a vaccine which targets mainly ParA likely to confer only limited
protection.
N. lactamica OMVs have also been used as a vaccine. N. lactamica is a
commensal bacterium which is similar to N. meningitidis but lacks capsular
polysaccharide, ParA (Perrin et al. 1999), and the ability to produce IgA protease
(Mulks and Plaut 1978).
Carriage of N. lactamica in childhood has been associated with the development
of immunity to meningococcal disease. Children carrying N. lactamica
demonstrate an increase in cross-reactive bactericidal antibodies when compared
with non-carriers (Gold et al. 1978). Carriage levels of N. lactamica have been
shown to exceed N. meningitidis in the under 5 year old age group, whilst N.
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meningitidis carriage becomes more frequent in later childhood (Cartwright et al.
1987). A more recent study investigated experimental nasopharyngeal
colonisation following inoculation of adult volunteers with N. lactamica and the
resulting protective immunity, and this demonstrated induction of cross-reactive
OPA antibodies but not bactericidal antibodies to N. meningitidis. In addition, this
study also found that N. lactamica carriage inhibited the acquisition of N.
meningitidis carriage (Evans et al. 2011).
Vaccination with N. lactamica OMVs was protective against challenge with a panel
of N. meningitidis strains in a mouse model of meningococcal septicaemia,
supporting the conclusion that this could be a potential N. meningitidis serogroup
B vaccine (Oliver et al. 2002). N. lactamica OMVs were used in a phase I clinical
trial with male adult volunteers in the UK. Although cross-reactive protection was
observed with OP, SBA levels were shown to be similar to those observed with a
meningococcal OMV vaccine against heterologous strains (Gorringe et al. 2009).
Therefore N. lactamica OMVs are unlikely to be used as a meningococcal
serogroup B vaccine.
Detergent extraction of OMVs lowers the level of endotoxin content, but it has also
been shown to damage or remove important immunogenic lipoproteins such as
factor H binding protein (fHbp). Use of native OMVs (nOMVs) as a parenteral
vaccine is impossible because of the very high levels of endotoxin, but an nOMV
has been administered via the intranasal route (Drabick et al. 1999; Katial et al.
2002). Two studies have been carried out by the Walter Reed Army Institute
(USA) into intranasal vaccination of an nOMV vaccine. The first study had 32
healthy adult volunteers intranasally vaccinated with an nOMV vaccine, this was
shown to be safe and able to induce a fourfold rise in SBA titre in 75% of subjects.
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The antibodies generated were shown to be specific for PorA and LOS (Orabick et
al. 1999). The second study vaccinated 40 healthy adult volunteers with a range of
dosages of the same nOMV vaccine. This study induced an increase in
homologous meningococcal IgA and IgG ELISA titres, but only 43% of subjects
showed a fourfold or greater rise in bactericidal titres.
The Walter Reed Army Institute has also developed a nOMV vaccine composed of
three antigenically diverse serogroup B strains which have been genetic modified
to disable IpxL 1 resulting in lower levels of endotoxin content, and synX gene
preventing capsule formation and LOS sialyation. This vaccine strain has also had
OpcA high expression stabilised, an additional PorA inserted and an additional
fHbp from H44ns to increase expression of fHbp. Initial studies have shown this
vaccine to be capable of inducting cross reactive bactericidal antibody in mice
(Zollinger et al. 2010) and also in humans in a phase I clinical trial (Keiser et al.
2011 ).
The use of recombinant proteins in vaccines has been heavily investigated with
many proteins identified as potential vaccine antigens. These include Neisserial
adhesion protein (NadA) (Comanducci et al. 2002), Neisserial surface protein A
(NspA) (Halperin et al. 2007), Transferrin binding proteins (Tbp) (West et al. 2001),
Opacity proteins (Opc) (Jolley et al. 2001), fHbp (Masignani et al. 2003; Fletcher et
al. 2004), and FetA (Thompson et al. 2003). However, the potential of these
vaccine antigens is limited by antigenic and phase variability and also varying
expression levels. Therefore a vaccine made up of these recombinant antigens is
likely to require the inclusion of more than 1 recombinant antigen.
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Identification of potential vaccine antigens has been carried out using reverse
vaccinology. This is a process whereby 600 potential surface-exposed or secreted
proteins were identified by genome mining the MC58 genome. Out of these 600
potential surface exposed or secreted proteins 350 were expressed in Escherichia
coli, purified and used to immunise mice. Serum was then assessed on its ability
to induce a bactericidal response, and bind to the surface of the bacteria. 29
proteins were able to induce a bactericidal response in the SBA and were
evaluated for sequence conservation across a panel of diverse strains. 5 vaccine
antigens identified by this process have been included in the Bexsero vaccine
along with NZ98/254 OMVs(Section 1.6.4)(Pizza et al. 2000; Bambini and
Rappuoli 2009).
1.6.4 Factor H binding protein containing vaccines
Factor H binding protein (fHbp) is a surface-exposed lipoprotein able to bind
complement alternative pathway factor H (fH), a protein able to down regulate the
classical and alternative complement pathways by converting C3b into iC3b and
thus enhance resistance to complement-mediated killing. fHbp has three variants
termed variants 1,2, and 3 or subfamilies A (variants 2 and 3) and B (variant 1).
This protein has been identified as an important vaccine antigen by reverse
vaccinology (Bambini and Rappuoli 2009) and by assessment of protein fractions
(Fletcher et al. 2004) and is included in the Novartis and Pfizer vaccines which are
currently in clinical trials.
Bexsero is a multicomponent vaccine composed of: N. meningitidis NZ98/254
OMV, used in the mass vaccination in response to a meningococcal outbreak in
New Zealand; NadA, important in attachment and invasion (Capecchi et al. 2005);
NHBA (Neisserial heparin binding antigen) present as a fusion protein with
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genome neisserial antigen (GNA) 1030. NH8A is possibly able to enhance
resistance to complement mediated killing by binding heparin. The final
recombinant vaccine antigen is also a fusion protein of fHbp with GNA 2091. This
vaccine has been administered to adults (phase 1) (Toneatto et 81. 2011) and
infants and toddlers (phase 2 and 3) as both 3 and 4 dose schedules (Find low et
81. 2010; Snape et 81. 2010). The vaccine has been shown to be safe and able to
induce bactericidal antibodies against a panel of strains selected to be
homologous with one of the vaccine antigens. Vaccine coverage has been
assessed by using the meningococcal antigen typing system (MATS) assay
(section 1.7.5), indicating 72.9% of 2007/2008 UK serogroup 8 disease would
have been covered by this vaccine (Findlow 2011).
A bivalent fHbp vaccine composed of lipidated LP2086 from fHbp subgroup A and
8, has also been developed. This vaccine has been administered to adults (phase
1) and adolescents 11-18 years (phase 2) and a phase 3 study is being planned in
2011. Results from phase 1 and 2 studies show that vaccination induced
bactericidal antibodies and >80% of vacinees had an hS8A titre 1:4 or greater
against a panel of diverse serogroup 8 strains. This vaccine is currently being
targeted for administration to adolescents (Jansen et 81. 2011). Potential coverage
of this vaccine will be established using the MeASure assay (section 1.7.6)
(McNeil et 81. 2011).
1.7 Current assays for measurement of immunity to meningococcal disease
Measurement of immune responses responsible for protection and identification of
correlates/surrogates of protection are a requirement for the development of
effective vaccines. There are animal models which have been used to assess
passive and active protection, and assays have been developed to assess both
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functional and non-functional immune responses. For the leading vaccine
candidates it has become important to assess the expression of the key antigens
used to assess vaccine coverage and thus assays have been developed to
measure antigen expression.
1.7.1 Serum bactericidal assay (SBA)
Bactericidal antibodies are important in host protection to meningococcal disease.
Antibody bound to meningococci engage C 1q via the Fc portion of antibody,
activating the classical complement cascade, which is then enhanced by the
positive amplification loop of the alternative pathway leading to deposition of C3b.
C3b deposition leads to formation of C5 convertase and the cleavage of C5 and
formation of the MAC complex. MAC inserts into the lipid bilayer forming a pore-
like structure which leads to lysis. An SBA uses serial dilutions of sera,
complement (human or rabbit) and bacteria, and a titre is assigned to the dilution
of serum which results in ~50% killing compared with a control.
The serum bactericidal assay is the accepted correlate of protection elicited by
vaccination (Frasch et al. 2009), however this assay is labour intensive and uses
significant volumes of sera. Additionally, work with live N. meningitidis requires
containment due to the respiratory infection risk of this ACDP2 organism.
A source of complement is a key reagent used in the SBA. Obtaining a human
complement source for use within the SBA is complicated by the levels of cross-
reactive antibodies acquired following nasopharyngeal carriage of N. meningitidis
and commensal Neisseria species. These antibodies can evoke meningococcal
bacteriolysis in the absence of test antiserum and cause interference in the results
of the assays. Large numbers of volunteers are screened to find serum or plasma
55
which contains little or no cross-reactive antibody to the strain of interest. Often
this results in a different complement source from a different individual being used
in assays against different strains, leading to poor inter-strain and inter-laboratory
assay comparability. As a result, baby rabbit complement has been used
frequently to evaluate meningococcal polysaccharide vaccine responses. rSBA
(SBA performed with baby rabbit complement) has been used to evaluate
meningococcal serogroup C polysaccharide conjugate vaccines in immunogenicity
and safety studies and vaccines were introduced in the UK in 1999, without a
phase III efficacy trial (Miller et al. 2001). Meningococci are more readily lysed by
rabbit complement due to the specificity of meningococcal fHbp to human fH and
therefore with rabbit complement this complement regulatory protein cannot
convert C3b to iC3b and thus reduce lysis of the bacteria (Granoff et al. 2009).
1.7.2 Opsonophagocytosis assay (OPA)
Opsonophagocytosis (OP) is a correlate of protection of S. pneumoniae vaccines
(Romero-Steiner et al. 2003) and evidence suggests that OP also plays an
important role in protection against meningococcal disease (Ross et al. 1987;
Balmer and Borrow 2004; Plested and Granoff 2008; Granoff 2009).
OP occurs following the binding of antibody to the surface of meningococci, and
the Fc portion of this antibody is able to bind C1q and initiate the classical
complement cascade which is enhanced by the positive amplification loop of the
alternative pathway leading to deposition of C3b. C3b can then act as an opsonin,
or C3b can be inactivated by factor H and factor I into iC3b which can also act as
an opsonin. The Fc portion of antibody binds with Fc receptors and the deposited
C3b/iC3b bind with complement receptors (CRs) 1 or 3 which are expressed on
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the surface of the phagocyte. These receptors crosslink and induce rearrangement
of actin, extension of pseudopodia and bacteria are then engulfed rapidly.
A variety of techniques have been developed to assess antibody-dependent
opsonophagocytosis. Published OPAs measure the uptake of either a fluorescent
bacterial target, OMV-coated fluorescent beads, the induction of a respiratory
burst response or direct bacterial killing. A classic OPA measures the uptake and
killing of bacteria via PMNs or HL60 cells, and the assay readout is a colony count
of viable bacteria (Plested et al. 2009). There are several examples of OPA
measuring the uptake of fluorescent OMV coated polystyrene beads (Lehmann et
al. 1998; Bassoe et al. 2000) or labelled meningococci (Taylor 2010). Lehmann et
al. 1999 measured the uptake of FITC-Iabelled ethanol-fixed bacteria. The FITC
stain binds to protein and therefore could mask surface epitopes and thus alter the
measurable opsonophagocytosis response. In addition, the bacteria were fixed
using ethanol which has also been shown to expose otherwise hidden epitopes
(Michaelsen et al. 2001). Other protocols have aimed to stain the bacteria
internally with BCECF-AM, a lipophilic stain which is non-fluorescent and able to
directly cross the bacterial membrane. Non-specific esterase activity is then able
to cleave the AM group, converting the dye to a lipophobic fluorescent dye unable
to leak out of the bacteria (Gorringe et al. 2009). In addition the bacteria were
killed with sodium azide and PMSF a method used to preserve the outer
membrane. OMV-coated fluorescent beads have also been used as a target in
OPAs (Lehmann et a/. 1998), with the advantage that they are easily
standardisable, whereas variation occurs between cultures. However, OMV-
coated beads have the disadvantage that they do not possess capsule and as a
consequence may expose epitopes not usually available on the surface of
meningococci.
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Alternatively other assays have been developed to measure the respiratory burst
response. These assays measure the conversion of dihydrorodamine 123 to
fluorescent rodamine 123 (which measures hydrogen peroxide) or dihydroethidium
to ethidium (which measures superoxide) following a respiratory burst response
initiated by opsonophagocytosis (Aase et al. 1995; Lehmann et al. 1998).
Lehmann et al. (1999) simultaneously measured both uptake of fluorescent OMV-
coated beads and respiratory burst.
The majority of opsonic assays measure the uptake of fluorescently-Iabelled OMV-
coated latex beads or meningococci, but do not measure the stimulation of a
respiratory burst response; the bactericidal function which kills the phagocytosed
bacteria. Similarly some assays measure respiratory burst response only and not
opsonophagocytosed bacteria which may overestimate protection as it does not
account for the respiratory burst response stimulated for example by N-
formylmethionylleucylphenylalanine (FMLP) (Elbim et al. 1994). TNF-a (Menegazzi
et al. 1994) and IFN-y (Ellis and Seaman 2004). Phagocytosis is not always
necessary for respiratory burst to occur (Phillips et al. 1990; Elbim et al. 1994).
Published OPA also vary not only in the incubation times, target and concentration
of assay components, but also in the phagocytic effector cells used. PMNs are
used in many assays, however this limits the throughput of the assay as this is
reliant on human donation. They have however been used successfully in small
scale investigations (Lehmann et al. 1999; Sassoe et al. 2000; Aase et al. 2003).
Other assays use the HL60 cell line which can be differentiated into granulocytic-
like phagocytic effector cell. This has the advantage that high thoughput screening
can be performed, and HL60 cells have been used for the assessment of
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meningococcal vaccines (Taylor 2010) and also for the assessment of
pneumococcal vaccines (Martinez et al. 1999; Romero-Steiner et al. 2003).
OPAs also vary in the complement source used. Some assays have used baby
rabbit complement (Taylor 2010), an easily standardisable source which has been
used in the SBA to assess serogroup A,C,Y and W135 vaccine responses
(Maslanka et al. 1997; Andrews et al. 2003; Keyserling et al. 2005; Kshirsagar et
al. 2007). Rabbit complement can be purchased in bulk therefore reducing assay
variation. Higher SBA responses are observed with rabbit complement in
comparison with human complement, and therefore the use of rabbit complement
can overestimate the protective response (Granoff 2009). It has been suggested
that this is a result of fH binding with fHbp. fH is able to cleave C3 and turn C3b (a
part of the C5 convertase) into iC3b a component able to contribute to
opsonophagocytosis but not in the formation of C5b-9 and thus a lower
bactericidal titres (1-2 log drop) are observed using human compared with rabbit
complement.
1.7.3 Whole Blood Assay
The whole blood assay (WBA) has been used to assess the total bactericidal
activity in the blood, which includes both SBA and OPA (Ison et al. 1995). WBA
can also be used to investigate host bacterial interactions as it is a model of
meningococcal bacteraemia. The WBA has been used in the assessment of
bactericidal activity in convalescent children where SBA and WBA were directly
compared. WBA was shown to be sensitive and able to detect higher levels of
bactericidal activity than the SBA, which is explained by the ability of this assay to
measure the contribution of other protective mechanisms (i.e. OP) (Ison et al.
1999). The main limitations of this assay are its requirement for fresh whole blood,
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which limits its uses for the assessment of clinical trial serum as it cannot be
performed in a high throughput manner and can only be performed at the sampling
site and repeat assays are not possible. Requirements for whole blood also could
contribute to high assay variation. Published WBA methods use heparin or citrate
as an anti-coagulant in the whole blood, both of which adversely affect
complement function.
1.7.4 T cell assays
Cell-mediated immunity has been assessed using both T-cell proliferation assays
and also measurement of cytokine production (Pollard et a/. 1999). Immunity to N.
meningitidis is humoral, however, T-cell help is important in developing
immunological memory response. This includes inducing antibody class switching,
affinity maturation, as well as inducing B cell proliferation. Proliferative responses
have been carried out using incorporation of [3H] thymidine into cells. A scintillation
counter can then be used to measure the radioactivity recovered from cells
following stimulation and this enables an assessment of the amount proliferation
that has occurred. Cytokine responses have been measured by a variety of
methods, including ELISA, Luminex bead arrays and intracellular cytokine
staining.
T-cell proliferation assays have been used to determine the reasons for poor
responses seen in infants following OMV vaccination. T-cell proliferative
responses and cytokine production has been compared between convalescing
infants and older children. Higher proliferative responses were observed in
children >10 years in comparison to younger children, and infants produced a TH1
profile, whilst older children produced a TH2 profile (Pollard et al. 1999). Following
intranasal vaccination with an OMV vaccine, T cell proliferative responses have
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also been shown to correlate highly with IgG and IgA titres measured in an OMV
ELISA (Oftung et al. 1999).
1.7.5 Meningococcal Antigen Typing System (MATS) assay
The development of meningococcal vaccines composed of proteins, which vary in
sequence and expression level in different meningococcal isolates, requires a
mechanism of establishing vaccine coverage. The MATS assay is a non-functional
sandwich ELISA developed to inform on the potential vaccine coverage if the
Bexsero novel vaccine is introduced. Bacteria are grown and detergent-treated to
extract capsule and expose antigens, a capture antibody specific for the antigen of
interest is coated onto a 96 well ELISA plate and then the detergent-treated
bacterial extract is added, this is followed by the addition of a biotinylated detection
antibody and incubation with streptavidin-HRP. The level of antigen in each isolate
is measured against a reference standard and assigned a relative potency (RP).
The RP is related to the positive bactericidal threshold (PBT) established where
80% of strains show an hSBA titre with pooled infant vaccinee sera. The vaccine
coverage is then derived from the proportion of strains that score a RP above the
PBT for at least one of the vaccine antigens (Donnelly et al. 2010). It is unlikely to
be able to predict the contribution of NadA to bactericidal killing as it has been
observed that this antigen is down-regulated in culture conditions (Biolchi et al.
2011 ).
1.7.6 MeASure assay
An alternative assay has been developed to assess the expression levels of fHbp
for Pfizer's bivalent factor H binding protein vaccine. Studies have demonstrated
this vaccine is able to induce bactericidal antibodies against Men B strains, and
variation in surface expression levels of fHbp influences the ability of anti-fHbp
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antibodies to induce bactericidal activity. Thus, a meningococcal antigen surface
expression (MeASure) assay has been developed to characterise surface
expression of all fHbp variants on the surface of intact bacteria. Bacteria are
incubated with a cross reactive mAb, followed by incubation with a fluorescent
secondary detection antibody before being analysed by flow cytometry. This
method was shown to be reproducible and robust. This assay will be utilised to
measure the expression levels of fHbp on the surface of circulating strains, and to
use this data to predict which serogroup B strains will be susceptible to vaccine-
mediated bactericidal activity (McNeil et al. 2011).
1.7.7 ELISA
Enzyme-linked immunosorbant assay is a commonly used non-functional assay,
which measures the antibody binding to either whole meningococci, OMVs or
purified proteins of interest. In addition this assay can be used to look at the levels
of different antibody subclasses and isotypes to deduce the contribution of these in
the immune response to meningococcal vaccines. ELISA has shown good
correlation with the functional S8A and OPA responses with homologous vaccine
strains (Aase et al. 1995), but also shown to correlate poorly with S8A against a
strain heterologous to the vaccine strain (Milagres et al. 1994). Evidence has
shown ELISA to be a poor measure of protection in an efficacy study in 1-21year
olds in Chile following vaccination with a meningococcal group 8 (15:P1.3) OMV
vaccine (Bosleqo et al. 1995), and in addition a study investigating vaccine
immunogenicity following vaccination of 15- 20 year olds in Iceland comparing two
OMV vaccines showed good correlation between the S8A and ELISA results
(Perkins et al. 1998). The inconsistency seen could be a result of the
measurement of total IgG by ELISA, which does not take into account the
difference in SBA and OPA activity of different IgG subclasses. Comparisons of
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IgG subclasses measured by ELISA with functional assay responses showed a
strong positive correlation between IgG1 and SBA and OPA (Naess et al. 1999).
Measurement of antibody avidity using ELISA could also be an important factor in
the antibody-induced protection for meningococcal disease. Avidity ELISA uses
sodium thiocyanate to discriminate weakly bound antibody from high affinity
antibody. An avidity index can then be used to compare sera (Vermont et al.
2002). In a study comparing avidity ELISA, total IgG ELISA and IgG1 and IgG3
ELISA with SBA, good correlations were shown between SBA and all ELISA
assays tested. Therefore no improvement in correlation was observed when using
an avidity ELISA over measuring total IgG, IgG1 or IgG3 ELISA (Vermont et al.
2002).
1.7.8 Animal models
Animal models are the only way to measure the immune response to a pathogen
in the context of all parts of the immune system and tissues. N. meningitidis
specifically binds human transferrin and lactoferrin in order to acquire iron, and
interactions of bacterial pili is specific for human CD46 as is the interaction of Opa
and Opc with CEACAM1; both of which are required for bacterial attachment and
invasion of the bacteria. In addition to this, N. meningitidis binds only human fH
(Granoff 2009), and therefore developing an animal model for this disease is
complex. In addition, the pathogenesis and disease progression from mucosal
colonisation to septicaemia and/or meningitis also makes the development of an
animal model complex.
There are several models described, including the mouse intraperitoneal challenge
model. This model does not follow the natural pathogenesis of meningococci,
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however septicaemia can be achieved following infection. High challenge doses
are required and this needs to be administered with an exogenous iron source
(Holbein 1981). This model does allow the investigation of protection by both
active and passive immunisation and bacteria can be recovered from the blood
(Gorringe et al. 2001).
Use of an exogenous iron source with the mouse infection model can cause
hyperferraemia, which can result in the activation of the complement system, a
reduction in opsonophagocytosis and also affects the T lymphocyte subsets.
Specifically this effects the receptors expressed on the lymphocyte surface and
the expansion of T cell subsets (Walker and Walker 2000). In order to avoid this, a
transgenic mouse model has been developed to express human transferrin, and
bacteraemia has been demonstrated in this model which was sustained for at least
48 hours, when compared with a wild-type mouse strain which cleared infection
quickly (Zarantonelli et a/. 2007).
Intranasal mouse models have been difficult to develop as this route of infection
resulted in colonisation followed by pneumonia and then bacteraemia. This is in
contrast to the course of human disease. A transgenic humanised mouse model
has been developed to express CD46, which has resulted in an intranasal
challenge model (following antibiotic treatment) without the requirement of an
exogenous iron source. Bacteraemia resulted and bacteria were able to cross the
blood brain barrier in this transgenic strain (Johansson et al. 2005).
Vaccines based on fHbp have been developed, and the absence of human fH
from the mouse and rat models may indicate that these models overestimate
protection because fHbp only binds human fH (Granoff 2009). A human fH
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transgenic mouse model has been developed. Immunisation of this transgenic
model with fHbp demonstrated lower bactericidal titres than that observed in the
wild type mouse model, attributed to the binding of fH with fHbp. However, no
differences were observed between transgenic and wildtype mice following
immunisation with a serogroup C polysaccharide vaccination (8eernink et al.
2011 ).
An infant rat model of infection is also used to assess passive protection provided
by mammalian serum to i.p infection with meningococci. This model does not
require an exogenous iron source but cannot be used to assess active
immunisation due to the short duration of meningococcal infection (Salit 1981). In
addition, this model also requires a high challenge dose (Toropainen et 81. 1999).
This model has shown that sera with a bactericidal titre are able to protect from
development of bacteraemia and in addition to this sera without a measurable
bactericidal titre were also able to confer protection (Welsch and Granoff 2004).
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1.8 Project aims
This project aimed to develop a high throughput, reproducible antibody-mediated
C3b/iC3b and C5b-9 deposition assay. This assay would then need to be
correlated with the functional SBA and OPA to determine whether it can be utilised
to predict the functional response.
This project also aimed to develop a high throughput duplexed OPA, able to
measure the uptake of fluorescent bacteria and the induction of an respiratory
burst response. This would then be correlated with an opsonic killing assay to
assess whether measuring both parameters would correlate with killing to a
greater degree than measuring either parameter on its own.
Complement is an important component of most of the assays used to assess
vaccine-induced immunity to meningococci. The final aim of this project was to
develop an antibody-depleted human complement source that could be used with
any strain of N. meningitidis to improve assay to assay comparability.
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1.9 Hypothesis
Assays used to evaluate meningococcal vaccine sera, such as the SBA, are
laborious and require large volumes of sera and therefore there is the requirement
to develop assays which are high throughput and use low volumes of sera to allow
evaluation of antibody-mediated responses against large strain panels. A high
throughput, flow cytometric assay measuring antibody-mediated C3b/iC3b and
C5b-9 will be developed and the hypothesis is that the values obtained from this
assay will correlate with results obtained in SBA and OPA assays. If this
hypothesis is correct the antibody-mediated complement binding assay will be
useful in identifying sera able to induce either bactericidal or opsonic activity. A
secondary hypothesis is that a threshold level of C5b-9 deposition will need to be
achieved for bactericidal activity to occur.
OP has been suggested as an additional immune mechanism important in
immunity to N. meningitdis. Current OPA assess either uptake of bacteria or
induction of a respiratory burst response. The hypothesis to be addressed in this
study is whether measurement of both uptake and induction of a respiratory burst
response will correlate with OPKA to a greater level than just measuring bacterial
uptake or respiratory burst alone.
Complement is an important reagent used in the assessment of meningococcal
vaccine-induced immunity and identifying a suitable human complement source
can be complicated by the high levels of pre-existing immunity. A third hypothesis
to be tested in this study was whether antibody could be removed from a
complement source whilst retaining complement function.
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Chapter 2: Materials and Methods
2.1 Laboratory reagents
2.1.1 List of Chemicals
Table 2.1.1.1 List of chemicals
Chemical
Alternative pathway radial immunodiffusion assay kit
Aluminum hydroxide
Ammonium Chloride
Bovine Serum Albumin (BSA)
C1q
C7depleted complement
Calcium Chloride
Cleanse fluid
Crystal violet
Deoxycholic acid
Dimethylformamide (DMF)
Dimethyl sulfoxide (DMSO)
EDTA
Ethylenediamine Tetraacetic Acid (EDTA)
Ethylenediaminedi (O-Hydroxyphenylacetic) Acid
(EDDHA)
Flow check Fluorospheres
Fetal calf serum (FCS)
Glucose
Glycine
Goat anti-human IgG - FITC
Goat anti-mouse IgG - FITC
Goat anti-rabbit IgG - FITC
Hanks buffered saline solution (HBSS)
Heparin
Horse blood agar
Hydrochloric acid
Kanamycin
L-glutamic acid
L-glutamine
Magnesium sulphate
Marvel
Mouse anti human C3b/iC3b- FITC
Mouse anti human SC5b-9
Mouse anti human SC5b-9
N,N-Dimethylformam ide
Phenylmethylsulphonyl fluoride (PMSF)
Phosphate buffered saline (PBS)
Potassium chloride
Potassium dihydrogen phosphate
Company of purchase
Binding site
Brenntag Biosector
Sigma Aldrich
Sigma Aldrich
Quidel
Quidel
Sigma Aldrich
Beckman Coulter
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Beckman Coulter
Biosera
Sigma Aldrich
Sigma Aldrich
Jackson Immunoresearch
Jackson Immunoresearch
Jackson Immunoresearch
Gibco
Becton Dickinson
Biomerieux
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Premier International
Foods, UK
Abcam
Dako
Quidel
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
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Protein G sepharose
Total haemolytic radial immunodiffusion assay kit
Lepirudin (Refludan)
RPMI1640
Sheath fluid
Sodium azide
Sodium chloride
sodium hydrogen carbonate
Sodium hydrogen phosphate
Sodium hydroxide
Sodium phosphate
Sucrose
Tris HCL
Trypan blue
Yeast extract
Zenon Mouse IgG labelling kit
Amersham Bioscience
Binding site
Movianto
Invitrogen
Beckman Coulter
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Sigma Aldrich
Invitrogen
Table 2.1.1.2 List of Suppliers Address
Company Address Web address
Beckman Coulter Ltd,
Beckman Coulter High Wycombe, UK www.beckmancoulter.con
BD Ltd., Oxford, UK
Becton Dickinson England www.bd.com
bioMerieux Ltd,
Biomerieux Basingstoke, UK www.biomerieux.com
Biosera Ltd, East
Biosera Sussex, UK www.biosera.com
Invitrogen Ltd. Paisley, www.invitrogen.com
Gibco UK
Invitrogen Ltd. Paisley, www.invitrogen.com
Invitrogen UK
Movianto Ltd, Bedford,
Movianto UK www.movianto.com
Premier International Foods, Premier International
UK Foods Ltd, UK www.premierfoods.co.uk
Sigma-Aldrich Company www.sigma-aldrich.com
Sigma Aldrich Ltd., Poole, UK
Brenntag Biosector Ltd,
Brenntag Biosector Denmark www.brenntag-biosector.
Quidel Quidel Ltd, Dorking, UK www.Quidel.co.uk
Amersham Biosciences www.amershambioscienl
Amersham Biosciences UK Ltd., Bucks., UK
Jackson Immunoresearch Jackson http://www.jacksonimmUi
Immunoresearch
Laboratories Inc. West
Abcam Grove, PA, USA
Dako Dako Ltd, Ely, UK www.dako.com
Hycult Hycult Biotech, Uden www.hycultbiotech.com
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2.1.2 Laboratory stock solutions
Blocking buffer (BB) used for SLAlCDA
2% (w/v) bovine serum albumin (BSA) dissolved in phosphate buffered saline
(PBS). This was then filter-sterilised and stored at 4°C until use.
Oulbeccos phosphate buffered saline (OPBS)
0.14 M sodium chloride, 9 mM sodium phosphate, 3 mM potassium chloride and
1.4 mM potassium dihydrogen phosphate into 1 litre of distilled water. This was
then sterilised and stored at 4°C until use.
DPBS-EDTA
17 mM EDTA added to 500 ml DPBS. This was then sterilised and stored at 4°C
until use.
OPBS-GA
1% (w/v) bovine serum albumin and 0.1% (w/v) glucose was added to 500 ml
DPBS. This was then filter-sterilised and stored at 4°C until use.
Ethylenediamine-Di (o-Hydroxy-Phenylacetic acid) (EDOHA) Solution
To make 1.5 mg/ml stock, 60 mg EDDHA was dissolved in 27.2 ml of 0.36 M
NaC!. The pH was adjusted to 7 using 6 M hydrochloric acid and then made up to
40 ml with dH20. This was then filter-sterilised and used immediately.
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Frantz medium
0.1 M sodium chloride (NaCI), 0.04 M sodium hydrogen phosphate
(Na2HP04.7H20), 0.02 M ammonium chloride (NH4CI), 1 mM potassium chloride
(KCI), 10 mM magnesium sulphate (MgS04.7H20), 0.03 M glucose, 0.01 M L-
glutamic acid, 0.2% (w/v) dialysed yeast extract and 0.13 mM L-cystein.HCL.H20
were prepared in 1 litre H20. The medium was pH adjusted to 7.4 with 5 M sodium
hydroxide (NaOH). This was then filter-sterilised and stored at 4°C until use.
Lysis buffer
0.15 M NH4CI, 9.5 mM sodium hydrogen carbonate (NaHC03) and 3 mM EDTA
then filter-sterilised and stored at 4°C until use.
OMV preparation buffer 1
0.1 M Tris-HCL pH adjusted to 8.6, 10 mM EDTA, 0.5% (w/v) deoxycholic acid.
This was then filter-sterilised and stored at 4°C until use.
OMV preparation buffer 2
50 mM Tris-HCL pH adjusted to 8.6, 2 mM EDTA, 1.2% (w/v) deoxycholic acid,
20% (w/v) SUcrose. This was then filter-sterilised and stored at 4°C until use.
OMV buffer 3
0.2 M glycine buffer pH adjusted to 8, and 3% (w/v) sucrose. This was then filter-
sterilised and stored at 4°C until use.
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RBAI dRBAI OPA assay buffer
1.2 mM CaCI2 and 1 mM MgS04 were added to 500 ml Hanks' balanced salt
solution (HBSS without calcium or magnesium), filter-sterilised and stored at room
temperature. Immediately before use, 2% (w/v) Marvel skimmed milk powder was
added.
RBA assay buffer with azide
1.2 mM CaCh and 1 mM MgS04 added to 500 ml Hanks' balanced salt solution
(HBSS without calcium or magnesium), filter-sterilised and stored at room
temperature. Immediately before use add 4% (w/v) Marvel skimmed milk powder
and 0.01 % (w/v) sodium azide to the required volume of solution.
Phenylmethanesulfonylfluoride (PMSF)
9.8 mM PMSF was prepared in 10 ml of isopropyl alcohol. This was then filter-
sterilised and stored at 40C until use.
Sodium azide
A 20% (w/v) solution of sodium azide was prepared and was filter-sterilised and
stored at 4°C until use.
Tissue culture medium
2 mM L-glutamine, 20% (v/v) heat inactivated foetal calf serum was added to 395
ml RPMI-1640 medium and stored until use at 4oC.
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ELISA wash buffer
50 mM Tris, 0.14 M NaCl, 0.05% Tween 20, pH 8.0 was filter-sterilised and stored
at 4°C until used.
ELISA Coating buffer
0.05 M carbonate-bicarbonate, pH 9.6. This was made up immediately before use
in the assay and filter-sterilised.
ELISA blocking buffer
50 mM Tris, 0.14 M NaCl, 1% (w/v) BSA, pH 8.0 was filter-sterilised and stored at
4°C until used.
ELISA stop solution
0.18 M H2S04
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2.2 Neisseria meningitidis
2.2.1 Bacterial strains used
All strains provided by HPA Meningococcal Reference Laboratory
Sequence Clonal
Strain Serogroup Serotype Serosubtype
Type Cluster
H44n6-SL B 15 7,16 32 32
M01-240101 B NT 19-1,15-11 1049 269
M01-240013 B NT 22,9 275 269
M01-240149 B 4 7-2,4 41 41/44
(3061 )
M01-240185 B 2a 5-1,10-8 11 11
M01-240355 B 1
22,14 213 ~213
(3063)
NZ98/254 B 4 7-2,4 41 41/44
Nm26 B 4 16 Unknown Unknown
NmP27 B 15 7, 16 Unknown Unknown
Table 2.2.1 N. meningitidis strains used in immunoassays.
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2.3 Preparation of bacteria for use in immunoassays
2.3.1 Growth of unstained N. meningitidis
All manipulations of N. meningitidis were performed within a flexible film isolator
(FFI). An aliquot was removed from the -70De freezer and was placed within the
FFI, and defrosted by placing within the 37De incubator. A disposable sterile
inoculation loop was then used to create a streak plate on horse blood agar
(Biomerieux) to check for contamination. 100 IJI (2 x 108 eFU/ml) of N. meningitidis
was spread onto another horse blood agar plate to create a lawn of growth, and
both were incubated overnight at 37°e with 5% eo2. Streak plates were checked
for contamination and growth from half a plate was resuspended into 10 ml Frantz
medium (containing 0.5 mg/ml EDDHA for iron restriction) using a disposable
sterile inoculation loop. This was then incubated for 4 h at 37DCwith shaking.
The bacteria in these cultures were killed by the addition of 100 IJI of fresh 20%
(w/v) sodium azide solution and 100 IJI of fresh 10 mM solution of PMSF, and
incubated for 48 h at 37De. A 100 IJIof this bacterial suspension was then spread
on a horse blood agar plate and incubated overnight at 370e with 5% e02 for
confirmation that all bacteria had been killed. The 10 ml culture was then
centrifuged at 3060g for 5 min and resuspended in 1 ml of PBS.
2.3.2 cryopreservation of N. meningitidis
Aliquots of N. meningifidis were prepared by inoculating 10 ml Frantz media with
30% (v/v) glycerol with half a plate of N. meningitidis growth. This was then
aliquoted and frozen at -70De until required.
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2.3.3 Gram staining
A loop full of bacterial suspension was spread onto the surface of a microscope
slide. This was then placed onto a hotplate to heat fix the sample to the slide. This
was then stained with crystal violet solution (0.981 g/ml) for 1 min. The slide was
then washed several times in sterile water before being submerged in iodine
solution (1.005 g/ml) for a further 1 min, this was again washed thoroughly with
sterile water and then briefly with ethanol. Finally the slide was counter-stained
with safarin (0.986 g/ml) for 30 s, and then washed and air dried before
examination under a light microscope. This procedure was done to check N.
meningitidis and HL60 cells for contamination.
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2.4 Staining of N.meningitidis
2.4.1BCECF-AMfluorescent staining of live N.meningitidis
10 ml cultures of N. meningitidis were grown as described in 2.3.1, and were
centrifuged for 5 min at 3060g, and resuspended into 900 ~I of HBSS. 100 ~I of 1
mg/ml solution of BCECF-AM was added and the solution incubated for 1 h with
shaking at 37°C and then centrifuged for 5 min at 3060g, before being
resuspended in 10 ml of PBS.
The bacteria were killed by adding 100 ~I of fresh 20% (w/v) sodium azide solution
and 100 ~I of fresh 10 mM of PMSF and incubated for 48 h at 37°C. 100 ~I of this
bacterial suspension was then spread on a horse blood agar plate and incubated
overnight at 37°C with 5% CO2 to confirm that all bacteria had been killed. This
was then centrifuged at 3060g for 5 min and resuspended in 1 ml of PBS.
2.4.2 Bacterial staining using various nucleic acid stains (PI, 7AAD and
SYTO 59)
Azide/PMSF-kilied unstained bacteria were centrifuged for 5 min at 3060g and
then resuspended to an OD600 nm of 2 using HBSS containing a range of
concentrations of nucleic acid stains (0-60 ~M), before being incubated for 30 min
at room temperature. The bacteria were then centrifuged for 5 min and washed in
HBSS. This step was repeated 4 times to remove any excess stain.
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2.4.3 Staining of N. meningitidis using S-(and-6)-carboxy SNARF®-1,
acetoxymethyl ester (SNARF-AM) and dihydrocalcein, AM.
10 ml of N. meningitidis cultures were grown as described previously (2.2.1) and
were centrifuged for 5 min at 3060g, and resuspended into 900 !-IIof HBSS. 100 IJI
of various SNARF-AM concentrations (0-150 !-Ig/ml) were added, and the solution
incubated for 1 h with shaking at 37°C. The stain bacteria were then centrifuged
for 5 min at 3060g, and then resuspended in 10 ml of PBS.
The bacteria were then killed as described in 2.4.1.
2.4.4 Staining of N. meningitidis using 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindodicarbocyanine-S,S'-disulfonic acid (DiIC1s(S)-DS) and PKH-
26 lipid anchoring stains.
Azide-PMSF killed unstained bacteria were centrifuged for 5 min at 3060g and
then resuspended in 10 ml of HBSS with a range of concentrations of PKH-26 (0-1
IJM) or DiIC1s(5)-DS (0-160 !-1M)and incubated for 30 min at room temperature.
The bacteria were then centrifuged for 5 min at 3060g and washed in HBSS, this
step was repeated 4 times to remove excess stain which was assessed by the
lack of dye visible in the HBSS wash buffer.
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2.5 Cell culture
2.5.1 Preparation of cell culture medium
All cell culture was performed in a class II microbiological cabinet, 120 ml of sterile
heat-inactivated foetal calf serum (FCS) was added to 500 ml of RPMI-1640
media. 5 ml was discarded from the media and 5 ml of a 200mM L- glutamine
solution was added. Medium was checked for sterility by incubating a sample of
media overnight at 37°C before being evaluated by gram staining (2.3.3) and a
visual check by microscopy. Media was then stored at 4°C until use.
2.5.2 Cell line maintenance
The HL60 cell line was obtained from the American Tissue Culture Collection
(ATCC). HL60 cells are a suspension culture and display a promyelocytic
morphology, with a doubling time of approximately 24 h. They carry a variety of
surface antigens characteristic of immature myeloid cells and can be differentiated
into granulocytic-like cells with the addition of N,N-dimethylformamide (OMF)
(Birnie 1988). This cell line was subcultured daily by adding 100 ml of growing
cells to 100 ml of media in a T175 flask. When cells were subcultured for 48 h, 50
ml of growing cells were added to 150 ml of media in a T175 flask. This was done
so that the cells were seeded to approximately 5 x 105 cells/rnl. Cells were
incubated at 37°C with 5% CO2
2.5.3 Cell counting and viability
Prior to differentiation, cells were counted and their viability was checked. Cells
were quantified using a haemocytometer. The haemocytometer was prepared by
sliding a glass cover slip over the cell counting chamber, to create a tight seal. A
20 1-11 sample of cells was taken from the culture and was added to 20 1-11 of trypan
82
blue (0.4% w/v), and incubated for 5 min at room temperature. A 10 1-11sample was
taken up using a pipette, and placed at the edge of the haemocytometer and then
slowly expelled so that the contents were drawn into the chamber by capillary
action. This was visualised under a microscope. Cells were counted from the grid
(figure 2.5.3), cells which appeared on a grid line were only counted if they were
on the top and right lines of each square.
Counting area
Figure 2.5.3 Haemocytometer grid used for cell counting.
The cell concentration was calculated by multiplying the live cell count by the
dilution factor, which was then multiplied by 1 x 104 to give the total cells/m!. This
number is derived from the volume underneath the cover slip being 0.0001 ml
(length x width x height; Le., 0.1 cm x 0.1 cm x 0.01 cm). Viability was determined
by dividing the number of live cells which appeared clear, by the number of dead
cells which absorbed trypan blue and therefore appeared blue, and multiplied by
100 to provide a percentage of live cells.
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2.5.4 Differentiation of HL60 cells
Cells were initially counted and the number of viable cells calculated. The volume
of cells required for a final concentration of 5 x 106 live cells/ml in 200 ml was
calculated and placed into 50 ml centrifuge tubes and centrifuged for 5 min at
400g. The supernatant was discarded and the pellets resuspended into 50 ml of
fresh culture media. In a separate 50 ml tube. 48.4 ml of media was mixed with 1.6
ml (0.8% (v/v)) of DMF. This was then added to a T175 tissue culture flask. where
a further 100 ml of media was added. The 50 ml of cells were then added to this,
to give a final volume of 200 ml in the tissue culture flask. The flask was then
incubated at 37°C at 5% C02 for 5 days before the differentiated cells could be
used in an assay.
2.5.5 Leukocyte extraction from fresh blood
Blood was collected from a donor into vacutainer tubes (Becton Dickinson)
containing heparin. The blood was diluted 1:10 in lysis buffer and incubated in a
3rC waterbath for 10 min. before being centrifuged at 400g for 5rnin. The
supernatent was discarded and the pellet washed in 25 ml DPBS-GA. The cells
were centrifuged for a further 5 min at 400g. before resuspension in 25 rnl of lYSis
buffer. Once again this was incubated for 10 min in a 3rc waterbath to lyse any
remaining red blood cells and the cells were centrifuged for 5 min at 400g and
resuspended in 5 ml of DPBS-GA before being counted for use
2.5.6 Cryopreservation and revival of HL60s
2.5.6.1 Crypopreservation
HL60s were made up to a concentration of 1 x 106 cells/ml in media with 10% (v/v)
DMSO. This was then aliquoted into 1 ml cryovials and the placed into a
5100 Cryo 1DCfreezing container which provides the 1DC/min cooling rate required
for the successful cryopreservation of cells. This was then put into the -80DC
freezer overnight, and the aliquots were stored in liquid nitrogen until required.
2.5.6.2 Revival of cryopreserved cells
Once the vial of cells has been removed from liquid nitrogen, the vial was placed
in a class II cabinet and the lid loosened to release any trapped liquid nitrogen, the
lid was then re-tightened and then placed in a 37°C waterbath until the cells were
thawed. The vial contents were transferred into a centrifuge tube. This was then
centrifuged for 5 min at 400g to remove any remaining DMSO. The pellet was then
resuspended in 10 ml of fresh media and then transferred into a tissue culture
flask and cultured at 37°C with 5% CO2
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2.6 OMV preparation
Frozen aliquots of N. meningifidis, stored at -70°C in Frantz media containing 30%
(v/v) glycerol, were thawed and grown on horse blood agar overnight at 3rC with
5% CO2, before being used to inoculate 20 ml of Frantz media with or without 0.5
mg/ml EDDHA for iron restriction, and incubated at 3rC with shaking (180 rpm)
for 5 h. This was then used to inoculate 300 ml Frantz in a 2 L flask, and then
incubated overnight at 3rC with shaking (180 rpm). Cultures were centrifuged at
4000g for 1 h and the supernatant discarded and pellets resuspended in OMV
buffer 1 at a 5:1 buffer:biomass ratio. This was centrifuged for 30 min at 20,000g
at 4°C, and the supernatant retained and centrifuged for a further 2 h at 125,000g.
The supernatant was discarded and the pellet resuspended in 3 rnl of OMV buffer
2 and centrifuged for a further 2 h at 125,000g. The final pellet was resuspended
in 1 ml OMV buffer 3 and the OMVs were homogenised and stored at -20°C
(Finney et al. 2008).
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2.7 Generation of Immune sera
2.7.1 Animals
All mice used to generate immune sera were female NIH or BALB/c mice (Harlan)
and were 6-8 weeks old at the beginning of the immunisation schedule. All rabbits
used in the generation of sera were female NZ white rabbits (Harlan) which were
2-3 kgs at the beginning of the immunisation schedule.
2.7.2 Vaccine preparation
Mice were immunised with 10 I-IgOMVs (total protein concentration) prepared with
0.33% (v/v) alhydrogel adjuvant. Alhydrogel was made up in PBS to a
concentration of 0.67% (v/v), this was mixed 1:1 with OMVs at the required
concentration. Each mouse received two 100 1-11 doses subcutaneously at two
separate locations, whilst rabbits received two doses of 500 1-11 subcutaneously.
Vaccines were given in a three dose schedule on day 0, 21, 28 before being
terminally bled on day 35 (Gorringe et al. 2001).
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2.8 Labelling of monoclonal antibody
2.8.1 Zenon labelling of monoclonal antibody
Zenon (Invitrogen) mouse IgG labelling reagent (5 I-II)was added to 100 1-11 of PBS
containing 10 I-Ig/ml antibody. The solution was incubated for 5 min at room
temperature before 5 1-11 of Zenon blocking reagent was added and incubated for a
further 5 min at room temperature before use.
A
Unlabelled IgG antibody
+
Zenon Labelled Fab
fragments (labelling
reagent).
! Incubate
B
Labelled Fab fragments
bound to the IgG
Mixed with non-specific IgG, this complexed
unbound Fab fragments, prevented cross-
labelling of the Fab fragments in experiments.
c
Figure 2.8.1 Zenon labelling method
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2.8.2 Alexa fluor 647 monoclonal antibody labeling
Alexa flour 647 monoclonal antibody labeling kit was used as described in the
manufacturer's protocol (Invitrogen, UK). Antibody was diluted to 1 mg/ml in 1 M
sodium bicarbonate buffer and 100 IJIof this antibody solution was added to a vial
of Alexa fluor 647 reactive dye, and incubated for 1 h with rotation. The purification
spin column was prepared during the hour incubation, 1 ml of purification resin
was added to a spin column and allowed to settle before centrifuging at 11~Og for
3 min to elute purification resin buffer. This was repeated until the resin bed was
approximately 1.5 ml. After centrifugation, 100 IJI of stained antibody was pipetted
directly into the centre of the resin bed and then centrifuged for 5 min at 11DOg
and the eluted antibody collected and stored at 4°C until use.
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2.9 Immunoassay methods
2.9.1 Surface binding assay (SLA)
Total antibody binding on the surface of meningococci was performed in U-bottom
96-well microtitre plates. 2 1-11of each test serum (heat inactivated) was added to
1981-11of target bacteria at an 0.0600 nm 0.1 in blocking buffer and incubated for 30
min with shaking (900 rpm) at 25.0°C and then centrifuged at 3050g for 5 min and
the supernatant removed and the pellet washed with 200 1-11of blocking buffer. The
wash step was repeated twice before the addition of 200 1-11FITC-Iabelled goat
anti-mouse/rabbitlhuman conjugate (Jackson Immunochemicals, USA) at 1:500 in
blocking buffer. This was incubated for 20 min at 4°C, before being washed twice
more with blocking buffer. The samples were then analysed by flow cytometry.
2.9.2 Complement deposition assay (COA) original method
Antibody-mediated complement deposition on the surface of meningococci was
measured using a flow cytometric assay performed in U-bottom 96-well microtitre
plates. For the assay, 5 1-11of each test serum (heat inactivated) was added to 90
1-11of target bacteria at an 0.0 600 nm 0.1 in a blocking buffer of 2% bovine serum
albumin (BSA) in PBS followed by 5 1-11of IgG-depleted human serum/plasma
(2.10.4) and the mixture incubated for 30 min with shaking (900 rpm) at 25.0°C
using a IEMs plate shaking incubator. This was then centrifuged at 3050g for 5
min and the supernatant removed and the pellet was then washed with 200 1-11of
blocking buffer. This was repeated twice before the addition of 200 1-11FITC-
labelled polyclonal sheep anti-human C3b/iC3b (Abcam) at 1:500 in blocking
buffer. This was incubated for 20 min at 4°C, before being washed twice more with
blocking buffer. The samples were then analysed by flow cytometry.
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2.9.3 CDA using a secondary antibody.
Antibody-mediated complement deposition on the surface of meningococci was
measured using a flow cytometric assay performed in U-bottom 96-well microtitre
plates. For the assay, 5 1-11 of each test serum (heat inactivated) was added to 90
1-11 of target bacteria at an 0.0 600 nm 0.1 in blocking buffer containing 2% BSA in
PBS followed by 5 1-11 of IgG-depleted human serum/plasma and the mixture
incubated for 30 min with shaking (900 rpm) at 25.0°C using a IEMs plate shaking
incubator. This was then centrifuged at 3050g for 5 min and the supernatant
removed and the pellet washed with 200 1-11 of blocking buffer. This was repeated
twice before the addition of either 200 1-11 anti-human mAb C3b/iC3b (Abcam) at
1:500 in blocking buffer or anti human mAb C5b-9 (Quidel) at 1:2000 in blocking
buffer. This was incubated for 20 min at 4°C, before being washed twice more with
blocking buffer. FITC-Iabelled anti-human IgG (Jackson Immunoresearch) at 1:500
in blocking buffer was incubated for 20 min at 4°C, before being washed twice
more with blocking buffer. The samples were then analysed by flow cytometry.
2.9.4 Duplexed complement deposition assay (dCDA). final method.
Antibody-mediated complement deposition on the surface of meningococci was
measured using a flow cytometric assay performed in U-bottom 96-well microtitre
plates. For the assay, 5 1-11 of each test serum (heat inactivated) was added to 90
1-11 of target bacteria at an 0.0 600 nm 0.1 in blocking buffer of 2% BSA in PBS
followed by 5 1-11 of IgG-depleted human serum/plasma and the mixture incubated
for 45 min with shaking (900 rpm) at 3rC using a IEMs plate shaking incubator.
This was then centrifuged at 3050g for 5 min and the supernatant removed and
the pellet washed with 200 1-11 of blocking buffer. This was repeated twice before
the addition of 200 1-11 anti-human C3b/iC3b (Abcam, UK) at 1:500 in blocking
buffer and anti human C5b-9 (Quidel, USA) at 1:2000 in blocking buffer. This was
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incubated for 20 min at 4°C, before being washed twice more with blocking buffer.
FITC-Iabelled anti-mouse IgG (Jackson Immunoresearch, UK) at 1:500 in blocking
buffer was incubated for 20 min at 4°C, before being washed twice more with
blocking buffer. The samples can then be analysed by flow cytometry.
2.9.5 Total haemolytic complement activity radial immunodiffusion assay
Complement function was determined using a total haemolytic complement radial
immunodiffusion assay kit (Binding Site, UK). Lyophilised calibrator and control
samples were reconstituted using distilled water to the indicated volume on the
vial, and all samples are kept pre-cooled on ice prior to the assay. 5 ~I of neat test
sample, calibrator dilutions (three doubling dilutions) or control samples were
added to wells of a sheep erythrocyte gel sensitised with anti-sheep erythrocyte
antibody and incubated overnight at 4°C before incubating at 3rc for 30 min. The
diameter of the lysis rings was then measured and calibrator dilutions plotted and
the complement activity calculated in CH100 units/ml from the standard curve.
2.9.6 Measurement of the alternative complement cascade using a radial
immunodiffusion assay
Alternative complement pathway activity was determined using an alternative
haemolytic complement radial immunodiffusion assay kit (Binding site, UK).
Lyophilised calibrator and control samples were reconstituted using distilled water
to the indicated volume on the vial, and all samples are kept pre-cooled on ice
prior to the assay. 5 ~I of neat test sample, calibrator dilutions (three doubling
dilutions) or control samples were added to wells of a sheep erythrocyte gel.
Incubate overnight at 4°C before incubating at 3rc for 30 minutes. The diameters
of the lysis rings were then measured and calibrator dilutions plotted and the
complement activity calculated from the standard curve.
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2.9.7 OPA- original method
Opsonophagocytosis (OP) of meningococci by HL-60 cells which had been
granulocytically differentiated with 0.8% (v/v) DMF for 5 days (2.5.4), was
measured using a flow cytometric assay performed in U-bottom 96-well microtitre
plates. 20 jJl of each test serum (heat inactivated) was diluted 1:10 in OP buffer
(Hanks balanced salts solution containing 2% (w/v) skimmed milk powder, 1.2 mM
CaCI2, and 1 mM MgS04) and added to 10 jJl BCECF-AM labelled N. meningtidis
(2.3.1) at 6.25 x 10B bacteria/ml in OP buffer, followed by 10 jJl of baby rabbit
complement and incubated for 7.5 min with shaking (900 rpm) at 37.0°C.
Differentiated HL60 cells, (American Type Cultures Collection, Rockville MD, USA)
at 2.5 x 107 cells/ml in OP buffer (50 jJl) were added and incubation continued,
with shaking, at 37.0°C for 7.5 min. OP was stopped by addition of 80 jJl of ice-
cold Dulbecco's PBS containing 0.02% (w/v) EDTA. The samples were then
analysed by flow cytometry.
2.9.8 Duplexed respiratory burst assay (dRBA) final method.
DMF differentiated HL60 cells were incubated with 100 ng/ml IFNy for 45 minutes
at 3rC. The cells were then centrifuged at 500g for 5 min before being
resuspended in HBSS with 50 jJg/ml dihydrodamine 123 (DHR123) stain and
incubated for 15 min with rotation to preload the cells with dye. 10 ul of DiIC1s(5)-
DS stained N. meningtidis at 6.25 x 10s bacteria/ml were incubated with 2 jJl sera
and 10 jJl IgG-depleted human plasma as a complement source in 18 jJl blocking
buffer (HBSS containing 2.0% skimmed milk, 1.2 mM CaCb, 1 mM MgS04), at
3rC for 7.5 min. 50 jJl DHR123 preloaded DMF-differentiated HL60 cells at 2.5 x
107 cells/ml were added and incubated at 3rC for a further 7.5 min. The assay
was then stopped with addition of 80 jJl of ice-cold Dulbecco phosphate-buffered
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saline containing 0.02% (w/v) EDTA. The samples were then analysed by flow
cytometry.
2.9.9 Opsonophagocytic killing assay (OPKA)
This assay was based on the method described by Plested and Granoff (2008). N.
meningitidis, stored at -70cC in Frantz media containing 30% (v/v) glycerol, were
thawed and grown on horse blood agar overnight at 3rC with 5% CO2. This was
used to inoculate 10 ml of Frantz media both with and without 0.5 mg/ml EDDHA
for iron restriction, and incubated at 3rC with shaking (180 rpm) for 4 h. Bacteria
were centrifuged and resuspended in BB before the OD 600 nm was measured and
the bacteria were diluted in BB to a concentration of 5 x 104 CFU/ml.
50 IJI of each dilution of heat inactivated serum was used in each well, with a
starting dilution of 1:2 which was diluted across the plate to a final dilution of
1:1024 using doubling dilutions. To this, 20 IJI of C7-depleted human complement
(Quidel) was added, together with 10 IJI of N. meningitidis at 5 x 104 CFU/ml to
give 500 CFU/well, and 20 IJI of DMF-differentiated HL60 cells. Each plate
contained a HL60 cell-only control, bacteria-only control, cell, bacteria and
complement-only controls in duplicate. Before the assay plate was incubated, 10
IJIof the control wells were transferred onto horse blood agar using the tilt method,
air dried and incubated overnight at 3rC with 5% CO2. The assay was then
incubated for 60 min at 3rC with shaking at 65 rpm. Each sample and control well
was then plated out onto horse blood agar using the tilt method, air dried and
incubated overnight at 3rC with 5% CO2. The following day colonies were
counted and a titre assigned to the reciprocal dilution which gave a >50% killing
compared with the bacteria, cells and complement-only control.
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2.9.10 SBA
The standard SBA protocol was used to assess the bactericidal activity of vaccine
sera (Findlow et al. 2006). N. meningitidis, stored at -70DC in Frantz media
containing 30%(v/v) glycerol, was thawed and grown on Columbia blood agar
overnight at 3rC with 5% C02 and then used to inoculate 10 ml Frantz media,
and incubated at 3rC with shaking (180 rpm) for 3 h. Bacteria were resuspended
in bactericidal buffer (BB), (Hanks buffered saline solution (invitrogen) and 1%
BSA (Sigma Aldrich)) before the OD 600 nm was measured and bacteria were
diluted in BB to a concentration of 6 x 104 CFU/ml.
20 1-11 of heat inactivated serum was used in each well, and from a starting dilution
of 1:2 was diluted across a microtitre plate to a final dilution of 1:1024 using
doubling dilutions. 10 IJI of 6 x 104 CFU/ml were added to every well followed by 10
IJI of human complement. Each test contained three controls: bacteria and
complement-only control, bacteria and heat inactivated complement-only control,
and test serum, bacteria and heat inactivated complement control. The assay was
then incubated at 3rC for 1 h with shaking at 65 rpm. Each sample and control
well was then plated out onto horse blood agar using the tilt method, air dried and
incubated overnight at 3rC with 5% CO2 The following day colonies were
counted and a titre assigned to the reciprocal dilution which gave a >50% killing
compared with the bacteria, and complement-only control.
2.9.11 Antibody (lgG, IgM, or IgA) ELISA
Antibody ELiSAs were performed using manufacturer's instructions (Bethyl
Laboratories). 100 1-11 of coating antibody (in ELISA coating buffer (2.1.2)) was
added to each well (96 well flat bottom plate) and incubated at room temperature
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(20-2S0C) for 1 h. The plate was then washed five times using ELISA wash
solution. 200 ~I of ELISA blocking buffer was added to each well and the plate
incubated for 30 min at room temperature (20-2S0C) before being washed a further
five times with ELISA wash buffer. 100 ~I of, either standard, or assay sample was
added to each well and incubated at room temperature (20-2S0C) for 1 h. The
plate was then washed five times using ELISA wash solution. 100 ~I horse raddish
peroxidise conjugated detection antibody was added to each well incubated for 1 h
at room temperature (20-2S0C) and then 100 ~I of 3,3',S,S'-Tetramethylbenzidine
substrate solution was added to each well. The plate was left in the dark to
develop for 15 min before the reaction was stopped using ELISA stop solution
(2.1.2). Sample absorbance was measured at 450 nm (within 1 h of assay
completion) and the OD of the standard curve used to extrapolate the sample
concentration.
2.9.12 IgG subclass ELISA
IgG subclass ELiSAs were performed using manufacturer's instructions
(Invitrogen). SO~I of coating antibody (in ELISA coating buffer) are added to each
well (96 well flat bottom plate), SO ~I of test sample or assay standard, and then
incubated at room temperature (20-25°C) for 30 min. The plate was then washed
three times using ELISA wash solution. 100 1-11 HRP detection antibody was added
to each well incubated for 30 min at room temperature (20-25°C). The plate was
then washed three times using ELISA wash solution and then 100 1-11 of TMB
substrate solution was added to each well. The plate was left in the dark to
develop for 10 min before the reaction was stopped using ELISA stop solution.
Sample absorbance was measured at 4S0 nm (within 1 hour of assay completion)
and the OD of the standard curve used to extrapolate the sample concentration.
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2.9.13 C1q ELISA
C1q ELlSAs were performed using manufacturer's instructions (Hycult, UK). 1001-11
of test sample or assay standard are added to precoated wells, and then
incubated at room temperature (20-25°C) for 60 min. The plate was then washed
four times using ELISA wash solution. 100 1-11biotinylated detection antibody was
added to each well incubated for 60 min at room temperature (20-25°C). The plate
was then washed three times using ELISA wash solution and then 100 1-11of
streptavidin-peroxidase. Finally 100 1-11of TMB substrate solution was added to
each well. The plate was left in the dark to develop for 20 min before the reaction
was stopped using ELISA stop solution. Sample absorbance was measured at 450
nm (within 1 hour of assay completion) and the OD of the standard curve used to
extrapolate the sample concentration.
2.10 Complement
2.10.1 Collection of plasma or serum
Volunteer blood was taken using appropriate Vacutainer tubes (Becton Dickinson,
UK) containing either: heparin, EDTA (anticoagulants), silica (clot activator) or no
additive. Following collection, tubes without additive had 100 I-Ig/ml of the anti-
coagulant lepirudin (Movianto, UK) added. Tubes were then centrifuged at 1000g
for 10 min to pellet the cells, the plasma, or serum was then removed and stored
at -80°C.
2.10.2 Antibody depletion of human plasma initial method
IgG depletion of heparinised plasma was performed on ice and utilised a column
containing 1 ml of ProteinG-Sepharose (Amersham Biosciences, UK). Using a 5
ml syringe, four column volumes of HBSS were pushed through the column to
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remove the 20% (v/v) ethanol storage buffer. Very slowly, a 1 ml aliquot of
complement source (human plasma or Pel-freez baby rabbit complement) was
loaded onto the column to allow IgG binding and the column was incubated on ice
for 5 min. 1 ml of ice-cold HBSS was pushed through the column to displace the
plasma/complement and the eluent collected and stored on ice for immediate use.
Four column volumes of HBSS was passed through to clean the column, followed
by four column volumes elution buffer and finally two column volumes of 20% (v/v)
ethanol storage solution and the column stored at 4°C (Taylor 2010).
2.10.3 Antibody depletion of human plasma method during development
Antibody depletion of plasma or serum was performed on ice and utilised a column
containing 1 ml of either Protein G, A or L Sepharose (Amersham Biosciences,
UK). Using a 5 ml syringe, four column volumes HBSS was pushed through the
column to remove the 20% (v/v) ethanol storage buffer. Very slowly, a 1 ml aliquot
of complement source was loaded onto the column to allow IgG binding and the
column incubated on ice for 5 min. 1 ml of ice-cold HBSS was pushed through the
column to displace the plasma/complement and the eluent collected and stored on
ice for immediate use. Four column volumes of HBSS were passed through to
clean the column, followed by four column volumes elution buffer and finally two
column volumes of 20% ethanol storage solution and the column stored at 4°C.
2.10.4 Antibody depletion of human plasma, final method
Volunteers gave blood which was anti-coagulated with lepirudin. Donors
consented to give blood and for it to be used for research, samples were taken
and anonymised by a trained phlebotomist. The sample was centrifuged at 500g
for 10 min and the supernatant was aliquoted and snap frozen until required for
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use. Lepirudin anti-coagulated human plasma was used as a complement source
and was antibody depleted using affinity chromatography with Protein G
Sepharose column. The column was equilibrated with three column volumes of
HBSS before one column volume of plasma was added (200 ml). This was
incubated for 5 min at 4°C before one column volume of HBSS was used to
displace the complement. The column was then washed with 3 column volumes of
elution buffer (0.2 M glycine pH 2.7 (HCI)) and incubated for 5 min at room
temperature before 3 column volumes of HBSS were used to displace the elution
buffer. The column was then stored in 20% in deionised water.
2.11 Flow cytometry
All assays were analysed using a Beckman Coulter FC500 flow cytometer
equipped with a 96-well microtitre plate reader.
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2.11.1 Data Analysis using MXP software (Beckman Coulter): Gating
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Figure 2.11.1 Histogram to illustrate gating strategy used for flow cytometry
data analysis.
Histograms illustrate a complement only background control (A) and a
homologous positive control serum (8).
To analyse the data a horizontal gate (marked in fig. 2.11.1) was drawn to include
at approximately 10% of the background control fluorescence. A Fluorescence
Index (FI) was calculated for each sample, which involved the multiplication of the
% of cells moving into the horizontal gate (%-gated), by the average fluorescence
of that population (X-mean). From the example above and FI was calculated.
FI = 8.35 X 1.84 = 15.4 (figure 2.11.1).
A FI was generated for each test serum and the FI of the control was subtracted to
result in an FI-C value.
E.g. 97.10 X 55.6 = 5398.8 - 15.4 = 5383.4 (figure 2.11.1).
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2.11.2 Data Analysis using MXP software (Beckman Coulter): Compensation
Compensation was required in experiments which included two f1uorochromes,
and was done to eliminate any spectral overlap. Initially an unstained control was
used to align the background auto-fluorescence to the first log decade in a dot plot
of both fluorochromes (figure 2.11.2 A.). The x-mean and y-mean is taken on the
background sample (0.479, 0.461). A positive control for the single fluorochrome
sample was assessed (figure 2.11.2 S.) and shows spectral overlap in the second
fluorochrome channel (in this case FL4). The data can then be compensated using
the MXP software until the y-mean is within 0.1 of the background y-mean (figure
2.11.2 C).
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Figure 2.11.2 Method of Compensation when using two fluorochromes
within the same assay.
Histograms illustrate a background control (A), a homologous positive control for
a single fluorochrome, and data once compensation has been completed (C).
2.11.3 Data analysis used in the surface labeling assay (SLA)
The bacteria were identified on the cytometer by their forward scatter (size) and
side scatter (granularity) (figure 2.11.3.1). 7500 bacteria were analysed for
fluorescence and a horizontal gate was drawn to include 10% of the population in
the conjugate only control. A fluorescence index (FI) was calculated for all
samples by multiplying the % gated by the x-mean (fluorescence intensity).
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Duplicate samples were analysed and an average taken of the FI before
subtracting the FI of the conjugate only control.
, , , '" 100 ' "" "1'0' ' , , '" 102 ' "'10~
SSlog
Region I Number I%Gated I X-Mean IV-Mean I
ALL 5807 100.00 2.57 9.64
E 4390 75.60 2.13 5.52
A.
ro--~
en......c
ID
>
ID
'+-
0
~
ID
_o
E
:::J
Z
Fl1log
Region I Number I%Gated I X-Mean IV-Mean I
o,LL 4390 100.00 0.672 ###
B.
Figure 2.11.3.1 Gating strategy used in data analysis of a surface labeling
assay.
Histograms illustrate forward scatter and side scatter gating for bacteria (A) and
the background fluorescence observed in a bacteria and conjugate only control
(8).
Events
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Figure 2.11.3.2 Overlay plot of SLA data.
This indicates the typical fluorescence observed with a conjugate only control, low
responding serum and high responding serum.
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2.11.4 Complement deposition assay (COA)
N. meningitidis were identified on the cytometer by the forward scatter (size) and
side scatter (granularity) (figure 2.11.4.1). 7500 bacteria were analysed for
fluorescence and a horizontal gate was drawn to include 10% of the population in
the conjugate and complement only control. A fluorescence index (FI) was
calculated for all samples by multiplying the % gated by the x-mean (fluorescence
intensity). Duplicate samples were analysed and an average taken of the FI before
subtracting the FI of the complement only control.
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Figure 2.11.4.1 Gating strategy used in data analysis of a duplexed
complement deposition assay.
The histograms show the forward scatter and side scatter gating for the bacteria
(A) and the complement, bacteria and conjugate only control for both pAb
C3b/iC3b (FITC) (B) and mAb C5b-9 (Alexafluor 647) (C).
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Figure 2.11.4.2 Overlay plot of COA data.
This overlay indicates the typical fluorescence observed with a conjugate only
control, complement only control and high responding serum.
2.11.5 Opsonophagocytosis Assay (OPA)
The HL60 cells were identified on the cytometer using forward scatter (size) and
side scatter (granularity) (figure 2.11.5.1). 7500 HL60 cells were analysed for
fluorescence and a horizontal gate was drawn to include 10% of the population in
the complement only control. A fluorescence index (FI) was calculated for all
samples by multiplying the % gated by the x-mean (fluorescence intensity).
Duplicate samples were analysed and an average taken of the FI before
subtracting the FI of the complement only control.
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Figure 2.11.5.1 Gating strategy used in data analysis of a duplexed
complement deposition assay.
The histograms illustrate the forward scatter and side scatter gating used with the
HL60 cells (A) and the fluorescence observed in a cells and OiIC1s(5)-OS stained
bacteria only control (B).
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Figure 2.11.5.2 Overlay plot of OPA data.
This plot indicates a typical HL60 cells only control, complement only control and
high responding serum.
2.11.6 Respiratory burst assay
Following compensation, horizontal gates in the DiIC1s(5)-DS channel (APC
equivalent) of a flow cytometer (Beckman Coulter FC500) were set against a
complement-only, no-antibody control to include approximately 10% of the
population. Horizontal gates in the R123 channel (FITC equivalent) of a flow
cytometer (Beckman Coulter FC500) were set against a complement-only, no-
antibody control to include approximately 10% of the population For each sample,
7,500 live HL60 cells were measured, and the percentage of cells showing
fluorescence in the appropriate gates (% gated) was multiplied by the mean
fluorescence of the gated population (X-mean) to calculate a fluorescence index
(FI); the Complement only control was subtracted from the FI to give a FI-C'.
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2.12 Statistics
2.12.1 Z test
The data from the antibody surface binding assay, antibody-mediated complement
deposition assay, respiratory burst assay and opsonophagocytosis assay are
presented as means of duplicate samples. Data from these experiments were
analysed for significance using a Z test, which uses the variance of the assay
performed to calculate a test statistic, with a significant difference of P<0.05
represented by * and a significant difference of P<0.01 represented by ** unless
otherwise stated. All error bars on figures represent standard deviations unless
otherwise stated.
2.12.3 T-test
Statistical significance from ELISA and radial immunodiffusion assays was
calculated using a two sample T-test. A significant difference of P<0.05 was
represented by * and a significant difference of P<0.01 represented by **.
2.12.4 Pearson's correlation coefficient
Correlation between data was calculated using a Pearson's correlation providing a
correlation coefficient r. Significance was assessed by a students t test of P<0.05
unless otherwise stated.
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Chapter 3 Development of a Duplexed C3b/iC3b and C5b-9 Antibody-
mediated Complement Deposition Assay
3.1 Introduction
Complement plays an important role in protection against meningococcal disease.
It contains more than 30 proteins, which playa role in inflammation, chemotaxis,
and elimination of invading microorganisms by lysis or opsonisation, and plays a
role in the development of an antibody response, and enhances the immunological
memory response (Morgan et al. 2005).
A central role for SBA has been established in protection against meningococcal
disease (described in 1.4.1). The importance of complement is also emphasised
by the observed high susceptibility of complement deficient individuals to
meningococcal disease (Walport 2001). SBA is accepted as a correlate of
protection against meningococcal disease (Frasch et al. 2009) and is currently the
primary method used in the assessment of vaccine elicited responses. SBA
measures immune bactericidal lysis initiated by the classical pathway leading to
the deposition of C3b, which combines with either components from the classical
pathway or the alternative pathway to form a C5 convertase which cleaves C5 and
leads to the formation of the membrane attack complex (MAC). This assay has
some drawbacks: it requires large amounts of serum, the technique is laborious
requiring containment facilities and strain selection can be restricted as the assay
complement source kills some strains without addition of antibody.
Protection has been demonstrated in the absence of bactericidal antibody
(Platonov et al. 2003; Toropainen et a/. 2006; Welsch and Granoff 2007) and
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opsonophagocytosis has been suggested as an additional mechanism of bacterial
killing important in meningococcal disease.
Previous work has been conducted to develop an assay which measures the
antibody-mediated complement deposition of C3b/iC3b using a sheep anti human
C3b/iC3b polyclonal antibody (Biodesign) (Welsch et al. 2003; Taylor 2010).
This chapter describes the development of a duplexed complement deposition
assay measuring both the deposition of C3b/iC3b and C5b-9 as potential
indicators of opsonic and bactericidal antibody levels. In addition results from the
duplexed assay are correlated with the functional SBA and OP assays.
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3.2 Development of the assay
3.2.1 Measurement of C5b-9 antibody-mediated MAC deposition on
meningococci
Assays measuring the antibody-mediated deposition of C3b/iC3b on the surface of
meningococci have been previously described (Welsch et al. 2003; Findlow et al.
2006; Taylor 2010), and the aim of this study was to measure concurrently
antibody-mediated deposition of C5b-9 membrane attack complex and C3b/iC3b
then to correlate these two findings with SBA and OPA, respectively. Antibody-
mediated deposition of C3b/iC3b assay was performed as previously described
(2.9.2) and demonstrated antibody-mediated C3b/iC3b deposition with
homologous and heterologous sera against strain M01240149 with a low
deposition observed against an alhydrogel control serum (figure 3.2.1.1).
Two suitable monoelonal antibodies were identified which were able to detect C5b-
9 deposition. mAb SC5b-9 (Quidel) was raised against purified C9 and has been
shown to bind to a neoantigen only expressed on SC5b-9 (membrane attack
complex which has bound to an S protein), MAC (C5b-9), Poly-C9 and on
denatured C9 (Quidel product specification). This was compared with an
alternative mAb C5b-9 (Oako), which was raised against poly C9 in the terminal
complement complex (TCC). It has been shown to react with both membrane
bound C5b-9 and the fluid phase SC5b-9 (Dako product specification sheet).
As neither of the monoelonals were conjugated to an fluorochrome, FITC-Iabelled
secondary antibody was used, and the samples were analysed using flow
cytometry. Several dilutions of each mAb were used to determine whether C5b-9
deposition could be detected. Both mAbs were able to detect deposition of C5b-9
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on the surface of the bacteria (figure 3.2.1.2 and 3.2.1.3); the Dako mAb required
a 1:50 dilution whereas the Quidel mAb was able to detect deposition at 1:500. 10-
fold greater FI-C' values were obtained for binding at C3b/iC3b than with either
C5b-9 (figure 3.2.1.1, 3.2.1.2 and 3.2.1.3). This might be expected as the C5b-9 is
the terminal complement component and is made up of many of the final
components of the complement cascade and C3b/iC3b are generated by several
pathways (Walport 2001).
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Figure 3.2.1.1 Antibody mediated C3b/iC3b deposition on N. meningitidis.
Antibody-mediated deposition of C3b/iC3b (1:500) on the surface of N.
meningitidis M01-240149 as detected by pAb FITC labelled sheep anti-human
C3b/iC3b. n=2 and error bars denote standard deviation.
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Figure 3.2.1.2 Antibody mediated C5b-9 deposition on N. meningitidis with
Quidel mAb.
Antibody-mediated deposition of C5b-9 on the surface of N. meningitidis
M01240149 as detected by Quidel mAb with a secondary label of FITC goat anti-
mouse IgG conjugate. n=2 and error bars denote standard deviation.
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Figure 3.2.1.3 Antibody mediated C5b-9 deposition on N. meningitidis with
Dako mAb.
Antibody-mediated deposition of C5b-9 on the surface of N. meningitidis
M01240149 as detected by the Dako mAb with a secondary label of FITC goat
anti-mouse IgG conjugate. n=2 and error bars denote standard deviation.
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3.2.2 Correlation of C5b-9 CDA with the SBA.
As both of the tested monoclonals were able to bind to both lytic and non-lytic
forms of the MAC, a correlation with the functional bactericidal assay (2.9.10) was
determined. A serum panel including a positive control rabbit serum and a
selection of high, medium, and low responding human sera were used to assess
each mAb. The antibody-dependent deposition of C5b-9 measured with either the
Quidel mAb or the Dako mAb was compared with the bactericidal titres obtained
against the same N. meningitidis strain M01240149. SBA titres and complement
deposition FI-C' values were Log10 transformed to align these ordinal and
continuous data sets and a Pearson product moment correlation coefficient was
calculated to establish the relationship between the bactericidal titre and the
measured deposition of C5b-9 (2.12.4).
The antibody-mediated deposition of C5b-9 measured by the Dako mAb had a
non- significant correlation (r=0.43), suggesting that this mAb had a poor ability to
distinguish between sera able to induce a high bactericidal response and sera
without a bactericidal response (figure 3.2.2.1). This result was consistent with
Drogari-Apiranthitou et al. who showed this mAb was unable to demonstrate a
relationship between the amount of C5b-9 detected on the bacterial surface and
the bactericidal titre (Drogari-Apiranthitou et al. 2002). Drogari-Apiranthitou et al.
(2007) used the Dako mAb in a study comparing C5b-9 deposition mediated by
sera with or without an SBA titre and showed higher C5b-9 deposition in a high
SBA titre serum compared to sera with low SBA activity. However, when using
mAb PorA in a dose-dependent manner, they were able to induce dose-dependent
bacterial lysis but not C5b-9 deposition.
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The antibody-mediated complement deposition measured using the Quidel mAb
was significantly correlated with bactericidal titre (r= D.77, P<D.D5) (figure 3.2.2.2)
and was therefore used for all further assay development.
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Figure 3.2.2.1 Correlation between log10 bactericidal titre and the log10 FI-C'
antibody-mediated deposition of C5b-9 measured using the Dako mAb
(r=0.43). Thick blue circle indicates where two points overlay.
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3.2.3 Conjugation of monoclonal antibody C5b-9.
The use of mAb C5b-9 (Quidel) and pAb C3b/iC3b antibodies in the same
duplexed assay required each antibody to be conjugated to a different
fluorochrome. This was advantageous to minimise the use of scarce reagents
such as serum and complement. pAb sheep anti human C3b/iC3b antibody was
purchased already conjugated to FITC, the Quidel mAb C5b-9 was only available
to purchase unconjugated, and therefore the conjugation method and the use of
an appropriate fluorochrome were investigated to be compatible with analysis
using the 2 laser Beckman Coulter FC500 flow cytometer. Ideally the fluorochrome
would be spectrally separate from FITC which is excited by the 488 nm laser. It
would be advantageous to use a fluorochrome excited by the 633 nm laser as this
would reduce or even negate the requirement for compensation, a procedure
which removes all spectral overlap from the flow cytometry results. Firstly a Zenon
Alexa fluor 647 nm labelling kit (Invitrogen) was used (2.8.1), which uses labelled
Fab fragments directed against the Fc portion of the antibody being conjugated (in
this case IgG2b). Any excess labelled Fab fragments remaining in solution are
then removed by gel filtration. This system has an advantage over directly labelling
the antibody as the process takes only 5 min. Labelling intensity can also be
altered by adjusting the concentration of labelled Fab fragments added to the test
antibody until a saturation point is reached.
The manufacturer's guidelines were followed for calculation of appropriate
amounts of Zenon Alexa flour 647nm labelled Fab fragments. A large Stokes shift
was observed between antibody-mediated C5b-9 deposition by the homologous
OMV rabbit serum compared to the complement only background control (figure
3.2.3.1) when using Zenon Alexa flour 647nm conjugated C5b-9 mAb. The
conjugation was repeated using the same method, however on several occasions
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the staining procedure failed, leading to the conclusion that this would not be a
consistent way of labelling the antibody.
In order to obtain a large volume of fluorescently labelled conjugate, which could
be used for all assays in this study thus improving assay reproducibility, the
Invitrogen custom conjugation service was used. Alexa fluor 647 fluorochrome
was chosen as it was excited by the 633 nm laser and was spectrally different
from the FITC-Iabelled C3b/iC3b conjugate, which was excited by the 488 nm
laser (figure 3.2.3.3), thus reducing the amount of compensation required during
analysis of COA results. Use of the custom conjugated antibody in a COA showed
a detectable Stokes shift of antibody-mediated complement deposition of C5b-9 on
to N. meningitidis 44176-SL by the OMV positive rabbit serum compared with the
complement only background control (figure 3.2.3.2).
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Figure 3.2.3.1 Overlay plot of C5b-9 deposition measured by Zenon labelled
C5b-9 mAb.
Overlay plot of antibody-mediated deposition of C5b-9 on N. meningitidis 44176-SL
showing a complement only control (black) and a positive OMV rabbit control
serum (purple) using Zenon 647 nm labelled mAb C5b-9 (Quidel).
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Figure 3.2.3.2 Overlay plot of C5b-9 deposition measured by Alexa fluor 647
labelled mAb.
Antibody-mediated deposition of C5b-9 deposition on N. meningitidis 44176-SL of
a complement only control (black) and a positive OMV rabbit control serum
(purple) using custom conjugated Alexa fluor 647 mAb C5b-9 (Quidel).
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3.2.4 Titration of monoclonal antibody C5b-9.
Following the successful conjugation of the mAb, a titration was performed to
identify the optimal antibody concentration for use in the assay. A COA was
performed against N. meningitidis 44176-SL using a range of mAb C5b-9 dilutions
from 1:100 to 1:16000. Antibody-mediated C5b-9 deposition on N. meningitidis
44/76-SL with homologous strain OMV rabbit control serum showed the response
began to decrease at the 1:4000 dilution with the optimal dilution found to be
1:2000 (figure 3.2.4.1). A significantly better response (Z-test) was observed at a
dilution of 1:2000 than using the conjugate at 1:4000 (P <0.01).
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Figure 3.2.4.1 Optimisation of antibody dilution for detection of C5b-9
deposition.
Antibody-mediated deposition of C5b-9 using OMV homologous rabbit control
serum on N. meningitidis 44/76-SL measured using different mAb C5b-9 conjugate
concentrations. Significance was determined by z-test (**P<O.01), and error bars
denote standard deviation.
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3.2.5 Correlation of antibody surface binding on killed or live N. meningitidis.
The use of killed bacteria has advantages as it allows the ability to grow and kill a
large stock for use over a large study, and it means that assays can be performed
without containment, eliminating variation between cultures, which is a
considerable problem when using N. meningitidis (Bai and Borrow 2010). It also
enables the assay to be performed outside of containment in a high throughput
manner, an important aspect of any assay required to assess large panels of sera
against a panel of strains. However, there have been concerns that killing the
bacteria could lead to normally hidden epitopes being exposed on the bacterial
surface. Michaelsen et al. (2001) described the effects of a variety of different
killing methods on the exposure of the PorB3 epitope, illustrating that ethanol
fixation and heat killing methods were very damaging to the bacterial surface and
altered the exposure of PorB3. Thus a comparison was made between the killing
method (2.3.1) utilised for the N. meningitidis used in this assay (azide/PMSF),
with live bacteria. Azide/PMSF bacterial killing method (2.3.1) was developed to
minimise any disturbance of surface epitopes with the azide acting by irreversibly
binding cytochrome c and therefore preventing respiration. PMSF was introduced
to prevent any protease degradation of surface proteins. The comparison between
killing methods was conducted using a total antibody surface binding assay,
(2.9.1) with a panel of low, medium and high responding human sera. Live and
azide killed bacteria were incubated with sera, washed and incubated with anti-
human-FITC conjugate and then fixed with 2% formaldehyde for 1 h and analysed
by flow cytometry. Total IgG binding for each test sera was compared between live
and azide killed bacteria (figure 3.2.5.1).
A significant positive correlation was observed between the total antibody binding
measured with live N. meningitidis against that measured with azide/PMSF-kilied
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bacteria (r= 0.93, P <0.01) (figure 3.2.5.1). Azide-killed bacteria showed a higher
FI-C than the live bacteria. This could be possibly due to disruption of capsule by
the killing process, but because of the high correlation any conclusions drawn
about the response would be similar in either live or killed bacteria. However this
reinforces the need to compare data obtained using killed bacteria with data
obtained with live organisms, particularly where killing is the readout of the
functional assay.
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Figure 3.2.5.1 Correlation of total antibody binding between live and killed N.
meningitidis.
Correlation of total antibody surface binding on live N. meningitidis strain H44176
with azide/PMSF-killed N. meningitidis strain H44/76 (r=O.93, P<O.01).
Significance was determined by t-test.
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3.2.6 Duplexing the measurement of C3b/iC3b and C5b-S.
Duplexing the measurement of G3b/iG3b and G5b-9 required care to ensure that
the complement deposition determined following duplexing was equivalent to
C3b/iC3b or C5b-9 deposition determined in isolation. Duplexing of the flow
cytometry analyses risks false readings resulting from either steric hindrance or
from fluorescence resonance energy transfer (FRET). FRET occurs when two
fluorochromes are 5 nm or closer and usually occurs between fluorochromes with
similar emission spectra (Szollosi et a/. 1998), this was not expected due to the
chosen fluorochromes; but was investigated. A duplexed assay was performed
(2.9.4) alongside separate assays measuring the G3b/iC3b (2.9.2) and C5b-9
deposition (2.9.3) and the results compared.
Antibody-mediated deposition of G3b/iG3b on to N. meningitidis M01240149
measured in the duplexed assay, correlated highly with the assay measuring this
response individually (r=O.99, P<O.01) (figure 3.2.6.1 a). The antibody-mediated
deposition of C5b-9 measured in the duplexed assay also correlated strongly with
the individual assay (r=O.95, P<O.01) (figure 3.2.6.1 b). Differences between the FI-
G' values could be seen in the measurement of G5b-9 deposition, with the
duplexed responses lower, possibly as a result of the small amount of
compensation applied to the data during analysis to remove spectral overlap
between the two fluorochromes used to label the antibodies. Therefore it was
concluded that the duplexed assay could be utilised.
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Figure 3.2.6.1 Correlation of duplexed antibody-mediated C3b/iC3b and C5b-
9 deposition on N. meningitidis M01240149 in comparison with C3b/iC3b
measured separately (r=0.99, P<0.01) (a) and C5b-9 measured separately
(r=0.95, P<0.01) (b).
Significance was determined by t-test.
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3.3 Optimisation
3.3.1 Optimisation of duplexed complement deposition assay - effect of
incubation time and temperature.
Previously published assays for measurement of antibody mediated C3b/iC3b
deposition were performed at 25°C (Welsch et al. 2003; Taylor 2010). However,
OPA and SBA both measure the functional effect of complement and are
incubated at 37°C, the biologically relevant temperature. The effect of
temperature was therefore investigated.
OPA uses 7.5 min incubation for opsonisation of antibody and initiation of
complement deposition (C3b/iC3b), whereas the SBA uses an incubation of 60
min for the deposition of C5b-9 membrane attack complex to measure bacterial
killing. Thus the optimal incubation time point for use in this duplexed assay was
investigated. The COA was performed at both 25°C and 3rC from 7.5 min up to
60 min.
There was a significant increase (P<0.05) in the deposition of C5b-9 and
C3b/iC3b when the assay incubation temperature was changed from 25°C to
3rC (figure 3.3.1.2 and 3.3.1.1 A-E). Thus the results supported the use of 3rC
for the first assay incubation temperature to provide the optimal response.
A smaller Stokes shift was observed when comparing C3b/iC3b deposition in the
complement only control and the homologous rabbit positive control serum at
25°C, than at 3rC (figure 3.3.1.4 and 3.3.1.5). This pattern was also seen when
comparing the deposition of C5b-9 (figure 3.3.1.6 and 3.3.1.7). Once again the
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peak shift between the controls and the positive rabbit serum was greater at
3rC than at 25°C.
Different incubation time points were tested at 3rC showing significant (P<0.05)
increases in antibody-mediated deposition of C5b-9 between 7.5 min and 15
min, 15 min and 30 min for homologous rabbit positive control serum tested. A
significant (P<0.05) increase in response between 30 min and 45 min was
observed (figure 3.3.1.3a). This pattern was also observed in the deposition of
C3bliC3b (figure 3.3.1.3b). There was no significant increase in response
observed following 60 min incubation. Therefore 45 min incubation gave the
optimum deposition of C5b-9. Deposition of C3b/iC3b was optimal at 30 min,
however an incubation of 45 min did not cause any significant difference
(P<0.05) in the deposition of C3b/iC3b.
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Figure 3.3.1.2 Optimisation of incubation temperature for C5b-9 deposition in
the first assay incubation.
Effect of incubation time at 25°C or 3rC antibody-mediated deposition of C5b-9
on N. meningitidis M01240149. Significance was determined by z-test (**P<O.01),
and error bars denote standard deviation.
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Figure 3.3.1.4 Overlay plot of antibody-mediated deposition of C3b/iC3b
following incubation at 37°C.
Assay performed with N. meningitidis M01240149.
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Figure 3.3.1.5 Overlay plot of antibody-mediated deposition of C3b/iC3b
following incubation at 25°C.
Assay performed with N. meningitidis M01240149.
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Figure 3.3.1.7 Overlay plot of antibody-mediated deposition of C5b-9
following incubation at 25°C.
Assay performedwith N. meningitidis M01240149.
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3.3.2 Comparison of antibody-mediated complement deposition at 25°C and
37°C and correlation with SBA.
The optimal temperature in the first assay incubation time point for the greatest
response (antibody-mediated complement deposition) was observed at 3rC.
Thus a study was performed to evaluate whether this change in temperature from
25°C affected the correlation of antibody-mediated complement deposition of C5b-
9 with SBA and OPA with C3b/iC3b, and whether the temperature change affected
assay reproducibility. A panel of 16 sera consisting of low, medium and high
responding human sera and rabbit sera homologous (high SBA) and heterologous
(low SBA) to the N. meningitidis test strain (M01240149) were assayed. Each
serum was assayed in duplicate and the assay was repeated three times by a
single operator and the results analysed.
Greater assay variation was observed in C3b/iC3b deposition at 3rC than at 25°C
(table 3.3.2.1), with more duplicates showing a higher % CoV. This pattern was
repeated in the antibody-mediated C5b-9 deposition results (table 3.3.2.2).
The correlation between antibody-mediated C5b-9 deposition and SBA titre was
higher at 3rC than at 25°C (r=O.84, P<O.05 at 3rC and r=O.54 at 25°C) (figure
3.3.2.3 and 3.3.2.4). This was also seen when measuring antibody-mediated
C3b/iC3b deposition and OPA (r=O.93, P<O.05 at 3rC and r=O.76, P<O.05 at
25°C) (figure 3.3.2.1 and 3.3.2.2).
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Intra-assay variability at 25°C <15% <35% >35%
16 sera in duplicate,
performed three times by 16 Sera with defined CoY 13 1 2
one operator on one day.
n=42
Intra-assay variability at 37°C <15% <35% >35%
16 sera in duplicate,
2 8performed three times 16 Sera with defined CoY 6
by one operator on one
day. n=42
Table 3.3.2.1 Summary of the CoV for the antibody-mediated C3b/iC3b
deposition at 25°C and 37°C.
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Figure 3.3.2.1 Correlation between OPA and C3b/iC3b deposition performed
at 37°C.
Correlation of antibody-mediated C3b/iC3b deposition on N. meningitidis
M01240149 performed at 3rC, with the OPA with 16 human sera (r=0.93,
P<0.05). Significance was determined by t-test.
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Figure 3.3.2.2 Correlation between OPA and C3b/iC3b deposition performed
at 25°C.
Correlation of antibody-mediated C3b/iC3b deposition on N. meningitidis
M01240149 performed at 25°C, with the OPA with 16 human sera (r=O.76,
P<O.05). Significance was determined by t-test.
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Coefficient of Variance (%)
Intra-assay variability at 25°C <15% >35%
16 Sera with defined CoV
<35%
2
16 sera in duplicate,
performed three times by
one operator on one day.
n=42
7 7
16 Sera with defined CoV
<35%
4
Intra-assay variability at 37°C <15% >35%
16 sera in duplicate,
performed three times
by one operator on one
day. n=42
6 6
Table 3.3.2.2 Summary of the CoY for the antibody-mediated C5b-9
deposition for 25°C and 37°C.
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Figure 3.3.2.3 Correlation between SBA and C5b-9 deposition performed at
37°C.
Correlation of antibody-mediated C5b-9 deposition on N. meningitidis M01240149
and SBA titre at 3rC with 16 human sera (r=O.84, P<O.05). Significance was
determined by t-test.
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Figure 3.3.2.4 Correlation between SBA and C5b-9 deposition performed at
25°C.
Correlation of antibody-mediated C5b-9 deposition on N. meningitidis M01240149
and SBA titre at 25°C with 16 human sera (r=O.54, P<O.05). Significance was
determined by t-test.
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3.3.3 Optimisation of incubation time for anti C3b/iC3b and C5b-9 conjugates
in the antibody-mediated complement deposition assay.
Following optimisation of the first incubation step combining serum, complement
and bacteria, the effect of incubation time with conjugate was also determined at
4°C, and was performed either with shaking at 900 rpm or stationary. The second
incubation temperature was kept at 4°C to prevent any further complement being
deposited on the bacterial surface. Significantly higher antibody-mediated C5b-9
deposition responses were observed following 20 minutes incubation with anti-
C5b-9, than at 10 min or 30 min (P<0.05) (figure 3.3.3.1 a). There was no
significant difference in the deposition of C3b/iC3b observed between any of the
incubation times tested (figure 3.3.3.1 b). Thus a second incubation of 20 min at
4°C would be adopted for the duplexed assay.
The effect of incubation with or without shaking was also determined. No
significant difference in deposition of C5b-9 (figure 3.3.3.2a) and C3b/iC3b (figure
3.3.3.2b) was observed with and without shaking. Thus the second incubation step
was maintained at 4°C without shaking.
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Figure 3.3.3.1 Effect of conjugate incubation time on antibody-mediated C5b-
9 (a) and C3b/iC3b (b) deposition on N. meningitidis M01240149.
Sera are rabbit or mouse sera raised against M01240149 OMVs. Significance was
determined by z-test (*P<O.05), and error bars denote standard deviation.
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Figure 3.3.3.2 Effect of incubation with or without shaking on antibody-
mediated C5b-9 (a) or C3b/iC3b (b) deposition on N. meningitidis
M01240149.
Sera are rabbit or mouse sera raised against M01240149 OMVs. Significance was
determined by z-test and error bars denote standard deviation.
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3.4 Precision of duplexed complement deposition assay measuring both
deposition of C3b/iC3band C5b-9.
The reproducibility of the duplexed assay was assessed using a panel of 20 low,
medium and high responding human sera and sera from rabbits raised against
homologous and heterologous OMVs to the test strain. These assays were
completed by three operators in triplicate, on three separate days, and data for
each serum was analysed to assess the precision of results. All assays were
conducted using the same sera and complement source and then analysed using
the same flow cytometer and protocol. The results were then analysed and the
coefficient of variance (CoV) calculated.
The intra-assay variability was low for antibody-mediated C3b/iC3b deposition,
with 14 sera with a CoV less than 15%, and the remaining sera all demonstrating
CoV less than 35%. There was more variation observed when this was assessed
with one operator completing three assays over three days, this was anticipated
and still remained acceptable with 16 out of 20 of the sera demonstrating CoV less
than 35% (table 3.4.1).
The intra-assay and inter-assay variability was low for antibody-mediated C5b-9
deposition, with 16 out of 20 sera showing CoV less than 35%. The inter-operator
variability was again acceptable with the 19 out of 20 sera with CoVs less than
35%. (table 3.4.2). This data was correlated with the bactericidal titre once again
and showed a highly significant correlation (r=0.82, P<0.01) (figure 3.4.1).
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Coefficient of Variance (%)
Intra-assay variability <15% <35% >36%
20 sera in duplicate,
performed three times by 20 Sera with defined CV 14 6 0
one operator on one day.
n=60
Inter-assay variability
<15% <35% >36%
20 sera in duplicate,
performed three times 20 Sera with defined CV 3 13 4
by one operator on
three days. n= 180
Inter-operator variability <15% <35% >36%
20 sera in duplicate,
20 Sera with defined CV 14 5 1performed three times by
three operators on one day.
n=180
Table 3.4.1 Assay precision for antibody mediated C3b/iC3b deposition.
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Coefficient of Variance (%)
Intra-assay variability <15% <35% >36%
20 sera in duplicate,
performed three times by 20 Sera with defined CV 15 5 0
one operator on one day.
n=60
Inter-assay variability
<15% <35% >36%
20 sera in duplicate,
2 15performed three times 20 Sera with defined CV 3
by one operator on
three days. n= 180
Inter-operator variability <15% <35% >36%
20 sera in duplicate,
20 Sera with defined CV 7 10 3performed three times by
three operators on one day.
n=180
Table 3.4.2 Assay precision for antibody mediated C5b-9 deposition.
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Figure 3.4.1 Correlation of SBA with C5b-9 deposition in optimised assay
conditions.
Correlation of antibody-mediated C5b-9 deposition and bactericidal titre with a
panel of 20 human sera and N. meningitidis M01240149 (r=0.82, P<0.05).
Significance was determined by t-test.
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3.5 Correlation of C5b-9 deposition with N. meningtidis H44/76 and
M01240185.
The correlation of C5b-9 deposition and bactericidal titres is important to evaluate
the fitness of the assay for more than one meningococcal strain. A significant
correlation has already been demonstrated with C5b-9 deposition and bactericidal
titres with N. meningitidis M01240149 (3.4.3). Using a panel of 40 high, medium
and low responding sera, bactericidal titres were correlated with C5b-9 deposition
with N. meningitidis H44/76 and M01240185.
Significant positive correlations were found with both H44/76 and M01240185
(figure 3.5.1). The correlation of C5b-9 deposition and bactericidal titre was lower
with M01240185 (r=0.53, P<0.05), than H44/76 (r=0.78, P<0.05). Due to these
varying levels of correlation any strain that is going to be used in the dCDA would
need to be assessed for correlation with SBA.
Another important aspect of using the dCDA is relating the deposition of C5b-9 to
the protective bactericidal level which is accepted as ~1:4 (Goldschneider et al.
1969). A C5b-9 deposition level was assessed to establish a level where
approximately 75% of sera samples tested could be correctly defined as from
protected or unprotected individuals, a level which is consistent with the MATS
assay. This level of C5b-9 deposition was established at 2.3 log10 C5b-9
deposition for H44/76 and 2.25 log10 C5b-9 deposition for M01240185 (figure
3.5.1).
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Figure 3.5.1 Correlation of antibody-mediated C5b-9 deposition and
bactericidal titre with H44/76 and M01240185.
Correlation of antibody-mediated C5b-9 deposition and bactericidal titre with
H44/76 (r=O.78, P<O.05) (a) and M01240185 (r=O.53, P<O.05) (b).
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3.6 Application of duplexed antibody-mediated complement deposition
assay to evaluate a candidate meningococcal vaccine enriched in heat
shock proteins.
The key objective for development of novel meningococcal vaccines is to provide
cross-strain protection. The use of heat shock proteins (Hsps) has been suggested
as a potential meningococcal vaccine as they are molecular chaperones that bind
peptides, and are able to present these to the immune system. Hsps carrying
peptides are able to induce innate immune responses, activate dendritic cells,
upregulate surface expression of MHC, and are also capable of delivering
peptides to dendritic cells leading to MHC antigen presentation, and development
of adaptive immunity.
A vaccine has been designed with an enriched content of heat-shock proteins
purified from N. meningitidis or N. lactamica in collaboration with Immunobiology
Ltd. Mouse serum raised against these vaccines have been assessed in the
duplexed antibody-mediated complement deposition assay against a panel of
diverse UK meningococcal case isolates.
Antibody-mediated C5b-9 deposition showed that the Hsp vaccine developed from
N. lactamica to have the greatest C5b-9 deposition against all strains tested.
M01240355 and M01240185 demonstrated the greatest antibody-mediated C5b-9
deposition in the N. lactamica Hsp vaccine preparation in comparison to the N.
meningitidis Hsp vaccines and positive OMV rabbit control, with NLV3 and NLV1
preparations giving a significantly (P<O.01) greater result than the buffer only
control (figure 3.6.1). When antibody-mediated C5b-9 deposition for N.
meningitidis H44/76 was compared with the bactericidal results obtained with the
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same strain, both assays showed both of the N. lactamica Hsp vaccines to provide
the greatest activity (figure 3.6.2).
Antibody-mediated C3b/iC3b deposition also showed the Hsp-enriched vaccine
developed from N. lactamica to have the greatest C3b/iC3b deposition against all
strains tested. Again M01240355 and M01240185 demonstrated greater antibody-
mediated C3b/iC3b deposition in the N. lactamica Hsp-enriched vaccine
preparation in comparison to the N. meningitidis Hsp-enriched vaccines and
positive rabbit control, with NLV3 and NLV1 preparation giving a significantly
(P<0.01) greater result than the buffer only control (figure 3.6.3).
150
M01240101
I COO
900
BOO
700
600
:t5OO~4OO
lOO
200
100
o
n=2
**
**
M)1 Buffet' only NMV9 NM NI.. V1 Nt
240101 SERA
M01240013
** **
- II--fvlJl Bufr.only N'_'\i:I NMV10 NLV1 NLY3
2«Xt13 SERA
H44/76
1500
HotAn6 BuH~unly NM\Iti NMV10 NLVI NLVJ
**
1000 **
SERA
MeSS
1000
900
aoo
700
600
':1500
-400
lOO
200
100
o
**
MC58 Buff.,only NM\19 NMV10 NlV1 NlYJ
SfRA
M012403SS
**lDO
90
00
70
60
:t 50
- 40
30
20
10
o
**
M)1 8u(f.roniy NM'va NMV10 NlVI NLV3
2.t0355 SE RA
M012401SS
1000
**
000
600
M)I Suff•• only NM~ NMV10 NLVI NlV3
2£I) 240185
SERA
M01240149
500
'9)
400
]50
300
':1250
-200
19)
100
50
Mll Buff.ronly NM\18 NMV10 NLV1 NLV3
2«1149 SERA
**
NM VB- N. meningitidis Hsps in HEPES buffer
NM V10- N. meningitidis Hsps in HEPES+ADP buffer
NL V1- N. lactamica Hsps in HEPES buffer
NL V3- N. lactamica Hsps in HEPES+ADP buffer
Figure 3.6.1 Antibody-mediated C5b-9 deposition mediated by mouse sera
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** denotes significance (P<O.01) of vaccine in comparison to the buffer only
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deviation. All samples were performed in duplicate (n=2).
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153
3.7 Application of duplexed antibody-mediated complement deposition
assay to evaluate immunity induced by purified outer membrane protein
complexes.
Outer membrane protein complexes were purified by Marzoa et a/. so tha the
complexes retained their native structure. This was done using N. meningitidis
H44n6 and knockout mutants of this strain producing five different complexes:
CxASR (PorA/PorB/RmpM), CxAS (PorA/PorS), CxSR (PorB/RmpM), CxS (PorB)
and CxChap (Chaperonin MSP63). The dCDA along with an OPA and an SLA
were used to investigate the immune responses induced by these protein
complexes. Mouse sera raised against CxABR was able to induce antibody-
mediated C3b/iC3b and C5b-9 deposition, opsonophagocytosis and bactericidal
activity against the homologous strain, showing the greatest activity of the
complexes (figure 3.7.1). Mouse sera raised against CxChap showed lower levels
of antibody mediated C3b/iC3b and C5b-9 deposition in comparison with anti-
CxABR but was found to be cross-reactive with heterologous strains inducing high
levels of C3b/iC3b and C5b-9 deposition across a panel of six strains (figure
3.7.1b) (Marzoa etal. 2011).
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Figure 3.7.1 Evaluation of immunity induced by purified outer membrane
protein complexes by SLA, dCDA and OPA.
Results of total antibody binding (SLA), C3b/iC3b deposition, MAC deposition and
OPA with (a) N. meningitidis H44/76 with mouse sera raised against complexes.
Results are presented as a percentage of anti-H44176 OMV mouse sera. (b) A
panel of N. meningitidis strains with anti-CxChap mouse sera. Results are
presented as a percentage of anti-CxChap mouse sera against H44176.
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3.S Application of duplexed antibody-mediated complement deposition
assay to evaluate NHBA-GNA1030 stability.
The dCDA has also been used in a study investigating the structural
characteristics and stability of NHBA-GNA1030, a component of 4CMenB vaccine.
dCDA was used to assess the thermal stability of the fusion protein. Antibody-
mediated C3b/iC3b and C5b-9 deposition, with mouse sera raised against NHBA-
GNA 1030 before and after heat stress for 10 days at 37°C, showed a reduction in
the ability to induce antibody mediated complement deposition (figure 3.8.1), this
same trend was seen with the avidity ELISA measuring the total 19Gand also with
SBA (Martino et al. 2011).
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Figure 3.S.1 Antibody mediated C3b/iC3b and C5b-9 deposition assay with
mouse sera raised against anti-NHBA fusion protein before and after heat
stress against N. meningitidis M01-2401 01.
Significance was determined by z-test (*P<0.05), and error bars denote standard
deviation.
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3.9 Discussion and further work
A central role for SBA has been established as a read out of protection against
meningococcal disease (Goldschneider et al. 1969; Fijen et al. 1989; Frasch et al.
2009; Granoff 2009). However, a number of observations that an absence of SBA
does not necessarily indicate an absence of protection, suggests a role for other
protective mechanisms. Opsonophagocytosis has been suggested as an alternate
mechanism which may be important in serogroup B disease (Ross et al. 1987;
Toropainen et al. 1999; Platonov et al. 2003; Plested et al. 2009). The importance
of complement has also been emphasised by the increased susceptibility to
meningococcal disease seen in individuals who are deficient in parts of the
complement cascade which contribute to opsonophagocytosis and SBA (Figueroa
and Densen 1991; Fijen et al. 1998; Hellerud et al. 2010). This is particularly
highlighted amongst individuals who lack components of MAC, demonstrating an
increased risk of meningococcal infection of 1000-10000 fold, in comparison to the
general population (Lehner et al. 1992). Disease in these LCCD individuals has a
lower fatality rate, thought to be attributable to less bacterial lysis and thus lower
levels of bacterial LOS released into the blood (Schneider et al. 2007). Individuals
who lack earlier components of the complement cascade also show an increased
susceptibility to disease and in the case of properdin deficiency show a much
poorer prognosis than LCCD individuals (Schneider et al. 2007).
This chapter describes the development of a duplexed antibody-mediated
complement deposition assay able to measure both C3b/iC3b and C5b-9, these
elements of the complement cascade are potential indicators of both opsonic and
bactericidal responses. There are several assays developed to measure the
deposition of complement on bacterial surfaces for a variety of organisms.
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The relative importance of the classical or alternative complement cascade has
been evaluated using C1q or factor B-depleted serum and investigation of the
difference in C3bliC3b deposition compared with control sera. C3b/iC3b deposition
in innate immunity to Streptococcus pyrogenes was found to be dependent on the
alternative complement cascade, and this was shown using a C3b/iC3b deposition
assay (Yuste et al. 2006). This assay involved the incubation of bacteria with
serum for 30 minutes at 3rC, followed by incubation with a fluorescent conjugate.
Measurement of C3b/iC3b deposition has also been used to identify the relative
importance of the classical complement pathway in innate immunity to
Streptococcus pneumoniae, this was done using sera from mice deficient in
complement components (Brown et al. 2002). This deposition assay required a 30
minute incubation of bacteria with serum at 3rC before incubating with a
fluorescent conjugate. Deposition of C3b/iC3b was also used to investigate the
role of S. pneumoniae capsule in the inhibition of complement deposition,
demonstrating capsule was able to inhibit complement deposition via IgG
dependent and independent mechanisms (Hyams et al. 2010), once again using
the same assay parameters as in Brown et al. (2002). Involvement of both
classical and alternative complement pathways in immunity to Francisella
tularensis has been demonstrated using a complement deposition assay
measuring the deposition of C3b/iC3b, and this study also investigated the
deposition of C5b-9. It was shown that C5b-9 was not able to assemble on the
surface of the bacteria. Deposition of both components was assessed in separate
assays which combined fixed bacteria with serum and incubated for 60 min at
3rC (Ben Nasr and Klimpel 2008). In addition to this, complement deposition
assays have been used to assess the effect of factor H binding to CspA in Borrelia
burgdorferi on deposition of C3, C6 and C5b-9, once again all measured
separately by incubating spirochetes with serum for 30 min at 37°C, and then with
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a fluorescent conjugate (Kenedy et al. 2009). Assays developed to measure
deposition of complement components have also been published for N.
meningitidis, and have been used to investigate the function of NhhA. This protein
involved in bacterial adhesion in the nasopharynx which also plays a role in
complement resistance (Sjolinder et al. 2008) as the deposition of C5b-9 was
increased in the Nhha knockout mutant. This assay incubated paraformaldehyde
fixed bacteria with 25% serum for 30 min at 3rC. Welsch et al. (2003)
investigated the ability of anti-GNA2132 to elicit C3b/iC3b deposition, using an
assay which incubates bacteria for 30 min at room temperature.
Most of these assays use similar protocols, incubating bacteria with a complement
source for between 20-60 min at 3rC, then incubating with mAb to detect the
specific complement source component, followed by a secondary incubation with a
secondary detection antibody (Brown et al. 2002; Drogari-Apiranthitou et al. 2002;
Yuste et al. 2006; Sjolinder et al. 2008; Kenedy et al. 2009). In contrast, there are
other assays which detect complement deposition using an incubation
temperature of 25°C (Welsch et al. 2003; Taylor 2010).
Previous assays developed for use with N. meningitidis have used either
azide/PMSF killed bacteria (Taylor 2010), or live bacteria (Welsch et al. 2003) and
this study investigated the correlation of total antibody surface binding on killed or
live N. meningitidis to establish whether using killed bacteria would be
representative of the response seen with the live bacteria (3.2.5). A comparison of
total IgG binding on killed bacteria or live bacteria showed a significant correlation
(r=0.93, P<0.01) (3.2.5). An additional observation was made that although the
correlation was high, the FI-C' values observed with the live bacteria were
consistently lower than with the killed bacteria, and could have been a result of
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capsule disruption during the killing process. However the high correlation gives
confidence in results obtained with killed bacteria. Using azide/PMSF killed
bacteria has several advantages over the use of live bacteria as it can reduce
assay variation, thus removing differences between cultures of the same bacterial
strain, which has been shown to be an important aspect of assay variation (Borrow
et al. 2005). Using killed bacteria also allows the assay to remain high throughput
as it can be performed outside microbiological containment (a requirement for any
assay using live N. meningitidis in accordance with UK safety standards), and
allows the assessment of large panels of sera against multiple strains, providing a
way to standardise assays between laboratories. The effect of the killing method
on the exposure of surface epitopes has also raised concerns about the use of
killed bacteria, with an observed increase in the exposure of PorB3 occurring
following killing with a variety of methods including azide, ethanol, antibiotic,
paraformaldehyde fixation or heat killing (Michaelsen et al. 2001). However the
strong correlation between total IgG binding between live bacteria and
Azide/PMSF killed bacteria supports the conclusion that this is a suitable killing
method to use.
Measurement of C5b-9 deposition required identification of a suitable anti-C5b-9
monoclonal antibody. Two different antibodies were identified, both of which were
reportedly able to bind to both lytic and non-lytic complement components
including fluid phase SC5b-9, TCC, MAC, poly C9 and also denatured C9 (product
details Quidel and Oako). As this assay requires several wash steps following
incubation with bacteria complement and serum, it would be unlikely to have any
fluid phase SC5b-9 detectable in this assay. It has been shown that a small
fraction <0.4 moles S protein per 1 mole of C5b-9 of membrane bound C5b-9 can
contain the S protein and this may be non-lytic (Bhakdi et al. 1988). In addition to
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this, poly C9 and denatured C9 are also non-lytic and thus it was important to
establish whether the measured antibody-mediated deposition of C5b-9 correlated
with SBA titre. The correlation of C5b-9 binding and SBA was poor (r=0.43) with
the Dako mAb C5b-9. This suggested that this antibody was unable to distinguish
between bactericidal and not bactericidal sera. However, the Quidel mAb C5b-9
correlated significantly (r=0.77, P<0.05) with SBA and was chosen for all further
assay development.
Drogari-Apiranthitou et al. (2007) used the Dako mAb in a study comparing C5b-9
deposition mediated by sera with or without an SBA titre and showed higher C5b-9
deposition in a high SBA titre serum compared to sera with low SBA activity.
However, when using mAb PorA in a dose-dependent manner, they were able to
induce dose-dependent bacterial lysis but not C5b-9 deposition. These authors
initially used both the Dako C5b-9 mAb and the Quidel C5b-9 mAb but in a whole
cell ELISA the Quidel C5b-9 mAb showed high assay backgrounds, reacting with
non opsonised meningococci, and thus the Dako C5b-9 was chosen for their
studies, and no comparison was made between the antibodies with regard to the
detection of bactericidal activity (Drogari-Apiranthitou et a/. 2002). The lack of
correlation between bactericidal response and C5b-9 deposition detected with the
Dako C5b-9 mAb was consistent with a poor correlation observed with this mAb in
this study (3.2.2.1). Other work has been conducted to investigate the role of
antibody in the protection against non-typhoidal Salmonella bacteremia, which
examined antibody-mediated C5b-9 deposition using the Dako C5b-9 mAb. This
work showed a good correlation between antibody-mediated C5b-9 deposition
detected with C5b-9 mAb (Dako) and bactericidal Salmonella killing (Maclennan
et al. 2008).
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Initial studies used unlabelled mAb and a FITC-Iabelled secondary antibody (2.8.1
and 2.8.2). For the use of C5b-9 mAb in a duplexed CDA this antibody required
conjugation to a spectrally separate fluorochrome from C3b/iC3b FITC. It was
important to choose the fluorochrome so that little compensation would be
required during analysis and to reduce the possibility of FRET. Alexa Fluor 647 nm
was chosen as it was excited by the 633 nm laser as opposed to the 488 nm laser
used to excite FITC (conjugate for pAb C3b/iC3b). Zenon labelling with labelled
Fab fragments directed against the Fc portion of antibody proved an inconsistent
conjugation method. Thus covalently labelled conjugate was obtained using
Invitrogen Custom Conjugation Service, which allowed a large volume of antibody
to be conjugated in a single procedure. The use of a single conjugate batch was
advantageous to reduce assay variation. The duplexed assay was performed in
parallel with separate assays to determine whether there were adverse results
observed when the fluorochromes were combined in a single assay. C3b/iC3b and
C5b-9 deposition correlated significantly with the duplexed assay measurements (r
= 0.99, P<0.05 and r = 0.95, P<0.05 respectively) showing that this assay could
be duplexed for the measurement of both antibody-mediated C3b/iC3b and C5b-9
deposition in a single assay.
It was important to optimise the assay temperature and time points as they were
considerably different to that used in the standard SBA protocol measuring the
functional lytic response of C5b-9 deposition and opsonic protocols (Lehmann et
al. 1998; Bassoe et al. 2000; Taylor 2010; Findlow 2011). In the SBA, bacteria,
complement and serum are incubated for 60 min at 3rC, whilst the initial CDA
method incubated bacteria, complement and serum for 30 min at 25°C. Results
demonstrated a significant (P<0.05) increase in antibody-mediated C3b/iC3b and
C5b-9 deposition was observed at 3rC in comparison to 25°C at all time points
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tested with the optimum incubation time found to be 45 min. Correlation between
bactericidal titre and complement deposition was also higher when performed at
3rc. In addition, the assay variation showed a reduction in reproducibility at
3rC. The incubation time point for addition of conjugates was also investigated
and it was found that the original time 20 min at 4°C without shaking was optimum.
In order to assess assay precision a selection of 20 high medium and low
responding sera were assayed by three operators three times on three separate
days. The assay precision showed that for both C3b!iC3b and C5b-9 deposition,
the coefficient of variance (CoV) was below 35% when the intra assay variability
was measured. Inter assay CoV was also below 35% as was the inter operator
variation, however 4 sera showed a CoV higher than 35% when comparing
precision between operators. Assay precision was good, and was equivalent to
other assays which measure the deposition of complement (Taylor 2010). CoVare
higher than those seen with ELISA which are typically set with an acceptance
criteria of a CoV :510% (Granoff et al. 1998) and is slightly higher than the reported
CoV :515% for intra assay variation reported for the validated SSA used in the
MeNZS vaccine trials (Martin et al. 2005). A meningococcal OPA CoV
demonstrated a comparable level of variance of :530% for intra and inter-assay
variation (Taylor 2010) which was lower than that observed with a pneumococcal
OPA, where much higher CoVs were observed (Romero-Steiner et al. 1997).
The dCDA has been utilised to measure antibody-mediated complement
deposition levels with sera raised against purified outer membrane protein
complexes. Mouse sera raised against CxASR (complex of PorN PorS! RmpM)
showed the greatest activity of the complexes assessed, but mouse sera raised
against CxChap (complex of chaperonin MSP63) showed lower levels of antibody
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mediated C3b/iC3b and C5b-9 deposition in comparison with mouse sera raised
against CxABR. However, CxChap was the only complex able to induce cross-
reactive antibodies with heterologous strains inducing high levels of C3b/iC3b and
C5b-9 deposition across a panel of six strains (figure 3.7.1 )(Marzoa et al. 2011).
The dCDA has also been utilised to show the reduction in immunogenicity of
NHBA-fusion protein following heat stress (figure 3.8.1 )(Martino et al. 2011) and
also to evaluate heat shock protein enriched vaccines (figure 3.6.1, 3.6.2, and
3.6.3).
Further investigation could include the assessment of assay linearity, assay
robustness and establishing the upper and lower limits of detection. Further work
should also investigate correlation of C5b-9 deposition and bactericidal titre
against further strains. It would be important to establish if there is a level of C5b-9
deposition which can predict a protective bactericidal titre of :51:4, and whether this
varies between strains or whether a consistent level of C5b-9 deposition can be
established.
This COA is not a replacement for the functional assays measuring complement-
mediated killing or phagocytosis of N. meningifidis. The SBA is an established
assay, and is accepted as a correlate of protection. However, the duplexed COA
provides a mechanism for assessment of large panels of bacterial strains against
large numbers of serum for clinical serological testing, this is because of the
requirement for small volumes of serum for each assay. In addition, the assay
requires no microbiological containment (all assays using live bacteria require
containment) facilitating high throughput assays, and the use of killed bacteria
reduces the growth to growth variation.
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Chapter 4: Development of a respiratory burst opsonophagocytosis assay
4.1 Introduction
Serum bactericidal activity is the accepted correlate of protection for serogroup
A,B,C,Y and W135 disease vaccines (Frasch et al. 2009), but other mechanisms
of protection, including opsonophagocytosis are likely to be important (Granoff
2009).
Opsonophagocytosis is the accepted correlate of protection for S. pneumoniae
vaccines (Romero-Steiner et al. 2003) and evidence suggests that the interaction
of complement binding antibodies and polymorphonuclear cells also plays an
important role in protection against meningococcal disease (Ross et al. 1987;
Balmer and Borrow 2004; Plested and Granoff 2008; Granoff 2009)(1.4.2).
Polymorphonuclear cells are important effector cells, phagocytosing opsonised
meningococci and then exposing them to either reactive oxygen species (ROS)
generated by the activation of NADPH oxidase, or hydrolytic granule proteins
causing killing of engulfed bacteria.
Resting polymorphonuclear cells consume little oxygen as they generate ATP
mainly by glycolysis, but following phagocytosis of opsonised bacteria they begin
to take up large amounts of oxygen. The uptake of oxygen is initiated by the
activation of an enzyme complex (NADPH oxidase) on the surface of the plasma
membrane which oxidises NADPH.
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Oxidation of NADPH releases two electrons which are used to reduce oxygen into
superoxide. Following phagocytosis of bacteria the intra-vacuolar pH increases
from 7.4 to 7.8 and then falls to 6.0. This fall in pH occurs because superoxide
radical is dismutated into hydrogen peroxide within the vacuole (Hampton et al.
1998).
Whilst it has been have shown that superoxide has a some bactericidal effect on
N. meningitidis, hydrogen peroxide (H202) has been found to be highly toxic to N.
meningitidis (Dyet and Moir 2006). H202 and derived hydroxyl radicals are able
cross the membrane and directly damage bacteria by lipid peroxidation, a process
where electrons are removed from the lipids in the cell membrane leading to
membrane damage (Hampton et al. 1998). In addition to this, H202reacts with iron
or copper salts to form hydroxyl radicals which cause DNA modification and strand
breakages. Alternatively myleoperoxidase converts hydrogen peroxide into
hypochlorous acid, which is highly potent, causing damage to membrane transport
systems (Albrich et al. 1986), adenosine triphosphate generating systems
(Barrette et al. 1989) and the origin of replication for DNA synthesis (Rosen et al.
1990).
Respiratory burst can be measured by a variety of different probes (Gomes et a/.
2005) each detecting a different reactive oxygen species. A variety of techniques
have been developed to assess antibody-dependent opsonophagocytosis. There
are several examples of opsonophagocytosis assays measuring the uptake of
fluorescent OMV-coated polystyrene beads (Lehmann et al. 1998; Bassoe et al.
2000) or labelled meningococci (Taylor 2010). In addition, killing assays have
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been developed to directly measure a bactericidal opsonic response (Plested and
Granoff 2008). However, these assays are laborious and require a large serum
volume which makes them unfeasible for use in the assessment of clinical trial
sera. Alternatively other assays have been developed to measure the respiratory
burst response. These assays measure the conversion of dihydrorodamine 123 to
fluorescent rodamine 123 (which measures hydrogen peroxide) or dihydroethidium
to ethidium (which measures superoxide) following a respiratory burst response
initiated by opsonophagocytosis (Lehmann et al. 1998). Lehmann et al. (1998)
measured both uptake of fluorescent OMV-coated beads and respiratory burst.
OMV beads have been used as targets in assays (Lehmann et al. 1998) as they
are easily standardised in comparison to whole bacteria, although these have the
disadvantage that they do not possess capsule and as a consequence may
expose epitopes not usually available on the surface of meningococci. Assays
have also been developed to measure both uptake of fluorescently stained
Staphylococcus aureus and induction of respiratory burst response (Perticarari et
al. 1991).
Previous studies measuring respiratory burst responses have used a variety of
different reagents (Lehmann et al. 1998; Gomes et al. 2005), with many of these
reagents measuring the production of either superoxide or hydrogen peroxide.
The majority of flow cytometric opsonic assays measure the uptake of
fluorescently-Iabelled OMV coated latex beads or meningococci, but do not
measure the stimulation of a respiratory burst response, the bactericidal function
which kills the phagocytosed bacteria. Similarly some assays measure respiratory
burst response only and not opsonophagocytosed bacteria which may
overestimate protection as it does not account for the respiratory burst response
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stimulated by N-formylmethionylleucylphenylalanine (FMLP) (Elbim et al. 1994),
IFN-y (Ellis and Beaman 2004) and TNF-a (Menegazzi et al. 1994). In addition,
phagocytosis is not always necessary for a respiratory burst to occur (Phillips et al.
1990; Elbim et at. 1994). Lehmann et al. (1998) showed that the level of
phagocytosis did not correspond with the level of respiratory burst response
measured.
The work described in this chapter aimed to develop a high throughput assay to
quantify both opsonophagocytosed bacteria and respiratory burst response within
HL60 cells. The starting method used was an OPA developed to measure the
uptake of bacteria stained with BCECF-AM using DMF-differentiated HL60 cells
and baby rabbit complement (Taylor 2010) (2.9.7). This work aimed to develop this
assay to measure the simultaneous measurement of respiratory burst and uptake
of opsonophagocytosed bacteria. The measurement of both parameters would
allow correlation with opsonic killing assays to assess whether the duplexed
response correlates to a greater level than either opsonophagocytosis or
respiratory burst response measured individually.
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4.2 Results
4.2.1 Investigation of different reagents to detect respiratory burst response
in differentiated HL60 cells.
Initial investigations compared different reagents able to measure hydrogen
peroxide production and investigated detection of superoxide production (table
4.2.1.1). This aimed to identify the most appropriate reagent for measurement of
reactive oxygen species in HL60 cells. All reagents tested were used at the
recommended maximum concentration (Invitrogen technical information sheet).
No response was observed using H2DCFDA and carboxy-H2DCFDA, but CM-
H2DCFDA demonstrated an FI-C' of greater than 1600 (figure 4.2.1.2). However
CM-H2DCFDA demonstrated a high response for both positive control serum and
negative non immune serum (figure 4.2.1.2). This result suggested that the
reagent may have been maximally converted to H2DCF. H2DCFDA and its
derivatives are photosensitive and can undergo some photoreduction converting
them to fluorescent H2DCF prior to exposure to hydrogen peroxide, this could have
caused the non-specific response observed (Gomes et al. 2005). Due to the
photosensitivity of these fluorochromes none would be suitable for use in a
respiratory burst assay (RBA). Both dihydroethidium and DHR 6G also showed no
detectable response (figure 4.2.1.3 and 4.2.1.4), whereas dihydrorodamine 123
was the only reagent which demonstrated a low response to negative control
serum and a high response to the positive control serum (figure 4.2.1.2) and has
been previously described (Lehmann et al. 1998; Bassoe et al. 2000; Aase et al.
2003; Walrand et al. 2003; Aase et al. 2007). DHR123 was chosen for all further
work.
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Non-fluorescent Fluorescent Additional information ROS
respiratory burst oxidised detected
reagent product
2',7'- H2DCF nla Hydrogen
dichlorodihydrofluorescei peroxide
n diacetate (H2DCFDA)
5- (and 6-) chloromethyl- H2DCF Retained within the cell Hydrogen
2',7'- following covalent binding to peroxide
dichlorodihydrofluorescei intracellular components
n diacetate (CM- (intracellular glutathione).
H2DCFDA)
5-(and-6)-carboxy 2',7'- H2DCF Negative charges impedes its Hydrogen
dichlorodihydrofluorescei leakage out of the cell. peroxide
n diacetate (Carboxy-
H2DCFDA)
Dihydrorodamine 123 Rodamine Reacts with H202 producing Hydrogen
(DHR 123) 123 H20 and fluorescent rodamine peroxide
123.
Dihydrorodamine 6G Rodamine Reacts with H202 producing Hydrogen
(DHR 6G) 6G H20 and fluorescent rodamine peroxide
6G.
Dihydroethidium (DHE) Ethidium Reacts with 202.- producing Superoxide
H20 and ethidium.
Table 4.2.1.1 Summary of the respiratory burst detection reagents (Games et
al. 2005).
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.DHR123
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Figure 4.2.1.2 Comparison of four respiratory burst detection reagents in
HLSOcells.
Comparison of four respiratory burst detection reagents in HL60 cells following
opsonophagocytosis of N. meningitidis M01240149 with rabbit or mouse anti-OMV
serum.
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Figure 4.2.1.3 Investigation into the use of dihydrorodamine SG (OHRSG)as
a respiratory burst detection reagent in HLSOcells.
The use of respiratory burst detection reagent DHR6G in HL60 cells following
opsonophagocytosis of N. meningitidis H44/76 with rabbit or mouse anti-OMV
serum.
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Figure 4.2.1.4 Investigation into the use of dihydroethidium (DHE) as a
respiratory burst detection reagent in HL60 cells.
Use of respiratory burst reagent dihydroethidium in HL60 cells following
opsonophagocytosis of N. meningifidis H44/76 with rabbit or mouse anti-OMV
serum.
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4.2.2 Optimisation of DHR123application during the assay- Comparison of
three different methods.
To establish the best protocol for use of DHR123 within the assay, a comparison
was made between three methods. The addition of DHR 123 with the bacteria (1st
incubation) was compared with both the addition of DHR123 with the HL60s (2nd
incubation) or with preloaded HL60 cells, which had been incubated with DHR123
before use in the assay. All methods used the same concentration of DHR123.
Preloading the HL60 cells gave a significantly higher response (P<O.01) compared
with the addition of DHR123 with either the cells or bacteria (figure 4.2.2.1). It was
therefore decided to optimise this HL60 cell preloading concentration and
incubation time with DHR123.
2500
• DHR123 added with bacteria
• DHR123 added with HL60s
• HL60s oreloaded with DHR123
**
** n=2
o
2000
1500.
~-u,
1000
500
NZ98/254 fe +ve (rabbit)
Sera
Figure 4.2.2.1 Comparison of different methods of DHR123addition into the
RBA using N. meningtidis NZ98/254.
Significance was determined by z-test (**P<O.01), and error bars denote standard
deviation.
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4.2.3 Optimisation of DHR 123 concentration and preloading incubation with
the HL60 cells.
The optimum concentration of DHR123 for use in the assay was investigated by
preloading the differentiated HL60 cells with a range of concentrations of DHR123.
The optimum concentration was shown to be at 50 J.,Jg/ml,this gave a significantly
(P<0.01) higher response than at any of the lower concentrations, with no
significant increase in response observed with the higher concentrations tested
(figure 4.2.3.1). The incubation time for preloading DHR123 into HL60 cells was
also investigated. A significantly higher response (P<0.01) was observed following
pre incubation of DHR123 with the HL60 cells for 15 min, and this response was
significantly reduced (P<0.01) at the longer incubation times (figure 4.2.3.2).
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Figure 4.2.3.1 Optimisation of DHR123 concentration in RBA.
Effect of increasing DHR123 reagent concentration on respiratory burst following
opsonisation of N. meningitidis NZ98/254 with rabbit anti-OMV serum. Significance
was determined by z-test (**P<0.01), and error bars denote standard deviation.
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Figure 4.2.3.2 Optimisation of DHR123 preloading incubation time.
Effect of increasing preloading incubation time with HL60 cells before use in a
respiratory burst assay on N. meningitidis M01240149. Significance was
determined by z-test (**P<0.01), and error bars denote standard deviation.
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4.2.4 Comparison of HL60 cells and fresh human polymorphonuclear cells
The HL60 cells are at the promyelocyte stage of maturation, isolated from a
patient diagnosed with promyelocytic leukaemia. Differentiation of the HL60 cells
can be induced into granulocyte maturation by chemicals including DMSO and
DMF. The differentiated HL60 cells provide a continuous supply of granulocytic
like cells (Gallagher et al. 1979; Koeffler and Golde 1980) facilitating use in large
assays enabling the high throughput nature of the assay. The use of fresh human
PMNs has disadvantages: it is heavily reliant on volunteer donation, and the PMNs
need to be isolated from the same volunteer on each occasion to allow
reproducibility, as a alternative volunteer may express different polymorphisms of
the FcyR. However, differences have been reported between HL60s and fresh
human polymorphonuclear cells. HL60s contain no lactoferrin or alkaline
phosphatase, and do not differentiate down the accepted maturation pathway for a
promyelocyte (Birnie 1988). The HL60 cells have been shown to lack specific and
secretory granules (Koeffler and Golde 1980; Nordenfelt et al. 2009), but can
phagocytose, express complement and Fcy receptors (Taylor 2010) and produce
superoxide, and are often used in assays measuring opsonophagocytosis
(Henckaerts et al. 2006; Guttormsen et al. 2008; Taylor 2010). It has also been
shown that HL60 cells have NADPH oxidase and myeloperoxidase and are
capable of producing a respiratory burst response (Teufelhofer et al. 2003). It was
important to compare the respiratory burst response of the HL60 cells with that of
human PMNs to ensure the response was representative, this was performed
using a panel of high, medium and low responding human sera. A significant
positive correlation was observed (r= 0.87, P<0.01) (figure 4.2.4.1). Thus, the
HL60s are a suitable alternative to PMNs.
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Figure 4.2.4.1 Correlation of respiratory burst observed with either HL60
cells or PMNcells.
Correlation of respiratory burst observed with either HL60 cells or PMN cells using
N. meningitidis M01240149 (r=O.87, P<O.01). Significance was shown by t-test.
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4.3 Optimisation of respiratory burst opsonophagocytosis assay (RBA)
4.3.1 Use of a priming agent
PMNs are stimulated in vivo by cytokines which are produced during immune and
inflammatory responses to pathogens (Ferrante et al. 1988; Khwaja et al. 1992;
Brechard et al. 2005). These cytokines can act in either priming sensitising
neutrophils to be more responsive to the pathogens encountered, or they can
directly stimulate the respiratory burst response. Previous studies have shown
TNF-o, IL-8, GMCSF, and IFN-y (Roilides et al. 1993; Elbim et al. 1994) to be
effective as priming agents for the respiratory burst response. In addition, TNF-a
and IFN-y have also been shown to directly stimulate the respiratory burst
response (Menegazzi et al. 1994; Ellis and Beaman 2004).
TNF-o, IL-8, GMCSF and IFN-y were initially used at 100 ng/ml and were
incubated with 2.5x107 HL60 cells/ml for 45 min prior to use in the assay. These
conditions were as described by Elbim et al. (1994). IFN-y gave a significantly
(P<0.05) higher respiratory burst response in comparison with unprimed samples
(figure 4.3.1.1), a moderate increase in background respiratory burst response
was also observed indicating there was a low level of direct stimulation. IL-8, TNF-
o and GMCSF did not induce a significant increase in respiratory burst response
(figure 4.3.1.1). Responses were correlated which confirmed that priming the cells
only altered the magnitude of response (figure 4.3.1.3).
The optimal IFN-y priming concentration was found to be 100 ng/ml, which gave a
significantly (P<0.05) greater response than the unprimed cells. No significant
difference was observed between 100 ng/ml and either of the higher priming
concentrations tested (figure 4.3.1.2).
180
The optimal incubation time was then established at 3 h (figure 4.3.1.4). At this
incubation time point, primed cells induced a response that was six times greater
than that observed with unprimed cells. It was also observed that the complement
only control (assay background) increased following priming with IFN-y, but was
not significantly affected by the preloading incubation time (figure 4.3.1.5).
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Figure 4.3.1.1 Comparison of cell primers in the RBA.
RBA to compare 100 ng/ml of either IL-8, IFN-y, GMCSF and TNFa as cell primers
using N. meningitidis M01240149 with rabbit serum. Significance was shown by z-
test (*P<0.05), and error bars denote standard deviation.
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Figure 4.3.1.2 Optimisation of IFN- V concentration for priming the cells in an
RBA.
Determination of the appropriate IFN-y concentration for priming the cells in an
RBA using N. meningtidis M01240149 with rabbit serum. Significance was shown
by z-test (*P<0.05), and error bars denote standard deviation.
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Figure 4.3.1.3 Correlation between unstimulated and stimulated (100 ng/ml)
samples in an RBA against N. meningitidis M01240149.
Significance was shown by t-test.
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Figure 4.3.1.4 Effect of increasing incubation time with IFN-y (100 ng/ml)
stimulation in an RBA against N. meningitidis NZ98/254.
Significance was shown by z-test (*P<0.05), and error bars denote standard
deviation.
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Figure 4.3.1.5 Overlay plots illustrating the effect of increasing incubation
time with IFN-y on the response observed in the complement only control
and positive control sera.
Effect of increasing incubation time with IFN-y on the complement only assay
control (A.) and homologous rabbit sera positive control (B.) performed in an RBA
against N. meningitidis NZ98/254.
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4.3.2 Effect of sodium azide in the assay buffer
When the respiratory burst response is stimulated, H202 is produced, which is then
catabolised into other ROS. Low levels of azide prevent this catabolism of H202
by inhibiting myeloperoxidase activity (Hampton et al. 1996). This was investigated
as a component of the assay buffer, to further optimise the fluorescent signal
achieved. The use of azide would not increase the amount of H202 produced but
prevent catabolism into other ROS (Walrand et al. 2003). A significantly higher
response (P<0.05) was observed with the addition of 0.01% sodium azide with the
homologous strain OMV positive control serum in comparison with the control. In
addition to this, no significant increase was observed in the non-immune control
serum test and thus non-specific background had not increased (figure 4.3.2.1).
This effect was seen with all sodium azide concentrations tested (figure 4.3.2.1).
Addition of sodium azide to the assay buffer, required the assessment of any
effect on HL60 cell viability. This was investigated by comparing the cells
incubated with or without the sodium azide buffer, for 2 h (the approximate length
of assay plus analysis by flow cytometry) and viability was determined using
trypan blue staining and enumeration with a haemocytometer (2.5.3). No
significant difference was observed for cells incubated with or without 0.01%
sodium azide addition (figure 4.3.2.2). Therefore 0.01% sodium azide was
introduced into the assay buffer.
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Figure 4.3.2.1 Investigation into the effect of sodium azide in RBA assay
buffer.
Investigation into the effect of sodium azide on the respiratory burst response in
HL60 cells using N. meningitidis M01 240149 with rabbit anti-OMV sera.
Significance was shown by z-test (*P<0.05). and error bars denote standard
deviation.
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Figure 4.3.2.2 Investigation into the effect of sodium azide on HL60 cell
viability following 2 hours incubation.
Error bars denote standard deviation.
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4.3.3 Effect of glucose addition to the assay buffer.
It has been well established that neutrophils require glucose to generate both ATP
through glycolysis and NADPH through the pentose phosphate pathway. The
presence of NADPH is essential for the respiratory burst reaction as it is
subsequently consumed by NADPH oxidase and leads to the production of
superoxide, hydrogen peroxide and other ROS (Freitas et al. 2009). It was
therefore important to evaluate the effect of glucose concentration in the assay
buffer on the respiratory burst response. Increased concentrations of glucose lead
to an increase in the respiratory burst response and the optimal concentration was
found to be 1 mM. Significantly greater (P<0.01) responses were observed at this
concentration compared with no glucose, 0.5 mM or 2 mM (figure 4.3.3.1).
**
**
n=2
**
2400
2300
2200
2100
~ 2000u::
1900
1800
1700
1600
0 20.25 0.5
Glucose concentration (mM)
4
Figure 4.3.3.1 Effect of glucose addition to the RBA assay buffer.
Effect of increasing glucose concentration on RBA using N. meningitidis
M01240149 and a high responding human serum. Significance was shown by z-
test (**P<0.01), and error bars denote standard deviation.
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4.4 Bacterial stains.
4.4.1 Investigation of alternative bacterial stains.
Dihydrorodamine 123 is excited by a 488 nm laser and emits fluorescence at 525
nm, this meant that we could not introduce the respiratory burst reagent directly
into the existing opsonophagocytosis assay (2.9.7) as the bacterial stain BCECF-
AM used in this assay would overlap spectrally, as it is also excited by a 488 nm
laser and emits at 525 nm (figure 4.4.1.1). The use of alternative stains was thus
investigated to complement the respiratory burst reagent.
JOO 400 500 61)0
Figure 4.4.1.1 Fluorescent spectra for BCECF-AM (green line) and DHR 123
(blue line).
Excitation indicated by dashed line, emission indicated by solid line.
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4.4.2 The use of Intracellular stains
BCECF-AM was a successful internal stain for the bacteria which was evident
from the strong uniform fluorescent peak detected by flow cytometry (figure
4.4.2.1), because of this other similar stains were investigated, this included
SNARF-AM (5-(and-6)-carboxy SNARF®-1, acetoxymethyl ester) which stains
internally by crossing the bacterial membrane before the acetomethyl ester is
cleaved by esterases leading to the stain being permanently retained. SNARF-AM
demonstrated uniform staining (figure 4.4.2.2), however the bacteria were weakly
fluorescent even at a stain concentration double that used for BCECF-AM and for
double the incubation period. The optimal staining concentration was achieved at
150 I-Ig/ml for 2 h (figure 4.4.2.2). SNARF-AM-stained bacteria were used in an OP
assay to assess whether the staining was sufficient to measure a detectable
bacterial uptake response (figure 4.4.2.3). No response was observed with
SNARF-AM-stained bacteria in comparison with the control assay using BCECF-
stained bacteria, indicating that SNARF-AM was not suitable for the detection of
opsonophagocytosis .
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4.4.3 DNA bacterial stains
Various DNA stains were assessed for their ability to stain N. meningitidis. These
were investigated as they would stain bacteria internally and not mask external
epitopes. Propidium iodide (PI) and 7MD-stained bacteria did not demonstrate
sufficient fluorescence to be considered as replacement bacterial stains, although
SYTO DNA stains were shown to be effective (figure 4.4.3.1). The SYTO dyes are
cell permeant stains which are non-fluorescent until they bind with nucleic acids,
and were chosen based on their emission spectra as they are excited by the 633
nm laser and emit at 670 nm, and if used this would result in a reduction of
spectral overlap with the respiratory burst reagent (DHR123). This stain provided
very bright and uniform staining (figure 4.4.3.1), and was used in an OP assay.
During analysis of the assay it was found that all HL60 cells demonstrated bright
staining, including undifferentiated cell populations and apoptosing and dead cell
debris (figure 4.4.3.2). A possible explanation is that the SYTO dye had leached
out of the stained bacteria and stained the HL60 cell nucleic acid. It was
impossible to differentiate between cells which had phagocytosed fluorescent
bacteria and cells just stained with free SYTO dye, therefore it was concluded that
this type of stain would not be suitable in a respiratory burst assay.
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4.4.4 Lipid stains
The lipophilic stain PKH-26 was assessed. This dye attaches to lipophilic tails
before diffusing into the cell membrane and has been previously used in
lymphocyte migration and proliferation studies (Givan et al. 1999; Batard et al.
2000) and also to stain Bordetella pertussis for use in an OPA (Hellwig et al.
1999). Bright and uniform staining was achieved with a concentration of 200 IJM
showing the optimal fluorescence (figure 4.4.4.1).
These stained bacteria were used in an OPA and compared with the OP response
in a duplexed RBA (figure 4.4.4.2). The OPA response using PKH-26-stained
bacteria was compared to BCECF-stained bacteria and very similar results were
obtained (figure 4.4.4.2 a and b). In addition, the PKH-26 OP response from a
duplexed RBA (PKH-26 stained bacteria and DHR123 respiratory burst reagent)
showed a similar trend (figure 4.4.4.2 c). These responses provided evidence to
suggest PKH-26 would be a suitable replacement stain for BCECF-AM, but would
require further investigation with a larger panel of sera.
194
I 11111111 '" 111111 I """I I" ""I
10' 10' 10' 10'
Fluorescence
FL2 Log
;:!
Cl)
c.....
a.>
>a.>
l+-
Q
L-
a.>
.0
E
::J
Z j l
Unstained
Cl)
c.....
a.>
>a.>
l+-
Q
L-
a.>
.0
E
:::l
Z
I I I I I '~~o I I I I III~~ I I I I ""~~2 I f I f I~~J
Fluorescence
FL2 LoO
10 !-1M PKH-26
~c:
a.>
>a.>
l+-
Q
L-
a.>
.0
E
:::l
Z
I 1111I1t1 1'1111111 '
10' 10'
Fluorescence
FL2 Log
cCI)'".....c:
a.>
>a.>
l+-
Q
L-
a.>
.0
E
::l
Z
100 uM PKH-26
I' , .. II 1'1 '" 'I
10' 10'
Fluorescence
FL2 Log
400 !-1M PKH-26
Cl)
c:.....
a.>
>a.>
l+-
Q
L-
a.>
.0
~ j \
Cl)
c.....
a.>
>a.>
l+-
Q
L-
a.>
.0
E
::l
Z
Cl).....c:
a.>
>a.>
l+-
Q
L-
a.>
.0
E
::l
Z
I 1'1"'1 ' I"" I 1'1111111 1'1111111
10' 10' 10' 10'
Fluorescence
FLZ Log
1 j..IMPKH-26
, , "" "I "" "" I
100 101
Fluorescence
FL2 Log
50 !-1M PKH-26
I I If '1"1 1,1 IIIIII I
10' 10'
Fluorescence
FL2 Log
200 !-1M PKH-26
Figure 4.4.4.1 Staining of N.
meningitis 44/76 using PKH-26
liooohillic stain.
195
10000 BCECF
9000 n=2
8000
7000
6000
0 5000-Lu..
4000
3000
2000
1000
0
ALOH (rabbit) NZ98/254 H44176-SL M01240355
a. (rabbit) (rabbit) (rabbit)
160
SERA
• PKH-25
140
120 n=2
100
<,> 80u..
50
40
20
0
b. ALOH (rabbit) NZ98/254 H44175-SL M01240355
(rabbit) (rabbit) (rabbit)
SERA • PKH-26
60
50
40 n=2
o 30...!.
LL
20
10
0
ALOH (rabbit) NZ98/254 H44176-SL M01240355
c. (rabbit) (rabbit) (rabbit)
SERA
Figure 4.4.4.2 Use of PKH-26 in an OPA.
(a) An OPA using SCECF-stained N. meningitidis NZ98/254 and rabbit anti-OMV
sera, (b) OPA using PKH-26 stained N. meningitidis NZ98/254 and rabbit anti-
OMV sera and (c) duplexed RSA with the OP data using PKH-26 stained N.
meningitidis NZ98/254 and rabbit anti-OMV sera. Error bars denote standard
deviation.
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4.5 Duplexing the assay
4.5.1 Correlation of duplexed assay responses with single assay responses.
A panel of low, medium and high responding human sera were used to investigate
the correlation of the duplexed RSA responses with the OPA and RSA individual
responses. All four assays were performed simultaneously: an RSA duplexed
assay measuring both respiratory burst and opsonic responses, an OPA with
PKH-26 stained bacteria, an OPA with SCECF-AM stained bacteria and an RSA
measuring respiratory burst response only, using DHR123 and unstained bacteria.
Responses were correlated to ascertain whether a duplexed assay was providing
the same response as the single-plex assay.
The opsonic response measured using PKH-26 stained bacteria in a duplex assay
correlated with the opsonic response using PKH-26 stained bacteria only, r=O.95
(P<O.01) (figure 4.5.1.1). Opsonic activity measured using PKH-26 labelled
bacteria correlated with the opsonic response measured using SCECF-AM
labelled bacteria, r=O.83 (P<O.01) (figure 4.5.1.2). The correlation between the
respiratory burst response R123 and the duplexed assay measurement of R123
was non-significant (figure 4.5.1.3), r=O.62. All assays were repeated three times
each giving similar correlations. The poorer correlation could have been
attributable to the spectral crossover between R123 and PKH-26. A possible
explanation for the poor correlation could be that when two spectrally similar dyes
are in close proximity FRET (fluorescence resonance electron transfer) can occur,
whereby excited energy from a donor molecule can be passed to an acceptor
molecule resulting in an increase in emission in the acceptor molecule. Therefore
this dye combination was not suitable for use in a duplexed assay with DHR 123 as
the respiratory burst reagent.
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Figure 4.5.1.1 Correlation of opsonic response for PKH-26 stained bacteria in
a duplexed assay vs the opsonic response of PKH-26 stained bacteria only
(r=0.95, P<0.01).
Significance was determined by t-test.
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4.S.2 Staining of killed bacteria with 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindodicarbocyanine-S,S'-disulfonic acid (DiIC1s(S)-DS).
Following the conclusion that PKH-26 would not be suitable for use in conjunction
with OHR123, OiIC1s(5)-OS was assessed as a possible alternative. This stain is
also a lipophilic tracer which has been used for long term tracing applications and
is excited by the 633 nm laser and emits at 675 nm. Therefore this stain should
require much less compensation with R123 as it is spectrally different.
Azide/PMSF killed N. meningitidis were stained with different concentrations of
OiIC1s(5)-OS to optimise the staining. Greatest fluorescence was observed with 20
IJM with equivalent staining observed at 40 and 80 IJM (figure 4.5.2.1). At higher
concentrations (160, 200 and 400 IJM) a reduction in fluorescence was observed,
with the lowest fluorescence occurring with the highest OiIC1s(5)-DS concentration.
At high concentrations of DiIC1s(5)-DS precipitation of the stain can occur and thus
may account for the poorer lipid staining on the bacteria. It was therefore
concluded that 20 IJM of DiIC1s(5)-DS would be optimal staining concentration for
bacteria at an 00600 of 2.0.
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4.5.3 Comparison of total antibody binding to DiIC1s(5)-DS stained or
unstained bacteria.
As DiIC18(5)-DS is a lipid stain and there was a concern that this could mask
surface epitopes and thus effect the amount of antibody able to bind to the
bacteria and thus the opsonic response. To assess this a total antibody surface
binding assay was performed on unstained bacteria, and bacteria stained with
DiIC18(5)-DS-stained bacteria or BCECF stained bacteria. This was conducted
with a panel of 17 high, medium and low responding rabbit and human sera.
Antibody binding to DiIC18(5)-DS-stained bacteria showed a strong positive
correlation with antibody binding to unstained bacteria (r = 0.92, P<0.01 )(figure
4.5.3.1). Antibody binding to BCECF-stained bacteria also showed a positive
correlation with that to unstained bacteria, (r = 0.79, P<0.01) (figure 4.5.3.2).
These results confirm that staining with DiIC18(5)-DS did not adversely affect the
total IgG binding to the bacteria and that when this was compared with BCECF,
DiIC18(5)-DS had the strongest correlation.
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4.5.4 Correlation of duplexed assay with single plex assay
It was important to compare an RBA using DHR 123 and unstained bacteria, with a
duplexed RBA using DHR123 and DiIC1s(5)-DS stained bacteria, an OPA with
DiIC1s(5)-DS stained bacteria and an OPA with BCECF stained bacteria. The
assays were performed with a panel of human and rabbit, low, medium, and high
responding sera.
The opsonic response measured using the DiIC1s(5)-DS stained bacteria in a
duplexed assay showed a positive correlation when compared with the opsonic
response measured using DiIC1s(5)-DS stained bacteria only (r=0.98, P<0.05)
(figure 4.5.4.1). The opsonic response measured using DiIC1s(5)-DS labelled or
BCECF-AM labelled bacteria also showed a positive correlation, (r=0.89, P<0.05)
(figure 4.5.4.2). The respiratory burst response measured with DHR123 only or in
a duplexed assay using DHR123 also demonstrated a positive correlation, r=0.88
(P<0.05) (figure 4.5.4.3).
DiIC1s(5)-DS stained bacteria and DHR123 was used as a dye combination in all
subsequent work.
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4.6 Assay precision
4.6.1 Precision of duplexed respiratory burst assay measuring both opsonic
uptake of N. meningitidis and the respiratory burst response.
The reproducibility of the duplexed assay for the measurement of OP activity and
respiratory burst assay was assessed using a panel of 21 sera consisting of low,
medium and high activity human sera and rabbit OMV sera homologous and
heterologous to the test strain N. meningitidis M01240149. These assays were
completed by three operators in triplicate on three separate days and data for
each serum was analysed to assess the precision of results. The results were
analysed by flow cytometry and the coefficient of variance (CoV) calculated from
the mean values derived from the duplicate of each serum.
The intra-assay variability was high for 12 out of 21 sera tested with a CoV of more
than 36%, and the remaining 9 sera demonstrating CoV less than 35%. There was
a higher level of variation observed when precision was assessed with three
operators completing three assays in one day, with 16 of the 21 sera tested with a
CoV higher than 35% (table 4.6.1.1). Assay variation between two assays showed
the percentage difference in response to vary between +100% and -100% when
two assays were compared (figure 4.6.1.1). Percentage CoV was higher than that
expected and higher than other comparable cell-based assays (Romero-Steiner et
al. 2003; Martin et al. 2005).
When the data was reanalysed as the two separate components of the assay,
respiratory burst response showed greater variation, with 15 of the 21 sera tested
showing CoV higher than 35% (table 4.6.1.3). The opsonic response appeared to
be much more reproducible with 16 out of 21 sera showing CoV less than 35%
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(table 4.6.1.2). This indicated that the respiratory burst was the cause of the high
levels of assay variation.
Thus further investigation was required to determine the cause(s) of assay
variation, and whether this could be resolved by introducing a fixation step at the
end of the assay.
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Coefficient of Variance (%)
20 Sera with defined CV
S35%
12
Intra-assay variability
20 sera in duplicate,
performed three times by
one operator on one day.
n=60
<15% >36%
o 9
20 Sera with defined CV
S35%
16
Inter-operator variability <15% >36%
20 sera in duplicate,
performed three times by
three operators on one day.
n=180
o 5
Table 4.6.1.1 Summary of duplexed RBA %CoV for 21 low, medium and high
responding human sera.
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Coefficient of Variance (%)
20 Sera with defined CV
~35%
5
Intra-assay variability
20 sera in duplicate,
performed three times by
one operator on one day.
n=60
<15% >36%
o 16
Table 4.6.1.2 Summary of opsonic response only, %CoV for 211ow, medium and
high responding human sera.
Coefficient of Variance (%)
20 Sera with defined CV
~35%
15
Intra-assay variability
20 sera in duplicate,
performed three times by
one operator on one day.
n=60
<15% >36%
o 6
Table 4.6.1.3 Summary of respiratory burst response only, %CoV for 21 low,
medium and high responding human sera.
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4.6.2 Effect of formaldehyde fixation of RBA
To establish whether fixation would reduce assay variation, a duplexed RSA was
performed twice. One assay was completed without fixation and one assay was
fixed with 1% formaldehyde for 15 min prior to being washed and then both assays
were analysed by flow cytometry at 0, 60 and 120 min following completion of
assay.
No variation was observed in the opsonic uptake response detected over 2 h
without formaldehyde fixation. This was consistent with results shown previously in
the precision testing of this assay (figure 4.6.2.1). When these results were
compared with the opsonic response in a fixed assay, fluorescence index was
reduced immediately and this further reduced over 2 h (figure 4.6.2.1).
High levels of variation were observed in the respiratory burst response over the 2
hours without formaldehyde fixation and confirmed the results observed during
assay precision testing (figure 4.6.2.2). Following assay fixation the FI showed a
50% reduction at 0 h and this continued to reduce over 2 h (figure 4.6.2.3).
This demonstrated that following fixation, the fluorescence was adversely affected
and this was not a suitable method to reduce assay variation. Therefore the RSA
could not be used for high throughput analysis and only to assess small numbers
of sera. It also indicated that the respiratory burst reagent degraded rapidly in the
absence of fixation. This again indicated the assay was only suitable for analysis
of small numbers of sera.
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Figure 4.6.2.1 Opsonophagocytosis response measured over 120 min
following completion of assay, with or without formaldehyde fixation.
Assay was performed with N. meningitidis M01240149 with mouse anti-OMV
serum. Error bars denote standard deviation.
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Figure 4.6.2.2 Respiratory burst response measured over 120 min following
completion of the assay with or without formaldehyde fixation.
RSA was performed against N. meningitidis M01240149 with mouse anti-OMV
serum. Error bars denote standard deviation.
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4.7 Discussion
With the observation that absence of SBA does not necessarily constitute an
absence of protection (Platonov et al. 2003; Welsch and Granoff 2007; Plested
and Granoff 2008; Plested et al. 2009). Opsonophagocytosis activity has been
suggested as an additional mechanism of protection (Granoff 2009), there have
been several published opsonophagocytosis assays that have been developed to
characterise protection from meningococcal disease. These assays have varied in
detection method: measurement of fluorescent OMV coated polystyrene beads,
uptake of labelled meningococci, measurement of the induction of the respiratory
burst response, as well as opsonic killing assays (Aase and Michaelsen 1994;
Lehmann et al. 1998; Plested and Granoff 2008).
This chapter describes the development of a high-throughput flow cytometric
duplexed respiratory burst assay, measuring both the uptake of fluorescent
bacteria and the induction of a respiratory burst response. Measurement of both
parameters may correlate better with killing than either response measured
individually. Measurement of respiratory burst individually does not account for the
response stimulated by N-formylmethionylleucylphenylalanine (FMLP) (Elbim et al.
1994), IFN-y (Ellis and Beaman 2004) and TNF-a (Menegazzi et al. 1994).
Lehmann et al. (1998) showed that the level of phagocytosis did not correspond
with the level of respiratory burst response measured. Low and medium response
sera induced the same level of respiratory burst, whilst the medium response
serum was able to induce much higher levels of phagocytosis.
Initial investigations attempted to measure a respiratory burst response in HL60
cells. The initial method used was an OPA developed to measure the uptake of
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bacteria stained with BCECF-AM using DMF-differentiated HL60 cells and baby
rabbit complement (Taylor 2010) (2.9.7). A number of different reagents for
measurement of the respiratory burst response were then compared. H2DCFDA,
CM-H2DCFDA, carboxy-H2DCFDA, DHR 123, DHR 6G, and DHE were
investigated, all of which measure the production of hydrogen peroxide except
DHE which measures the production of superoxide. In order to detect a respiratory
burst response, the detection of hydrogen peroxide was thought to be more
appropriate than superoxide as hydrogen peroxide has been shown to be more
bactericidal against N. meningitidis (Roos et al. 2001; Dyet and Moir 2006).
When the different reagents were compared in a respiratory burst assay, no
responses were observed with H2DCFDA, Carboxy-H2DCFDA, DHR 6G, and
DHE. Non-specific fluorescence was observed with CM-H2DCFDA, with similar
fluorescence seen with the negative control serum and the homologous OMV
rabbit control serum. This was possibly a result of photoreduction of CM-H2DCFDA
to H2DCF during the course of the assay, as these compounds can be highly
photosensitive (Games et al. 2005). DHR123 was the only reagent which
demonstrated low fluorescence with the negative control and high fluorescence
with the homologous OMV rabbit control sera, and was chosen for all further assay
development. DHR 123 is used for detection of respiratory burst in other assays
(Aase et al. 1995; Lehmann et al. 1998; Bassoe et al. 2000; Walrand et al. 2003;
Freitas et al. 2009). HE and H2DCFDA have also been successfully used for
detection of ROS. However, the assay protocol used to test these reagents was
not necessarily optimal for all the reagents tested, but the assay had been
optimised for the measurement for opsonophagocytosis of N. meningitidis, and
therefore a reagent which could be used within the existing protocol was required.
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Thus no further investigation was conducted into the other reagents as DHR123
was able to detect the ROS of interest and within the assay parameters.
Other investigators have introduced DHR123 into the assay protocol in different
ways, some introducing DHR123 in the assay buffer with the cells (Lehmann et al.
1998) and others pre-loading the cells with the dye (Aase et al. 1995; McCloskey
and Salo 2000; Walrand et al. 2003; Brechard et al. 2005; Aase et al. 2007). Three
different methods were compared: preloading the HL60 cells, introduction of
DHR123 during the first assay incubation (opsonisation of bacteria, sera and
complement) or during the second assay incubation (addition of differentiated
HL60 cells). A significantly (P<0.05) higher respiratory burst response was
detected with DHR123 preloaded HL60 cells.
The preloading incubation time and the DHR123 concentration were then
optimised showing a significantly higher response with 15 minutes preloading of
HL60 cells with DHR 123 at a concentration of 50 jJg/ml.
DMF differentiation of HL60 cells produced granulocytic-like cells, and these are
commonly used in opsonophagocytosis assays (Romero-Steiner et al. 2003). The
use of PMNs is reliant on volunteer donation and this restricts the numbers of
samples which can be assessed in an assay, using HL60s allows larger numbers
of sera to be evaluated in a single assay. Use of PMNs from different volunteers
also introduces an additional variable in the assay, which may result in poor assay
reproducibility. HL60s are a promyelocytic leukaemia cell line, which do not
differentiate down the accepted maturation pathway for a promylocyte (Birnie
1988). HL60s have been reported to lack both specific and secretory granules,
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important in delivery of the membrane bound component of NADPH oxidase and
thus a lower respiratory burst response would be expected in comparison to
neutrophils, however a respiratory burst has been demonstrated in HL60s
(Nordenfelt et al. 2009) and they have been shown to be useful for investigations
measuring ROS production (Teufelhofer et al. 2003). It was therefore important to
compare HL60 cells with PMNs to assess whether the response of HL60s was
representative. A positive correlation was found when PMNs and HL60s were
compared in a respiratory burst with a panel of high, medium and low responding
human sera, leading to the conclusion that HL60s are a suitable cell line for the
detection of a respiratory burst response.
The introduction of a priming agent was investigated to see whether this could
improve the respiratory burst signal. Reagents were selected on the basis to prime
the cells, rather than directly stimulate the cells. FMLP, IFNy and TNFa have all
been shown to directly stimulate the respiratory burst response, but IFNy and
TNFa have also been shown to prime PMNs without stimulation of the respiratory
burst response, perhaps due to differences in the concentration, incubation time
and detection methods used when investigating the cytokine effects (Elbim et al.
1994; Menegazzi et al. 1994; Ellis and Beaman 2004). TNF-a, IL-8, GMCSF and
IFN-y have been shown to be able to prime neutrophils to be more responsive to
pathogens, and produce greater quantities of oxygen radicals when stimulated
(Phillips et al. 1990; Roilides et a/. 1993; Elbim et al. 1994). TNF-a, IL-8, GMCSF
and IFN-y were compared, and IFN-y showed a significant (P<0.05) increase in
assay response. The concentration and incubation time of IFN-y with HL60 cells
were optimised to 100 ng/ml for 3 hours prior to use within the assay. It was
observed that priming of HL60 cells with all of the cytokines tested moderately
increased the assay complement-only background, but this increase was not
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affected by the incubation time used. HL60 cells primed with cytokines were
compared with unprimed HL60 cells with a panel of mammalian sera, and showed
that cells primed with the different cytokines correlated with unprimed HL60 cells,
thus increasing the magnitude of the response but not alter the pattern of
response. Something not investigated during this work was the effect of
combinations of priming cytokines. Further work should investigate whether this
could further improve the respiratory burst within the HL60 cells. This may be more
representative of in vivo conditions where multiple priming cytokines would be
present during inflammation.
During the respiratory burst response hydrogen peroxide is produced, which
during this assay reacts with the DHR123 to form fluorescent rodamine 123 and
water (Invitrogen technical information sheet). The production of hydrogen
peroxide during the respiratory burst leads to a number of bactericidal chemicals
being produced following catabolism of hydrogen peroxide, a reaction which
occurs very quickly (Hampton et al. 1996). Sodium azide was used to inhibit the
myeloperoxidase activity and provide opportunity for the reaction with DHR123 to
occur. Very low levels of sodium azide were introduced into the assay buffer and a
significant (P<O.05) increase in assay respiratory burst response was observed.
As sodium azide itself is toxic, and therefore a further investigation was performed
to check for any impact on cell viability with sodium azide in the assay buffer. No
difference was found with or without sodium azide.
One further assay parameter investigated was the optimisation of glucose levels in
the assay buffer. Neutrophils require glucose to generate ATP and NADPH
through the pentose phosphate pathway, and NADPH is essential for the
respiratory burst response to occur, as it is consumed by the NADPH oxidase and
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leads to the production of superoxide, hydrogen peroxide and other ROS. As the
assay buffer contains 2% skimmed milk as a blocking agent the buffer already
contained glucose but this was at an unknown level. A range of concentrations of
glucose were introduced into the assay buffer and a significant (P<0.01) increase
in assay response was observed at 1 mM additional glucose, at higher levels 2
and 4 mM glucose a significant reduction in response was observed. 1 mM
glucose was therefore introduced into the assay buffer. Other published work
investigating the optimum experimental conditions required for measurement of
neutrophil respiratory burst, has found a glucose concentration of 0.5 mM to be
optimum, not showing any significant difference at higher concentrations (Freitas
et al. 2009).
An alternative bacterial fluorescent stain was required to measure uptake of
bacteria because DHR 123 and BCECF-AM had overlapping excitation and
emission spectrums (figure 4.4.1.1). BCECF-AM was used as a bacterial stain
because it stains internally, BCECF-AM is membrane permanent and once inside
the bacteria the AM ester group is cleaved by non-specific internal esterases,
resulting in a charged BCECF which leaks out of the bacteria at a low rate. This
method of internal bacterial staining does not mask surface epitopes, an important
consideration when utilising stained bacteria in assays assessing antibody induced
immune responses. Fluorescent labelling of meningococci for use in flow
cytometric assays has involved the use of the FITe, Rhodamine Green-X or Texas
Red labelling (Lehmann et al. 1998). These stains bind to amine groups, which
may mask surface epitiopes. Alternatively, OMV-coated fluorescent polystyrene
beads have also been used as phagocytic targets (Lehmann et al. 1999; Bassoe
et al. 2000; Martinez et al. 2002), however this method raises the issue of
relevance to the intact bacterial targets.
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Initial studies focused on an alternative fluorescent stain which would be able to
stain meningococci internally. SNARF-AM was shown to stain N. meningitidis
weakly even at very high stain concentrations and incubation times. When the
stained meningococci were assessed in an OPA, no detectable OP response was
observed. As this was the only suitable alternative AM dye, alternative stains were
considered. Syto dyes are nucleic acid stains which passively diffuse through cell
membranes to stain nucleic acid, and these stained N. meningitidis strongly and
uniformly (figure 4.4.3.1). However, when Syto stained bacteria were used in an
OPA, the stain was observed to leak out of the bacteria and diffuse into all HL60s,
as shown by the bright staining of all cells including dead HL60s (figure 4.4.3.2).
This made the stain unsuitable for use in the RBA.
PKH-26 dye attaches to lipohilic tails before diffusing into the cell membrane and
has been shown in previous studies to be an effective stain for lymphocyte
migration and proliferation studies (Givan et al. 1999; Batard et al. 2000). Bright
uniform staining was achieved with N. meningitidis, and following an OPA a
response was achieved at a lower level when compared with BCECF stained
bacteria, but was able to distinguish between the ALOH control serum and the
homologous OMV rabbit serum. In order to establish whether PKH-26 stained
bacteria could be used in conjunction with DHR123 to measure both uptake and
induction of a respiratory burst response, assays measuring either OP with PKH-
26 stained bacteria or RB with DHR123 preloaded HL60 cells were compared with
the duplexed assay measuring both parameters. A significant strong positive
correlation was observed with PKH-26 in the duplexed and singleplex assays
(r=0.95, P<0.05). No significant correlation was observed for DHR123 used in the
singleplex and duplexed assay (r=0.62). As PKH-26 and DHR123 were excited by
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the 488 nm laser, the observed poor stain compatibility could be attributed to the
occurrence of FRET (fluorescence resonance electron transfer). FRET has been
found to occur in situations where stains are within close proximity (5 nm), the
energy from excitation of a donor molecule is able to pass to an acceptor molecule
resulting in an increase in emission in the acceptor molecule (Ciruela 2008).
As PKH-26 was successful as a bacterial stain, a similar lipophilic dye to PKH-26
was assessed. DiIC1s(5)-DS stains using the same mechanism as PKH-26,
however it is excited by the 633 nm laser. DiIC1s(5)-DS has been used previously
to label and track embryonic cells, chosen for its ability to label strongly and
permanently (Fraser 1996). DiIC1s(5)-DS stained uniformally and maximally at 20
IJM,with increasing concentrations staining less well, caused by stain precipitation
(Invitrogen information sheet). When DiIC1s(5)-DS stained N. meningiiidis were
tested for compatibility with DHR123, again assays measuring either OP with
DiIC1s(5)-DS stained bacteria or RB with DHR 123 preloaded HL60 cells were
compared with the duplexed assay measuring both parameters. Significant
positive correlations were observed with both DiIC1s(5)-DS stained N. meningitidis
used in an OP and in the duplexed assay. Significant positive correlations were
also observed between DHR123 measured in the duplexed assay and DHR123
measured in an RB.
Assay precision was investigated for the duplexed assay using a selection of high
medium and low responding sera, assayed by three operators three times on a
single day. High variance was observed between operators and by one operator
with 16 of 21 sera having a CoV higher than 36%, which are higher than those
seen with ELISA where a typical acceptance criteria is set a S10% (Granoff et al.
1998). Other functional assays have reported CoV S15% for intra-assay variation
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reported for the validated SBA used in the MeNZB vaccine trials (Martin et al.
2005). Whereas a meningococcal OPA demonstrated a comparable level of
variance of s30% for intra and inter-assay variation (Taylor 2010) which was lower
than that observed with a pneumococcal OPA where much higher CoV have been
observed (Romero-Steiner et al. 2003). Measurement of respiratory burst
response by DHR123 has been reported to have good inter-assay variance (CoV
<10%) when using high responding serum, this variance increased with lower
responding serum (Lehmann et al. 1998). When the opsonic response and
respiratory burst response were analysed separately, the respiratory burst
response provided the greatest variation with CoV comparable to the measured
duplex response, whereas CoVs for intra-assay opsonic response showed 16 of
21 sera with a CoV <35%. This indicated that the variation resulted from the R-123
signal (respiratory burst response). This variation has also been observed by
Lehmann et al. who noted constant drift in R-123 signal with time after incubation
(Lehmann et al. 1998). However, DHR123 has been used successfully by other
investigators (Aase et al. 1995; Lehmann et a/. 1998; Bassoe et al. 2000), and is
perhaps not a problem if small numbers of samples are being tested, however this
assay was being developed as a high-throughput assay and therefore sample
stability over several hours is required whilst analysis by flow cytometry occurs.
To investigate whether this assay would be fixable, two duplexed assays were
performed either fixed with 1% formaldehyde for 15 min or unfixed, both assays
were analysed by flow cytometry at 0, 60 and 120 min after completion of the
assay. The unfixed opsonophagocytic response was consistent over the time
period tested, but fixation reduced the detectable opsonic response. Unfixed
respiratory burst response was variable over time, but following fixation showed a
progressively lower response over 120 minutes. Formaldehyde was therefore not
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compatible with either DHR123 or DiIC1s(5)-DS. Loss of R-123 signal could have
been because R-123 is sequestered by the mitochondria, and following fixation the
mitochondrion's membrane potential is lost resulting in the R-123 signal being lost
out of the cell (Poot et a/. 1996). In addition to this, R-123 is photosensitive and
this feature may also have contributed to the observed loss of signal and the
variation in signal observed between assay duplicates. The results also showed
that DiIC1s(5)-DS was sensitive to formaldehyde fixation.
DHR123 was found to be variable in the developed assay, yet because the assay
was developed for high-throughput use, the variation seen with the R-123 signal
was unacceptable subsequently the assay is only suitable for assessment of small
panels of sera. The R-123 signal was also found to be unfixable and therefore
future work would need to assess whether any other ROS detection agent would
be useable within the assay, focusing on a fixable reagent to improve assay
precision. These results found do show that caution should be applied assay using
DHR123 as a respiratory burst agent and that assay results need to be assessed
for precision, before data can be interpreted.
In addition to reagent selection, it would also be important for the development of
this assay to correlate the response of the duplexed assay (opsonophagocytosed
bacteria and respiratory burst) with the OP killing assay, with respiratory burst
alone and OPA (opsonophagcytosed bacteria) only. This would inform if a
duplexed assay would show a stronger correlation with the OP killing assay than
either phagocytosed bacteria or respiratory burst only.
The development of an assay which could measure both bacterial uptake and
respiratory burst induction would be a valuable tool for the assessment of a
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functional antibody response. The high-throughput nature would be a requirement
for use to assess large numbers of clinical sera, something which is difficult,
laborious and requires large volumes of serum with existing opsonic killing assays.
However, this work has shown this not to be possible with currently available
reagents. This work could be completed with the development of further
respiratory burst reagents.
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Chapter 5: Development of a human complement source for use in
immunoassays
5.1 Introduction
The pivotal role of complement in protection against meningococcal disease is
evident from the marked increase in disease susceptibility seen in complement
deficient individuals (Figueroa and Densen 1991; Hellerud et al. 2010). A central
role for SBA has been established in the protection against meningococcal
disease (1.4.1). Thus the serum bactericidal assay is currently the primary method
used in the assessment of vaccine-elicited responses. However, other studies
have shown protection in the absence of bactericidal antibody and that OP may
play an important role in protection from disease (Granoff 2009). Antibody-
mediated C3bliC3b deposition is able to induce OP through deposition onto the
bacterial surface followed by binding to CR1/3 receptors on the surface of the
granulocyte (Ross et al. 1987).
The use of a human complement source in these functional assays has been
problematic for many years (Santos et al. 2001). This results from the large
amounts of cross-reactive antibodies in the human population acquired by
nasopharyngeal carriage of different N. meningitidis and commensal Neisseria
strains, which can evoke meningococcal bacteriolysis in the absence of test
antiserum and cause interference in the results of the assays. A human
complement source can be obtained from a hypogammaglobulinaemic patient
(rare in the population and these individuals are treated with immunoglobulin
preparations). Alternatively, large numbers of volunteers are screened to find
serum or plasma which contains little or no cross-reactive antibody to the strain of
interest. Often this results in a different complement source from a different
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individual being used in assays against different strains leading to poor inter-strain
and inter-laboratory assay comparability. Baby rabbit serum has been used as a
complement source in both SBA and OPA (Findlow et al. 2007) due to the
absence of intrinsic bactericidal antibody and this is used as the complement
source for Men C and Men A SBAs (Maslanka et al. 1997; Andrews et al. 2003;
Keyserling et al. 2005; Kshirsagar et al. 2007). However, investigators have shown
that the use of rabbit complement results in increased bactericidal titres (Santos et
al. 2001). Initial studies suggested this was caused by the presence of low avidity
anti-MenB capsular antibody; absorption of these antibodies reduced bactericidal
titres but they were still not comparable with titres achieved using human
complement (Findlow et al. 2007). More recent work has now shown the increased
bactericidal titres results from the specificity of meningococcal factor H binding
protein for human factor H which leads to an overestimation of functional antibody
activity using baby rabbit complement (Granoff 2009). The availability of a
standard source of human plasma/serum for use as a complement source in both
the SBA and OPA is thus a key issue for the assessment of meningococcal
vaccines (Martin et al. 2005).
This study set out to develop a universal human complement source that could be
utilised in any immunoassay against any strain of N. meningitidis by optimising the
method for antibody depletion and assessing the effect on complement function.
This study also investigated depletion of large batches of plasma and the
reproducibility of the method.
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5.2 Results
5.2.1 Optimisation of complement source used- Plasma or Serum?
Initially, the use of either plasma or serum and the effect of anti-coagulant were
investigated in order to optimise the complement source used in meningococcal
immunoassays. The complement source used in previous investigations (Taylor
2010) was derived from plasma bags purchased from the National Blood Service.
It was impossible to know the length of time following extraction from the patient
before the sample was frozen and therefore this complement source may have
been variable as complement activates at room temperature and maintenance of
an intact complement cascade, requires storage at -80°C (Bjorkholm et al. 1986).
The products from the National Blood Service are routinely frozen at -20°C within
24 h, with the potential for loss of complement activity (Bjorkholm et al. 1986;
Belmusto-Worn et al. 2005; Livorsi et al. 2010). Blood products collected at the
National Blood Service are most commonly directly mixed with either Heparin (14-
17 U/ml) or EDTA (1.8 mg/ml) (ethylenediaminetetraacetic acid) as an anti-
coagulant. EDTA and heparin have been shown to have inhibitory effects on the
complement cascade (Mollnes et al. 2002), and therefore the effect on the
complement system would need to be investigated.
An alternative to Heparin or EDTA is to use lepirudin (also known as Refludan) as
an anti-coagulant. Lepirudin is an anti-thrombic drug which has been developed
for individuals presenting with an allergy to heparin. Lepirudin is a recombinant
hirudin, a naturally occurring peptide in the salivary glands of leeches. This has
been widely used in complement research as it reportedly does not interfere with
the complement cascade (Mollnes et al. 2002). Alternatively serum could also be
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used as a complement source. However, the activation of the coagulation pathway
has also been shown to disrupt the complement cascade (Amara et al. 2008).
To investigate alternative complement sources, blood was taken from volunteers
and anti-coagulated with EDTA (1.8 mg/ml), heparin (14-17 U/ml), lepirudin (100
lJg/ml) or isolated as serum in a serum separator tube which contains clot
activators (silica particles) and a gel layer used to separate the serum from the
coagulated pellet of cells. Blood was taken from a volunteer and immediately
processed (2.10.1) to minimise complement activation. All samples were then IgG-
depleted using a 5 ml protein G Sepharose column (2.10.2) before being analysed
in a CDA measuring antibody-mediated deposition of C5b-9 and C3b/iC3b.
No deposition of C5b-9 or C3b/iC3b was seen with rabbit serum raised against
OMVs prepared from the same strain with EDTA anti-coagulated plasma as a
complement source (figure 5.2.1.1 a and b). This was because EDTA is a very
potent complement inhibitor as it binds Ca2+ and Mg2+ which are required for a
functional complement pathway (James 1982).
No significant (P<0.01) difference in C3b/iC3b deposition was observed with
homologous strain rabbit anti-OMV serum when comparing heparin or lepirudin
anti-coagulated plasma. However, both of these complement sources resulted in
significantly higher C3b/iC3b deposition than observed with EDTA anti-coagulated
plasma and serum (figure 5.2.1.1a). Lepirudin anti-coagulated plasma had
significantly (P<0.01) higher C5b-9 deposition with homologous strain OMV rabbit
serum in comparison to heparin, EDTA and serum (figure 5.2.1.1b).
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When serum was used as the complement source in the COA a further
resuspension step was required because the samples began to form a gel during
the assay.
To further evaluate the complement sources, lepirudin, heparin and EOTA plasma
and serum were compared in the OPA (2.9.7). Lepirudin, EOTA and heparin anti-
coagulated plasma were compared with serum in the opsonophagocytosis assay.
A significantly (P<0.01) higher opsonic activity was observed with lepirudin anti-
coagulated plasma than any other complement source, with no opsonic activity
observed at all with EDTA anti-coagulated plasma (figure 5.2.1.2).
This assay was also performed using serum as a complement source, the
samples could not be analysed using the flow cytometer as the samples had
become gel-like (as in the COA). However, a further resuspension step failed,
rendering this complement source unusable for the OPA.
Baby rabbit complement has been used as a complement source in published OP
assays (Maslanka et a/. 1997; Taylor 2010), as it can be bought in large batches
and lacks cross-reactive antibodies, improving inter-strain and inter-assay
comparability. A comparison was made between baby rabbit complement and
lepirudin as a complement source in the OPA. Significantly (P<0.01) higher
responses were observed with baby rabbit complement (figure 5.2.1.3). This is
likely to have occurred as fHbp is specific for human factor H and the recruitment
of this negative regulator only occurs in assays using human complement and thus
the results using baby rabbit complement are higher than those with the human
lepirudin-treated complement.
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The results from this series of experiments supported the choice of lepirudin anti-
coagulated plasma as a complement source.
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Figure 5.2.1.1 Comparison of different anti-coagulated complement sources
in the dCDA.
Antibody-mediated C3b/iC3b (a.) or C5b-9 (b.) deposition on the surface of N.
meningitidis M01240149 using either lepirudin, heparin, EDTA anti-coagulated
blood or serum as a complement source, mediated by homologous strain OMV
rabbit serum. Significance was determined by z-test (**P<O.01), and error bars
denote standard deviation.
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Figure 5.2.1.2 Comparison of different anti-coagulated complement sources
in the OPA.
Comparison of OP activity using lepirudin, heparin and EDTA anti-coagulated
complement sources on the surface of N. meningitidis M01240149 mediated by
homologous rabbit anti-OMV serum. Significance was determined by z-test
(**P<O.01), and error bars denote standard deviation.
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Figure 5.2.1.3 Comparison of baby rabbit and human complement in an OPA.
OPA with N. meningitidis M01240149 comparing the activity of lepirudin anti-
coagulated complement source and baby rabbit complement. Significance was
determined by z-test (**P<O.01). and error bars denote standard deviation.
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5.2.2 Comparison of total haemolytic complement activity comparison of
complement sources.
Plasma samples anti-coagulated with either heparin or lepirudin were compared
with serum in a total haemolytic complement assay kit (The Binding Site, UK). This
was performed to determine whether the classical pathway of the complement
cascade was intact. The total haemolytic complement assay measures the
classical and alternative complement cascade, by measuring the lysis circle
formed following complement activation. Lysis circle radii from the standard curve
and the control wells were used to derive the activity in the different complement
types tested (figure 5.2.2.1). The heparinised blood demonstrated a double ring of
complement lysis. This was a result of low haemolytic complement activity,
possibly as a result of complement pathway dysfunction. Heparin has previously
been shown to interfere with complement activity and has a factor H binding site
thus potentially able to remove factor H from the complement, which might explain
the haemolytic pathway dysfunction (Mollnes et al. 2002). The complement activity
seen for lepirudin anti-coagulated blood was high at 1130 CH100 units/m!. This
high level of activity was consistent with the antibody-mediated C5b-9 deposition
results reported in 5.3.1 (figure 5.2.2.1 i) and lepirudin's reported non-interference
with the complement cascade (Mollnes et al. 2002). Lepirudin anti-coagulated
complement activity was shown to be higher than that seen using serum as a
complement source (figure 5.2.2.1). Lepirudin therefore showed the greatest
classical pathway function (figure 5.2.2.1), opsonic activity (figure 5.2.1.2) and
antibody-mediated C5b-9 deposition (figure 5.2.1.1). Lepirudin anti-coagulated
plasma was thus used in all further studies.
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Figure 5.2.2.1 Total haemolytic complement activity in different complement
sources.
(a) (b) and (c) Total haemolytic complement activity lysis rings measurable for
assay standard curve. (d) Negative control PBS only sample and (e) positive
control complement sample. (f) Standard curve used to derive the complement
activity of the test samples. Test samples serum (g) heparin (h) or lepirudin (i).
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5.3 Optimisation of antibody depletion of plasma - ELISA assessment of
efficiency and reproducibility of antibody depletion.
The antibody-mediated immunity to meningococcal disease is primarily IgG-
dependent but there is also a role for IgA and IgM. IgG is able to initiate a range
of effector functions including MAC deposition and bacteriolysis, and also
C3b/iC3b deposition and OPA (Naess et al. 1999). Studies investigating the
contribution of IgG subclass to activate human complement show IgG1 = IgG3 >
IgG2 » IgG4 (Naess et al. 1999). Effective complement activation can also be
mediated by IgM. However, IgM has been shown not to interact with phagocytes,
whereas IgA does not bind C1q and is therefore not able to activate the classical
complement pathway. However, IgA has been shown to activate the alternative
pathway (Vidarsson et al. 2001). In addition, IgA is not able to mediate
complement bactericidal activity. However, it is able to induce some phagocytic
activity and respiratory burst response (Vidarsson et al. 2001). The contribution of
the different antibody classes and subclasses to complement activation varies,
thus it was important to assess if any were removed following depletion with
different matrixes.
Native plasma was compared with antibody depleted plasma anti-coagulated with
lepirudin depleted by either: protein G Sepharose which binds IgG1, IgG2, IgG3,
IgG4 (high affinity), protein L Sepharose which removes IgG, IgM, IgA, IgE, IgO
(all high affinity), and protein A Sepharose which removes IgG1, IgG2, IgG4 (high
affinity) IgA, IgO, IgM, IgE (low affinity) (Thermo technical information sheet).
No significant (P<0.01) reduction in IgA was observed between native plasma and
protein A-depleted plasma. This could be explained by the low affinity binding of
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protein A Sepharose with IgA (table 5.3.1). The greatest reduction in IgA was
observed following protein L depletion, and was found to be significant (P<O.01),
and was consistent with the expected high affinity binding of IgA by protein L (table
5.3.1). A significant (P<O.01) reduction was also observed in IgA following
depletion with protein G (table 5.3.1). This was unexpected as protein G is
reported to remove all IgG subclasses but not IgA (Thermo technical information
sheet).
A significant (P<O.01) decrease in IgM was observed between the native plasma
and plasma antibody-depleted with protein L, protein A or Protein G (table 5.3.1).
This reduction was expected following depletion with protein L or A as they are
reported to bind IgM with high and low affinity respectively. The significant
(P<O.01) reduction in IgM observed following depletion with protein G was
unexpected as this is not reported to bind IgM (Thermo technical information
sheet).
Following depletion with protein G there was a significant (P<O.01) reduction in
IgG (table 5.3.1). This resulted in almost no detectable IgG by ELISA. Significant
(P<O.01) falls in IgG were also observed following depletion with protein A or L
(table 5.3.1). The drop in IgG was minimal for both these depletion methods. This
was expected for depletion with protein A, however protein L binds IgG to high
affinity and only low levels of IgG were removed. This would perhaps suggest that
the binding sites available were saturated by binding IgM and IgA.
The removal of IgG was further investigated using an ELISA to assess the
depletion of each subclass. Significant (P<O.01) reductions in IgG1 were observed
between native plasma, protein G depleted plasma and protein A depleted plasma
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(table 5.3.1). Depletion of IgG1 using protein G was complete with no detectable
IgG1, which was consistent with the predicted outcome. No significant depletion of
IgG1 was observed with protein L-depleted plasma (table 5.3.1). This was an
unexpected finding as protein L is reported to bind all antibody to high affinity,
although this was consistent with the total IgG ELISA result which indicated a
significant but low level reduction in IgG (Thermo technical information sheet).
Significant reductions (P<O.01) in IgG2 were observed between native plasma and
protein G and L depleted plasma. Depletion of IgG2 using protein G was complete
(table 5.3.1). There were significant (P<O.01) reductions in IgG3 following
depletion with protein A and protein L, with no detectable levels of IgG3 seen
following depletion with protein G (table 5.3.1). This result was unexpected for
protein A depletion as this does not bind IgG3 (Thermo technical information
sheet). Protein G and protein L depleted plasma showed a significant (P<O.01)
reduction in IgG4 (table 5.3.1).
Thus protein G depletion was selected as the optimum method which provided the
lowest assay background due to the complete removal of IgG.
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Mean mg/ml of Immunoglobulin
Native ProteinG Protein A Proteinl
depleted depleted depleted
plasma plasma plasma
IgA 2.0 1.5 ** 2.0 0.5 **
IgM 2.8 0.6 ** 1.2 ** o **
IgG 3.4 0.04 ** 3.0 ** 2.8 **
IgG1 6.5 o ** 2.4 ** 6.1
IgG2 3.0 o ** 3.1 1.6 **
IgG3 3.8 o ** 1.4 ** 1.2 **
IgG4 0.9 o ** 0.8 0.4 **
Table 5.3.1 Antibody EliSAs comparing antibody depletion methods.
Significance was measured by t test (**P<0.01).
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5.4 Optimisation of antibody depletion of plasma - Assessment of
complement function using radial immunodiffusion assays.
As described earlier, using human complement in immunoassays is problematic,
in order to achieve a human complement source which could be used for assays
using all strains, the depletion of antibody was investigated. Native plasma was
compared with antibody-depleted plasma, depleted using either: protein G
Sepharose which removes IgG1, IgG2, IgG3, IgG4 (high affinity), protein L
Sepharose which removes IgG, IgM, IgA, IgE, IgD (all high affinity), or protein A
which removes IgG1, IgG2, IgG4 (high affinity) IgA, IgD, IgM, IgE (low affinity).
Total haemolytic complement activity was significantly (P<O.01) reduced following
removal of antibody with all depletion methods, with the greatest reduction
observed following depletion with protein G (figure 5.4.1). The alternative pathway
also showed significant (P<O.01) reduction in activity (figure 5.4.2), however there
was no significant (P<O.01) difference observed between the depletion methods.
This observed loss in function was attributable to a dilution effect resulting from the
affinity chromatography.
Overlay plots comparing the complement-only control measuring C3b/iC3b
deposition, showed that the protein G-depleted complement had the lowest
background complement deposition (figure 5.4.3a). Antibody-dependent C3b/iC3b
deposition measured using homologous rabbit sera, showed only small differences
between depletion methods (figure 5.4.3b). Overlay plots comparing the
complement only control measuring C5b-9 deposition, showed that protein G-
depleted complement had the lowest background control (figure 5.4.4a). Antibody
dependent C5b-9 deposition measured using homologous strain OMV rabbit sera
showed only small differences between depletion methods (figure 5.4.4b). A low
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assay background from protein G-depleted plasma, and a high level of antibody-
mediated C3b/iC3b and C5b-9 deposition with homologous strain OMV rabbit
sera, similar to that observed with all other depletion methods and also native
plasma, lead to the conclusion that protein G depletion was optimal.
These results indicated that the best reduction of assay background without
reduction in positive response was achieved by protein G depletion. This was
surprising as protein L depletion was expected to remove all antibody types with
high affinity and although IgG is considered to be the most significant contributor
to initiation of the classical complement cascade, IgM and IgA are considered to
play a smaller role (Naess et al. 1999; Vidarsson et al. 2001). It was possible that
protein L produced poorer depletion results due to saturation of binding to the
column. A possible way of improving the depletion results obtained with protein L
would be to dilute the plasma being used with the column, but it was considered
that alteration of plasma concentration used in the depletion would significantly
change the concentration used in the assay, altering the assay parameters.
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Figure 5.4.1 Comparison of total haemolytic function following depletion
methods using either protein A, protein L or protein G Sepharose.
Significance was measured by t-test (**P<O.01. * P<O.05). and error bars denote
standard deviation.
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Figure 5.4.2 Comparison of alternative complement cascade haemolytic
function following depletion methods using either protein A, protein L or
protein G Sepharose.
Significance was measured by t test (**P<O.01). and error bars denote standard
deviation.
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Figure 5.4.3 Overlay plot illustrating the difference in C3b/iC3b deposition
achieved with either protein A, protein L, protein G depleted complement or
native complement.
Overlay plot illustrating the difference in C3bliC3b deposition in an (a.)
complement only control and (b.) homologous strain OMV rabbit sera when using
complement depleted with either protein A (green), protein L (blue) or protein G
(red) Sepharose or native complement (black). Assay performed using N.
meningitidis M01240149.
Cl)....c
ID
>
ID......o
~
ID
.0
E~z
a. Fluorescence
63
Cl) ,....
C
ID
>
ID......o
~
ID
.0
E
::l
Z
b. Fluorescence
246
47
f/)......c:
ID
>
ID-o.....
ID..a
E
::J
Z
42
Cl)......c
Q)
>
ID
I
J
f
.....
ID..a
E
::J
Z
Figure 5.4.4 Overlay plot illustrating the difference in C5b-9 deposition
achieved with either protein A, protein L, protein G depleted complement or
native complement.
Overlay plot illustrating the difference in C5b-9 deposition in an (a.) complement
only control and (b.) homologous strain OMV rabbit sera using complement-
depleted with either protein A (green), protein L (blue) or protein G (red)
Sepharose or native complement (black). Assay performed using N. meningitidis
M01240149.
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5.5 Effect of addition of C1q on complement activity
Removal of antibody using protein G provided the optimal reduction in IgG (table
5.3.1), and produced the lowest COA background (figure 5.4.3 and figure 5.4.4).
However, when the total haemolytic complement activity was assessed, a
significant reduction was observed with the lowest activity seen in protein G-
depleted plasma compared with the other depletion methods tested (figure 5.4.1).
Protein G has been used for the purification of C1q (Kolb et al. 1979) and it was
hypothesised that following antibody binding to the column Fc receptors were left
exposed and this subsequently leads to the binding of C1q, resulting in removal of
both antibody and C1q from the plasma. C1q is a vital part of the initiation of the
classical pathway, a reduction in C1q concentration would reduce the classical
haemolytic activity of complement (Kolb et al. 1979).
ELISA confirmed the low levels of C1q present following antibody depletion of
plasma (figure 5.5.1). Addition of C1q (Quidel) back into the antibody-depleted
complement was investigated to determine if this would restore the lytic activity of
complement. A range of C1q concentrations was used around that present in
normal human plasma (approximately 77 j.Jg/ml) (Kolb et al. 1979) and the
concentration observed prior to antibody depletion (40 j.Jg/ml). C1q was added
back into the protein G-depleted complement source and a COA was performed to
look at the effect on C5b-9 and C3b/iC3b deposition. This showed significant
(P<0.01) increases in the antibody-mediated C5b-9 deposition (figure 5.5.2a),
whilst C3b/iC3b deposition decreased (figure 5.5.2b). Total haemolytic activity was
measured and compared with the complement prior to IgG depletion. The levels of
total haemolytic complement activity were restored to 72% of the original activity
before IgG depletion (figure 5.5.3). Addition of C1q restored the antibody-depleted
complement source and would therefore be used in future assays.
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Figure 5.5.1 C1q ELISA comparing C1q concentration before and after IgG
depletion of complement.
Error bars denote standard deviation.
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Figure 5.5.2 Addition of increasing concentrations of C1q to dCDA.
Antibody-mediated complement deposition of C5b-9 (a) or C3b/iC3b (b) on the
surface of N. meningtidis NZ98/254 with a high responding human serum following
addition of various concentrations of C1q (Quidel). Significance was measured by
z test (**P<0.01). and error bars denote standard deviation.
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5.6 Large scale antibody depletion from plasma.
T0 test sera from large clinical trials it is important to use the same complement
source for comparability. The production of large scale batches of plasma which
had been antibody-depleted was therefore investigated.
The optimised IgG depletion method was scaled up to process upto 250 ml of
plasma in a single batch. Initially blood was taken from 10 volunteers with plasma
obtained using Lepirudin as an anti-coagulant (2.10.1). This was then split into
several batches to be processed on a 250 ml protein G column. The large scale
process, unlike the rapid small scale process, required the plasma to remain at
4°C for several hours, which could have resulted in the loss of complement
function. The reproducibility of the large scale process was assessed, by
comparing large scale depletion batches all derived from the same pooled plasma.
IgG-depleted plasma from 2 x 200 ml batches was prepared. 200 ml of plasma
was thawed and passed through the protein G column. Then flow through fractions
were collected (figure 5.6.1), aliquoted and frozen at -80°C. Following this,
antibody was eluted from the column using 0.1M glycine HCI (pH 2.7) to clean the
column. Each depletion batch had a very similar chromatogram (figure 5.6.1).
Batches of protein G-depleted plasma were assessed using ELISA to compare the
consistency of antibody depletion. Significant (P<0.01) reduction in IgA was
observed between native plasma and both batches of protein G-depleted plasma.
A significant (P<0.01) difference was observed in the amount of IgA removed in
each batch (table 5.6.1). A significant (P<0.01) reduction in IgM was observed
between native plasma and both batches of protein G-depleted plasma, with no
significant difference observed between batches (table 5.6.1). Following depletion
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with protein G a significant (P<O.01) reduction in IgG was observed and this was
consistent between the batches tested (table 5.6.1), this was also the case for
IgG1, IgG2, IgG3 and IgG4 with no detectable IgG in either batch (data not
shown).
A comparison of total haemolytic activity between the two batches of depleted
plasma showed no significant difference in either classical complement haemolytic
activity or alternative pathway haemolytic activity (figure 5.6.2 and figure 5.6.3).
Complement batches showed highly similar overlay plots for using antibody-
mediated C3b/iC3b and C5b-9 deposition (figure 5.6.4). Batch variation was
investigated further by comparing antibody-mediated C3b/iC3b and C5b-9
deposition. Significant (P<O.01) variation between complement batches was
observed with 1 of 4 sera in both the antibody-mediated C3b/iC3b (figure 5.6.5) or
C5b-9 (figure 5.6.6) deposition, with all other sera tested showing no significant
(P<O.05) differences. Batch variation was also compared in the
opsonophagocytosis assay. A significant (P<O.05) difference between complement
batches was again observed in one of the four sera tested (figure 5.6.7).
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Figure 5.6.1 Chromatogram illustrating IgG depletion of lepirudin-treated
plasma using protein G.
Chromotagram indicates the fractions of depleted complement collected for snap
freezing (a.), and the IgG removed and eluted from the plasma with O.2M Glycine
HCL (b.).
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Mean mg/ml of Immunoglobulin
Native ProteinG Protein G Significance between
Batch 1 Batch 2 batches
IgA 2.0 1.5 ** 1.00** Significant difference
between batches (P<0.01).
2.8 0.6 ** 1.07** No significant difference
between batches.
IgG 3.4 0.04 ** 0.08** No significant difference
between batches.
Table 5.6.1 Comparison of antibody depletion between batches of protein
depleted plasma.
Significance was measured by Hest (**P<0.01).
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Figure 5.6.2 Comparison of total haemolytic activity of two batches of
plasma following depletion with protein Gadding 40 fJg/ml of C1q.
Error bars denote standard deviation.
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Figure 5.6.4 Overlay plot illustrating consistency between depleted plasma
batches in a dCDA.
Overlay plot illustrating antibody-mediated (a) C3b/iC3b and (b) C5b-9 deposition
on N. meningitidis NZ98/254 for a homologous strain OMV rabbit control serum
using antibody-depleted plasma from batch 1 and batch 2.
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Figure 5.6.5 Antibody-mediated C3b/iC3b deposition on N. meningitidis
NZ98/254 comparing antibody-depleted plasma from batch 1 and batch 2.
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Figure 5.6.6 Antibody-mediated C5b-9 deposition on N. meningitidis
NZ98/254 comparing antibody-depleted plasma from batch 1 and batch 2.
Significance was determined by z-test (*P<O.05), and error bars denote standard
deviation.
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Figure 5.6.7 Opsonophagocytosis assay using N. meningitidis M01240013
comparing antibody-depleted plasma from batch 1 and batch 2.
Significance was determined by z-test (*P<O.05), and error bars denote standard
deviation.
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S.7 Discussion
Complement source is a key component used in the COA and other functional
assays used to assess antibody-induced bacterial lysis and opsonophagocytosis
of N. meningitidis, and the optimisation of the complement used and the extraction
method are important to allow the use of a single human complement source for
all strains. Use of a human complement source in these assays has been
problematic, complicated by the large amounts of cross-reactive antibodies in the
population resulting from nasopharyngeal carriage of different N. meningitidis and
commensal Neisseria strains (Cartwright et al. 1987). Large numbers of volunteers
are screened to find a complement source which contains little cross-reactive
antibody to a specific strain, resulting in different complement sources being used
in assays against different strains and leading to poor inter-strain and inter-
laboratory comparability. The antibody-mediated C3b/iC3b deposition assay
initially used antibody-depleted human heparinised plasma, which was routinely
antibody-depleted using a 1 ml protein G column immediately before use (2.10.2).
Other assays have successfully used baby rabbit complement to assess the
antibody induced bacterial lysis and opsonophagocytosis for N. meningitidis. Baby
rabbit complement has been used in SBAs to assess serogroup A, C, Y and W135
vaccine responses (Maslanka et al. 1997; Andrews et al. 2003; Keyserling et al.
2005; Kshirsagar et al. 2007). Baby rabbit complement has been used as it is
easily standardisable and can be purchased in bulk, reducing assay variation and
it had no cross-reactive antibodies to cause high assay backgrounds. However,
serum bactericidal assays using baby rabbit complement have been shown to give
higher responses than that achieved using human complement, (Zollinger and
Mandrell 1983; Santos et al. 2001; Granoff 2009) potentially overestimating the
protection afforded. Correlation between the rSBA and the hSBA has been shown
using serogroup C N. meningitidis, but weaker correlations have been shown with
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serogroups A, W135 and Y (Gill et al. 2011). In addition, investigations have
indicated that the high levels of IgM in vaccinee sera could cause increasing levels
of bactericidal activity in the rSBA whereas this was not shown to affect the
bactericidal titre measured with the hSBA, thus resulting in false assessment of
protective efficacy (Santos 2010). Some of the differences between rabbit and
human complement could be attributed to the specificity of meningococcal fHbp
with human factor H (Granoff 2009). Factor H is able to cleave C3 and turn C3b (a
part of the C5 convertase) into iC3b, a component able to contribute to
opsonophagocytosis but not in the formation of C5b-9. Thus, lower bactericidal
titres (1-2 log drop) are observed using human compared with rabbit complement
(Granoff 2009). In addition to factor H, meningococci have other surface
expressed proteins which contribute to resistance to complement mediated killing.
Both PorA and type IV pili are able to bind C4 binding protein (Jarva et a/. 2005), a
protein which plays a role in proteolysis of the C4 classical complement cascade
component. The recruitment of these negative regulators of the complement
cascade could significantly increase survival of bacteria in serum (Schneider et al.
2006; Schneider et al. 2007). Human complement is therefore the optimal
complement source for use in these assays and has been widely used as a
complement source in SBA against N. meningitidis serogroup B.
This study optimised the complement source used, comparing plasma anti-
coagulated with lepirudin, EDTA, heparin or serum. Lepirudin anti-coagulated
plasma has significantly (P<0.01) higher levels of C3b/iC3b and C5b-9 deposition
and OP activity. This result is explained as lepirudin is an anti-thrombic drug which
has been reported as an anti-coagulant which does not activate complement
(Mollnes et al. 2002), whereas the use of both EDTA and heparin as
anticoagulants in plasma isolation or clot activators in serum isolation can
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negatively affect the activation of complement. It is generally accepted that
complement activation cannot occur with EDTA present as this chelates Ca2+ and
Mg2+(James 1982) and heparin also inhibits complement activation (Mollnes et al.
2002). The mechanism of complement dysfunction is unknown, but heparin has
been shown to have two binding sites for fH (Blackmore et al. 1996; Blackmore et
al. 1998) and this could have contributed to the dysfunction in the complement
cascade observed in the total haemolytic radial immunodiffusion assay (5.2.2). In
addition to this N. meningitidis can express neisserial heparin binding antigen
(NHBA) (Findlow et al. 2010) a potential route of additional fH binding and
complement regulation. Therefore a complement source with higher
concentrations of heparin than is found in normal human plasma (as added during
the plasma processing) could also affect assay results.
It was observed that samples using serum as a complement source became gel-
like in the OPA and therefore could not be analysed by flow cytometry, perhaps a
result of incomplete removal of clotting factors, rendering serum unusable as a
complement source in this assay. Higher OPA values (P<0.01) were obtained with
a rabbit complement source when compared with the IgG-depleted human
complement source, possibly because of the specificity of negative complement
regulators for human complement.
Aase et al. 2007 used human serum as a complement source with a Bordetel/a
pertussis OPA and depleted antibody from the human serum using a protein G
column, this method was also used in Taylor 2010. No comparison has been
made between the functional affect of antibody depletion from plasma using other
available matrices. Thus, this study compared antibody depletion by affinity
chromatography using either protein G, A, or L (2.10.1), and also investigated the
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functional total haemolytic activity and the alternative haemolytic activity of the
complements.
Plasma was compared before and after antibody depletion using a radial
immunodiffusion assay able to detect either the function of the classical
complement cascade or the alternative complement cascade. Following antibody
depletion with protein A, G and L, a significant (P<0.01) fall in total haemolytic
activity was observed. The largest fall in haemolytic activity in comparison to the
native plasma was observed following depletion with protein G, which was
attributed to the removal of C1q (figure 5.5.1), possibly caused by binding to
exposed heavy chain constant region 2 in the Fc portion of IgG which had bound
to protein G (Kolb et al. 1979; Hombach et al. 2005). This is significant as C1q is
an important component in the initiation of the classical pathway and thus affects
the haemolytic function of the complement (Kolb et al. 1979). C1q was added back
into the antibody-depleted complement in a range of concentrations near to that of
the native levels found in serum (77 ~g/ml) (Kolb et a/. 1979). This caused
significant (P<0.01) increases in the antibody-mediated C5b-9 deposition and the
total haemolytic activity was restored to 75% of the original haemolytic level.
Unexpectedly, the C3b/iC3b deposition levels were shown to significantly (P<0.01)
fall as the C5b-9 deposition levels increased. The reason for this requires further
investigation.
To further this work, it would be interesting to purify native C1q from the protein G
following depletion of antibody from plasma and reintroduce this to the IgG-
depleted plasma. It is possible that the endogenous C1q may improve the total
haemolytic pathway function to a greater degree than that observed when
purchased C1q is added.
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Further work should also include investigations into whether antibody depletion
removes other components of the complement cascade from the plasma. For
instance properdin, C2, C4 and the late complement components C5- C9, as
deficiency in any of these components will also affect the function of the
complement.
Significant (P<O.01) reductions in alternative haemolytic activity were seen
following depletion with protein A, G and L. The fall in alternative pathway activity
was consistent between all the depletion methods used, possibly a result of a
small dilution effect of processing the plasma on the column.
Plasma depleted using protein A, G or L was then compared in the antibody-
mediated C3b/iC3b and C5b-9 deposition assay. Overlay plots demonstrated the
lowest assay background (bacteria, complement and conjugate without test
serum) following depletion with protein G, with all the depleted and native plasma
showing comparable antibody-mediated deposition of C3b/iC3b with homologous
OMV rabbit sera against M01240149. This same pattern was repeated with
antibody-mediated deposition of C5b-9, and suggested that the use of protein G
produced the best complement source. However the reduction in antibody was
also linked to the reduction in total pathway function.
Following depletion of antibody using either Protein A, L or G the IgA, IgM, and
IgG content was compared with native plasma. Protein G removed IgA, IgM and
all subclasses of IgG, and produced plasma which had a low assay background
when tested in the antibody-mediated C3b/iC3b and C5b-9 deposition assay,
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whilst retaining the similar measurable deposition levels as the native plasma.
Protein G is reported to bind only IgG1, IgG2, IgG3 and IgG4. Therefore the
removal of IgM and IgA although to a lesser extent, was unexpected. Some of this
reduction in IgM and IgA could have been a result of a dilution effect observed
following processing the plasma in this way. Protein A affinity chromatography also
removed a significant proportion of IgG3, a protein it reported not to bind, however
significant reductions in IgM and IgG1 were observed. Protein L removed
significant levels of IgM and IgA and significant reductions in IgG2, IgG3 and IgG4
were also observed. However the level of reduction was much less in comparison
to protein G depletion. This was an interesting result as protein L is reported to
bind all antibody to high affinity, but in this experiment did not remove IgG as
effectively as protein G. This may have been because the protein L column had
reached its binding capacity (20 mg/ml). Diluting the plasma would have perhaps
improved the antibody removal achieved using this matrix, however this would
have impacted on its use in the various assays. In addition to this antibody binding
to protein L will only occur if the immunoglobulin has the appropriate kappa light
chain. Lambda light chains and some kappa light chains are unable to bind. thus
making this a less favourable method of depletion as there is an approximate 2: 1
ratio of kappa : lambda light chain in humans and thus a third of antibody will not
be able to bind (thermo technical information sheet). The results from protein G
depletion confirmed almost complete depletion of IgG and the lowest assay
background without significant effect on the assay response. This was therefore
the optimal complement source.
Large scale depletion was completed for two batches derived from the same
pooled sample of lepirudin-anti-coagulated plasma. The batches were compared
for classical and alternative pathway function in a haemolytic assay, antibody
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ELISA and in both the antibody-mediated C5b-9 and C3b/iC3b deposition assay
and the OPA. Large scale depletion produced a complement source which was
functional and showed no significant difference between batches in either the total
or alternative haemolytic assays. This batch consistency was also confirmed in the
IgM, totallgG, with a significant but small difference in IgA observed. Similar levels
of complement activity in the COA and OPA were confirmed. This illustrated that
the method of depletion was reproducible when using the same plasma (mixture of
10 volunteers). Further work should investigate reproducibility of a larger number
of complement batches from different volunteers as this could potentially cause
significant variability between batches. In addition to this it would be important to
compare sero-negative (for the test strain) normal human complement with IgG
depleted complement in an SBA against a panel of high, medium and low
responding human sera.
The optimal complement source was found to be lepirudin anti-coagulated plasma
which had been antibody-depleted using protein G with C1q (Quidel) added at 40
IJg/ml prior to use in an assay. Further work could investigate whether by replacing
the C1q (Quidel) with endogenous C1q purified from the protein G column, could
improve the functionality of the complement. Further work could also investigate
the function of the other components of the complement system. The development
of an antibody-depleted complement source which is functional in OPA and SBA is
important as it will improve assay reproducibility, as the same complement source
can be used across all strains and could be used in inter-laboratory
standardisation of these assays.
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Chapter 6: General discussion
6.1 General discussion
A correlate of protection is 'a specific immune response to a vaccine that is closely
related to protection against infection or disease' (Plotkin 2010). The development
of a correlate requires knowledge of the immune mechanisms involved in
protection. Often there are multiple mechanisms involved and therefore co-
correlates are required to assess protection. Alternatively, a true correlate may not
be achievable either because the mechanism of protection is unknown or difficult
to measure, and in this case a surrogate of protection can be used which
correlates with the true correlate of protection.
Measurement of immune responses responsible for protection, and identification
of correlates of protection, are a requirement for the development of effective
vaccines. Correlates can be used for licensure of potential vaccines where
demonstration of efficacy is not possible via clinical trials; for example when
disease levels are too low to assess efficacy, such as meningococcal disease.
Correlates are also important in the identification, development and assessment of
pre-clinical novel vaccine candidates. There are many adaptive immune
responses which can correlate with protection. Correlates of protection for
vaccines mediated by antibody production are the most understood, although
multiple mechanisms are likely to protect against infection, and thus for some
diseases multiple co-correlates might be required for vaccine assessment.
Vaccination-induced memory Band T cells are likely to be important in diseases
with long incubation periods, for example Hepatitis B, where B cell memory
measured by ELiSPOT is a surrogate of protection. Antibody levels of >10 mlU/ml
(measured by ELISA) are protective after vaccination but after several years 50%
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of vacinees are found to be seronegative. Despite this the established B cell
memory is able to produce antibodies following stimulation with antigen and confer
protection (Chen et al. 1990). For infections with a very rapid disease onset (for
example N. meningitidis or H. influenzae), loss of circulating antibody could result
in a vaccinee becoming susceptible where the invasion of the organism is faster
than the generation of antibody by memory B cells (Anderson et al. 2000). When a
3 dose Hib vaccine schedule was introduced in the UK with children <1 year, the
vaccine efficacy was observed to be lower than in countries which had introduced
a booster dose. Although a memory response to Hib polysaccharide had been
demonstrated in vacinees with no circulating antibody, due to the rapid disease
onset vaccine effectiveness only increased following the introduction of a booster
dose and catch up campaign, and thus circulating antibody is required at the time
of infection, to provide protection (Ladhani et al. 2008).
For some vaccines, correlates of protection are well defined, for example tetanus
and diphtheria vaccination antitoxin levels of 0.1 !-Ig/ml have been shown to be
protective. There are some rare exceptions to this where high levels of antibody
are detected, but this is thought to be a result of poor diffusion of antibody into
areas of toxin production (Bjorkholm et al. 1986; Livorsi et al. 2010). In addition,
neutralizing antibody levels of 0.7 neutralisation units have been shown to be
protective for yellow fever (Mason et al. 1973) and a neutralisation antibody titre of
1:10 is protective for Japanese encephalitis (Hombach et al. 2005). Following
measles vaccination, antibody plays an important role in protection and an
antibody microneutralisation titre of 2:200 mlUlml is sufficient to protect from
disease, but titres of 2:1000 mlUlml are required for protection from both infection
and disease (Chen et al. 1990). In the case of measles, the role of antibody is
accepted as a correlate of protection. However, it is clear that cellular immunity is
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important in immunocompromised individuals, where protection has been
observed in the absence of antibody. Conversely, it has also been observed that in
the absence of cellular immunity, vacinees do not become susceptible when
antibody levels are sufficient (Zolopa et al. 1994).
For many other vaccines the correlate(s) of protection are not so clear. The
development of new smallpox vaccines such as modified vaccinia Ankara (MVA)
which is delivered by injection rather than by scarification, cannot use the
accepted correlate of protection, which is vesicle development. For these vaccines
neutralisation antibody levels of 1:20 are considered to be required for protection
(Sarkar et al. 1975). However, it has become clear that CD8+ T cells are important
in reducing the severity of disease as without CD8+ T cells, vaccinees with
neutralising antibody were susceptible to mild disease (Amanna et al. 2008).
Vaccination with the pneumococcal 13 valent conjugate vaccine (Prevnar 13),
induces serotype-specific protective pneumococcal antibodies. ELISA has been
used to measure vaccine induced protection, with protective IgG levels accepted
at 0.35 !-Ig/ml. This was established in a study comparing data in a meta-analysis
from three clinical trials in South African, American Indian and Northern Californian
infants, vaccinated with the 7 valent Prevnar vaccine (Siber et al. 2007).
Opsonophagocytosis is thought to be the most important mechanism of
pneumococcal vaccine induced-immunity (Musher et a/. 1986) and it has been
shown that IgG in infants and elderly are not always able to induce
opsonophagocytosis (Romero-Steiner et al. 1999). In addition, the relationship
between ELISA titre and functional opsonic antibody is also thought to vary with
serotype (Henckaerts et al. 2006). Measurement of opsonophagocytosis is
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therefore increasingly important in the evaluation of pneumococcal vaccines
(Goldblatt et al. 2010).
A defined correlate of protection for B. pertussis vaccines has not yet been
identified. B. pertussis is the causative agent of whooping cough, which colonises
the respiratory epithelium and has a number of virulence factors which have
shown immunomodulatory effects. ELISA has been used to measure the
antibodies against these virulence factors. Protection provided by acellular
pertussis vaccines has been shown to correlate with levels of antibody to pertussis
toxin, pertactin and fimbriae (Storsaeter et a/. 1998). The protection induced by
these multi component vaccines is complex, and the role of antibodies to each of
these antigens is controversial as is the threshold level of protection. However,
measurement of functional antibody responses is increasingly important in vaccine
licensure and evaluation. Complement-mediated serum bactericidal activity has
been shown to be of low importance in protection to B. pertussis (Fernandez et al.
1999), whereas some studies have suggested a role for opsonophagocytosis
(Aase et al. 2007). It has been observed that neutrophils do not contribute in
clearing B. pertussis in naive mice, but playa significant role in mice which have
received either a previous infection, or have been passively protected, suggesting
a significant role for antibody-mediated opsonic protection (Andreasen and
Carbonetti 2009). In addition to this, pertussis toxin (PT) has been observed to
inhibit neutrophil recruitment (Kirimanjeswara et al. 2005). B. pertussis is able to
survive intracellularly within phagocytes via entry through FHA-CR3 interaction,
and bacteria have been recovered from mouse macrophages after 21 days of
infection (Hellwig et al. 1999), suggesting the importance of measuring killing or
induction of a respiratory burst response in measuring protective immunity. The
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complexity of vaccine induced immunity to B. pertussis makes it likely that several
factors may correlate with protection.
The role of antibody in protection from meningococcal disease was first identified
in 1913 following the treatment of patients with meningitis with immune serum
produced in a horse (Flexner 1913). The opsonic and bactericidal role of antibody
was first described in 1918 (Kolmer 1918; Matsunami 1918) and N. meningitidis
serum bactericidal activity is now accepted as the correlate of protection for
vaccines against serogroups A,B,C,Y and W135, reviewed in (Frasch et al. 2009).
Goldschneider et al. (1969) demonstrated an inverse relationship between
serogroup B meningococcal disease incidence by age and SBA titres of ~1:4
(Goldschneider et al. 1969). However, data from a more recent UK seroprevalence
study have shown a different relationship. Whilst maternal antibodies persist
disease incidence is low, when these wane disease incidence increases, and then
declines during childhood peaking again in late teenagers. SBA titres showed no
significant change until approximately 12 years old when carriage rates increase,
resulting in a low disease rate in the absence of bactericidal antibody titres in 2-12
year aids (Trotter et al. 2007).
The meningococcal C conjugate vaccine was introduced into the UK childhood
vaccination schedule without direct efficacy studies, with vaccine efficacy
measured after the introduction of the vaccine, using rSBA as the surrogate of
protection (Miller et al. 2001; Andrews et al. 2003). The introduction of this vaccine
has been successful in not only inducing protection for serogroup C
meningococcal disease, but also reducing carriage of this serogroup and thus also
inducing herd protection (Trotter et al. 2007). The ability of rSBA to confer
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protection to meningococcal disease is accepted and is used for conjugate
vaccine licensure.
Serogroup B OMV vaccines have been used in clonal epidemics in Norway, Brazil,
NewZealand, Cuba and Chile, with good correlations with SBA titre and vaccine
efficacy. However, protection is serosubtype-specific, providing little protection
against a diverse panel of serogroup B strains.
The Goldschneider et al. (1969) study also found that a negative titre of <1:4 did
not predict disease susceptibility as many individuals with titres below 1:4 did not
develop disease. This suggests that SBA titres may underestimate protection, an
observation which has been reported on many occasions (Ison et al. 1999; Welsch
and Granoff 2004; Welsch and Granoff 2007; Finney et al. 2008; Plested et al.
2009). In addition, evidence for the involvement of other protective mechanisms
has been demonstrated in the infant rat model of meningococcal bacteriemia with
passive protection achieved with serum which has an SBA titre of <1:4 (Welsch
and Granoff 2004) and passive protection has also been achieved with IgG2a B
polysaccharide mouse serum in a C6 deficient rat strain (Toropainen et al. 2006).
To fully understand the role of assay results as surrogates of protection the assay
must be fully characterised, including the target bacteria, antibodies and source of
complement.
The use of live or killed bacteria, or OMV coated fluorescent beads, is an
important consideration in the development of these assays and their relevance
with in vivo responses. The use of live bacteria presents problems with
reproducibility and throughput and assays using live bacteria can be laborious and
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in the case of N. meningitidis also present a safety concern. Due to the respiratory
hazard associated with N. meningitidis any potential aerosol must be contained.
Therefore the use of killed bacteria not only improves assay reproducibility as it
removes the growth to growth variation, but also allows an in vitro assay to be
performed without containment and greatly improves assay through-put as it
removes the growth of bacteria and colony counting; both time consuming
activities.
In this study, the use of killed bacteria as targets for both the duplexed COA and
RSA was investigated and, total antibody binding between live and Azide/PMSF
killed bacteria, C5b-9 deposition on Azide/PMSF killed bacteria and SBA, and
C3b/iC3b and OPA all demonstrated good correlations (3.2.5, 3.2.6). These
correlations show that killed bacteria are suitable for use in the in vitro assays
developed in chapters 3 and 4.
Determination of vaccine coverage from new vaccines is important when
considering implementation, and there is a requirement for alternative methods as
the SBA requires a large volume of serum to assess bactericidal activity against
multiple strains. It is not straight forward to establish vaccine coverage with the
leading N. meningitidis serogroup B vaccine candidates (Giuliani et al. 2006; Jiang
et al. 2010), as this depends on antigen expression levels as well as the cross
reactivity of induced antibody to the different antigen variants. Assays have been
developed to inform on the vaccine coverage including the meningococcal antigen
typing system (MATS) and the meningococcal antigen surface expression assay
(MeASurE). The MATS assay has been used to measure vaccine coverage of the
Bexsero Novatis vaccine (Donnelly et al. 2010). However, this assay has been
designed for assessment of Sexsero vaccine coverage and is therefore unsuitable
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for the assessment of other vaccines. In addition, this assay uses pooled sera
from 13-months-old children to establish a positive bactericidal threshold for each
antigen, where the relative potency above this threshold represents where 80% of
Men B strains are killed in SBA. However, this threshold level could vary markedly
with different age groups and the reliance on pooled sera may inflate the
protective threshold due to the action of synergistic antibodies (Vu et al. 2011).
The MeASure assay measures the expression of all fHbp variants using a mAb,
this has been designed for use with the bivalent fHbp vaccine (McNeil et al. 2011)
(1.7.6). However, this assay is only able to assess expression of fHbp. The
developed dCDA could be used to assess antibody-mediated C3b/iC3b and C5b-9
deposition with a large panel of bacteria, to indicate the potential vaccine
coverage. This assay is not limited to the measurement of expression of specific
antigens and, as it utilises very low serum volumes, this maximises the number of
strains which can be assessed with this assay.
The developed dCDA and the RBA both use very small volumes of serum, this
aspect is particularly important for pediatric clinical trials where serum volumes
obtained may be much lower. SBA and WBA require a minimum of 40 1-11 serum
per test, and as it is becoming increasingly important to evaluate novel serogroup
B vaccine candidates against large panels of strains to assess the coverage that a
vaccine can provide, assays which use low sample volumes are desirable. The
described dCDA and RBA require a small serum volume (5 1-11 and 2 1-11
respectively) and would enable the analysis of larger panels of bacteria with the
limited serum volumes available in paediatric trials. The dCDA also measures two
parameters, thus increasing the amount of information measured by the serum
sample.
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Previously described antibody-mediated complement deposition assays have not
been designed for high throughput use or only measure the single C3b/iC3b
parameter (Welsch et al. 2003; Taylor 2010). Additionally, assays designed to
measure C5b-9 deposition were unable to demonstrate a correlation between SBA
and C5b-9 deposition (Orogari-Apiranthitou et a/. 2002). The development of an
antibody mediated C3b/iC3b and C5b-9 deposition assay, able to measure two
complement components is a valuable tool in the assessment of large scale
clinical trial sera.
In addition to the number of tests which can be performed, the number of samples
which can be analysed in a day is also important. The assays developed in
chapter 3 and 4 have been developed for high throughput. Most assays are titre-
based and require analysis of serial dilutions whilst the dCDA and RBA use single
point dilutions and this greatly increases the sample numbers which can be
assessed in a single day.
The dCOA has been used in a study investigating immune responses induced by
protein complexes. Five different complexes were assessed: CxABR
(PorA/PorB/RmpM), CxAB (PorA/PorB), CxBR (PorB/RmpM), CxB (PorB) and
CxChap (Chaperonin MSP63). Anti-CxABR mouse sera were able to induce
antibody-mediated C3b/iC3b and C5b-9 deposition, opsonophagocytosis and
bactericidal activity against the homologous strain, showing the greatest activity of
the porin complexes. Anti-CxChap mouse sera showed lower levels of antibody
mediated C3b/iC3b and C5b-9 deposition in comparison with anti-CxABR but was
found to be cross-reactive; with heterologous strains inducing high levels of
C3b/iC3b and C5b-9 deposition across a panel of six strains (Marzoa et al. 2011).
In addition, the dCDA has also been used in a study investigating the structural
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characteristics and stability of NHBA-GNA 1030, a component of the 4CMenB
vaccine. Antibody-mediated C3b/iC3b and C5b-9 deposition was used to assess
the effect of thermal stability on the immunogenicity of the fusion protein. Both
antibody-mediated C3b/iC3b and C5b-9 deposition were reduced with mouse sera
raised against heat stressed NHBA-GNA 1030, and the same trend was seen with
the avidity ELISA measuring the total IgG (Martino et al. 2011).
During the development of the duplexed CDA, antibody mediated C3b/iC3b
deposition performed as a singleplex assay was used to identify immunity induced
by immunisation with DNA expression library pools. A DNA expression library was
developed by Yero et al. (2007), this library was split into 10 pools of which
antibodies induced by one of these pools was able to confer partial protection in
the infant rat model. This pool was then split into further subgroups and analysed
by SBA, whole cell ELISA and CDA. Significant (p<0.05) increases in C3b/iC3b
deposition were observed between pre and post vaccination groups for pool L8-D.
This data was consistent with SBA (Yero et al. 2007). Recombinant proteins were
generated from the expression library and used to immunise mice. Sera generated
from protein NMB0938 were able to induce significant increases in C3b/iC3b
deposition following vaccination and NMB0938 is able to induce cross-reactive
bactericidal activity against a panel of strains (Pajon et al. 2009; Sardinas et al.
2009).
The dCDA could be used to assess antibody-mediated C3b/iC3b and or C5b-9
deposition in other bacteria. This could apply to S. pneumoniae where the
deposition of C3b/iC3b could be used to indicate the opsonic activity of antibodies,
useful for the assessment of large serum numbers with large panels of S.
pneumoniae strains. This assay could also be applied to Streptococcus aga/aetiae,
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H. influenzae, B. pertussis or other bacterial pathogens where the role of antibody
and complement is thought to be important. The suitability of using the dCDA with
other bacterial targets would require investigation for each application.
The importance of SSA and complement in immunity to meningococci is
emphasised by the observation that individuals deficient in complement not only
have an increased susceptibility to meningococcal disease but to also to recurrent
infections. Individuals deficient in late complement components (C5b-9) are at
1000 fold greater risk of developing meningococcal disease and also suffer
recurrent attacks, often of less common capsule types (Fijen et al. 1989; Lehner et
al. 1992). This supports the role of SBA in immunity to meningococcal disease.
However LCCD individuals present with meningococcal disease usually during the
teenage years, which indicates a role for another mechanism in protection. Even
though LCCD individuals are unable to clear bacteria via SBA, vaccination of
these individuals with A, C, W135, Y polysaccharide vaccines showed a reduced
risk of developing meningococcal disease, indicating a role for a different
mechanism, perhaps an opsonic response (Platonov et al. 2003). Individuals who
are deficient in properdin (an important stabiliser of the alternative pathway C3
convertase) also more frequently present with meningococcal disease, and it has
been observed that this is associated with a poorer prognosis than disease in
LCCD individuals. The reason for this is unknown, but some suggestions are that
this results from an inability to clear bacteria via either opsonophagocytosis or
serum bactericidal activity (Schneider et al. 2007).
The source of complement is very important for in vitro assays measuring antibody
functions that depend on complement components. Baby rabbit complement has
been used in SBAs for N. meningitidis serogroup A,C,Y, W135 polysaccharide
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vaccines (Maslanka et al. 1997) but also in the assessment of opsonic responses
(Martinez et al. 2002; Newcombe et al. 2004). Baby rabbit complement is also
used in opsonophagocytosis assays for group B streptococcus (Guttormsen et al.
2008), and also S. pneumoniae (Henckaerts et al. 2006). It is used as it provides a
complement source which contains no cross reactive antibody and is readily
available, allowing inter-laboratory standardisation. It is now considered that
human complement is the most appropriate complement source for the evaluation
of serogroup B meningococcal vaccines, due to the presence of meningococcal
complement binding proteins specific for human complement components (Granoff
2009). Binding of human factor H to fHbp on the surface of meningococci has
been shown to reduce SBA titres by 1-2 logs when compared with the titres
achieved in an SBA using baby rabbit complement (Granoff 2009). It has also
been observed that the change in titre between rSBA and hSBA is most variable
with high levels of N. meningitidis serogroup C anti-caspular IgM antibodies,
whereas the difference in response between rSBA and hSBA for IgG2 was found
to be mimimal when this was investigated with H. influenzae (Mandrell et al. 1995;
Santos et al. 2001). In addition to this, an SBA titre may be measurable in an rSBA
but no titre may be detectable with the hSBA. This is an important observation as
this may lead to a false assessment of protective immunity when using rabbit
complement in the SBA. Gill et at. (2011) demonstrated correlation with rSBA and
hSBA and serogroup C meningococci, however also showed weaker correlations
with A, W135 and Y. A moderate correlation with rSBA and hSBA with serogroup
A meningococci were also reported by (Findlow et al. 2009), however it was also
observed that in this study the percentage of subjects with putatively protective
titres were similar with either rSBA or hSBA.
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As discussed in chapter 5, generating a human complement source is firstly reliant
on volunteer donation. Also the donated plasma/serum has to be screened for
cross reactive antibody acquired by nasopharyngeal carriage of different N.
meningitidis and commensal Neisseria strains, which can mediate meningococcal
bacteriolysis in the absence of test antiserum and cause interference in the results
of the assays. These complement sources, which are low in cross reactive
antibodies against the strain of interest. may be high against another and therefore
different complement sources from different individuals are often used with
different strains, resulting in poor assay comparibility.
The development of a large scale method of IgG-depleting human plasma,
described in chapter 5, provides a functional complement source which is able to
be utilised with all meningococcal strains in SBA, OPA and CDA. The use of a
Single complement source in a clinical trial, comparing responses across panels of
strains, is desirable and would allow comparisons of titres between strains and
improve assay reproducibility. Development of a large scale process able to
produce a batch of antibody-depleted complement sufficient to assess a large
study is important as previous studies have only depleted small volumes of
complement (Santos 2010). Although the work described in chapter 5 discusses
the utility of this complement source for evaluation of N. meningitidis protective
immunity. an antibody-depleted complement source would also be a useful
reagent for use in investigations with other pathogens.
Another important consideration for the complement source is whether to use
serum or plasma. and then subsequently which anticoagulant. The whole blood
killing assay is a measure of both opsonic and bactericidal response. For this
assay either citrate or heparin are used as anticoagulants which has been
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highlighted as a potential problem, due to the possible interference of these
anticoagulants with the complement cascade (Mollnes et al. 2002). Heparin has
been shown to bind 13 complement proteins and has two binding sites for factor
H, potentially able to alter assay results (Ison et al. 1995). This concern is also
applicable to the plasma used as a complement source in in vitro assays, as
interference of the chosen anticoagulant could alter assay results. Lepirudin was
found to be the most appropriate anticoagulant as this has previously been
described to not activate the complement system and was shown to provide
plasma with the greatest complement lytic activity (Mollnes et al. 2002).
Further investigations
The dCDA has been shown to be sensitive and reproducible. However, to transfer
the dCDA for use in a clinical trial setting, further assay qualification would be
required to demonstrate the utility of this assay as a surrogate for OPA and SBA.
An important development in the dCDA would be the investigation of the
relationship between measured FI-C' and the SBA titre, to determine at what level
of complement deposition a bactericidal or opsonophagocytic response is
detectable. As the dCDA is sensitive in comparison with the SBA, at low levels of
deposition of C5b-9, it is likely that a threshold of deposition needs to occur before
a bactericidal response is achieved. This could be investigated by comparison of
FI-C' from a panel of sera, with the SBA response detected at different dilutions.
This work would require a detailed investigation with lower responding sera and a
diverse panel of strains.
Responses determined with human sera using the dCDA have been correlated
with OPA and SBA, but to develop this as a reliable tool in assessment of pre-
clinical vaccines it would also be important to investigate the correlation of the
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SBA with the dCDA response with a range of high medium and low responding
mouse serum, to assess whether a correlation is achieved also with mouse serum.
Investigation of assay robustness would help to identify the capacity of the assay
to remain unaffected by small alterations to the assay method, which would help to
inform on the assay reliability, an important aspect of any assay used in a clinical
trial setting. In addition, it would be important to establish the upper and lower
limits of detection for the assay and to also establish assay acceptance criteria.
This ensures that results are only reported from assays which have worked to the
specified criteria and that any assay problems can be identified and corrected as
they appear. Importantly the assay positive and negative controls should be within
a defined range, which can be established by monitoring the assay over time.
The developed dRBA was demonstrated to be suitable for small sample sizes, but
poor assay reproducibility was demonstrated with larger sample numbers as the
respiratory burst reagent demonstrated drift in signal during the time taken for flow
cytometric analysis.
A new more stable respiratory burst detecting reagent is required to allow
increased numbers of sera to be analysed in a single assay. This may be possible
with the increasing availability of flow cytometers which are able to detect a much
wider variety of reagents.
If a duplexed uptake and respiratory burst assay could be developed then it would
be essential to investigate the responses generated by this assay in comparison
with functional killing assays, to ascertain whether the duplexed response
correlates more highly than the single parameter measurements. In addition to
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this, assay qualification would be required to ascertain assay precision, linearity,
robustness and upper and lower detection limits.
Development of the dCDA has shown the assay to be reproducible, sensitive and
a potential surrogate of protection for assessment of responses to meningococcal
vaccines in both a preclinical and clinical setting. Although the dRBA has shown
some reproducibility problems when dealing with very large numbers of sera, it is
still useful for the assessment of small panels of serum. However with further work
and the availability of new reagents and equipment this may become a useful
surrogate for the assessment of meningococcal vaccines. The correlations
performed with both of these assays with the functional OPA and SBA was
performed against three strain, it would be important to continue this work to
assess the correlations against a panel of disease isolates that represents the
diversity of the meningococcal population.
Complement is an important component of a range of functional antibody assays,
and the IgG-depletion method developed in this study shows great promise to
provide complement suitable for use in any assay. Further studies are required to
characterise the complement components before and after IgG depletion and to
compare SBA and OPA responses obtained with a panel of sera against a panel
of representative strains. Investigations will be needed to establish the dilution
effect on the plasma following processing, which could be done using an albumin
ELISA to evaluate the albumin concentrations before and after. The IgG-depleted
complement could allow inter-laboratory standardisation for assays with a common
complement source and different laboratories could calibrate their results obtained
with their complement source against a recognised standard.
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The variability of the depleted batches still requires further investigation. In chapter
5, only 2 batches from the same pooled plasma were compared to assess the
reproducibility of the depletion method. It would be important to examine the
variation observed across more batches of plasma collected from different groups
of volunteers, as it would be anticipated that this could introduce differences in
complement function in a range of assays.
This study has developed a duplexed antibody-mediated C3b/iC3b and C5b-9
deposition assay, which has the potential for assessment of meningococcal
disease and other vaccines. This is particularly important for the assessment of
strain coverage afforded by a vaccine, and this assay has the potential to be an
alternative to the MATS or MeASure assays. In addition, this study has also begun
the development of a universal complement source, developing a large scale
method of antibody depletion able to produce functional complement. A universal
complement source is of huge value for vaccine assessment as complement-
mediated mechanisms of protection apply to a wide range of pathogens.
285
Bibliography
Aase, A., G. Bjune, E. A. Hoiby, E. Rosenqvist, A. K. Pedersen and T. E.
Michaelsen (1995). "Comparison among opsonic activity,
antimeningococcal immunoglobulin G response, and serum bactericidal
activity against meningococci in sera from vaccinees after immunization
with a serogroup B outer membrane vesicle vaccine." Infect Immun 63(9):
3531-3536.
Aase, A., T. K. Herstad, S. Merino, K. T. Brandsdal, B. P. Berdal, E. M.
Aleksandersen and I. S. Aaberge (2007). "Opsonophagocytic activity and
other serological indications of Bordetella pertussis infection in military
recruits in Norway." Clin Vaccine ImmunoI14(7): 855-862.
Aase, A. and T. E. Michaelsen (1994). "Opsonophagocytic activity induced by
chimeric antibodies of the four human IgG subclasses with or without help
from complement." Scand J Immunol 39(6): 581-587.
Aase, A., L. M. Naess, R. H. Sandin, T. K. Herstad, F. Oftung, J. Holst, I. L.
Haugen, E. A. Hoiby and T. E. Michaelsen (2003). "Comparison of
functional immune responses in humans after intranasal and intramuscular
immunisations with outer membrane vesicle vaccines against group B
meningococcal disease." Vaccine 21(17-18): 2042-2051.
Abdillahi, H. and J. T. Poolman (1988). "Neisseria meningitidis group B
serosubtyping using monoclonal antibodies in whole-cell ELISA." Microb
Pathog 4(1): 27-32.
Albrich, J. M., J. H. Gilbaugh, 3rd, K. B. Callahan and J. K. Hurst (1986). "Effects
of the putative neutrophil-generated toxin, hypochlorous acid, on membrane
permeability and transport systems of Escherichia coli." J Clin Invest 78(1):
177-184.
286
Amanna, I. J., I. Messaoudi and M. K. Slifka (2008). "Protective immunity following
vaccination: how is it defined?" Hum Vaccin 4(4): 316-319.
Amara, U., D. Rittirsch, M. Flierl, U. Bruckner, A. Klos, F. Gebhard, J. D. Lambris
and M. Huber-Lang (2008). "Interaction between the coagulation and
complement system." Adv Exp Med Bioi 632: 71-79.
Anderson, P., D. L. Ingram, M. E. Pichichero and G. Peter (2000). "A high degree
of natural immunologic priming to the capsular polysaccharide may not
prevent Haemophilus influenzae type b meningitis." Pediatr Infect Dis J
19(7): 589-591.
Andreasen, C. and N. H. Carbonetti (2009). "Role of neutrophils in response to
Bordetella pertussis infection in mice." Infect Immun 77(3): 1182-1188.
Andreoni, J., H. Kayhty and P. Densen (1993). "Vaccination and the role of
capsular polysaccharide antibody in prevention of recurrent meningococcal
disease in late complement component-deficient individuals." J Infect Dis
168(1): 227-231.
Andrews, N., R. Borrow and E. Miller (2003). "Validation of serological correlate of
protection for meningococcal C conjugate vaccine by using efficacy
estimates from postlicensure surveillance in England." Clin Diagn Lab
ImmunoI10(5): 780-786.
Bai, X. and R. Borrow (2010). "Genetic shifts of Neisseria meningitidis serogroup B
antigens and the quest for a broadly cross-protective vaccine." Expert Rev
Vaccines 9(10): 1203-1217.
Bakir, M., A. Yagci, N. Ulger, C. Akbenlioglu, A. "ki and G. Soyletir (2001).
"Asymtomatic carriage of Neisseria meningitidis and Neisseria lactamica in
relation to Streptococcus pneumoniae and Haemophilus influenzae
colonization in healthy children: apropos of 1400 children sampled." Eur J
EpidemioI17(11): 1015-1018.
287
Balmer, P. and R. Borrow (2004). "Serologic correlates of protection for evaluating
the response to meningococcal vaccines." Expert Rev Vaccines 3(1): 77-
87.
Bambini, S. and R. Rappuoli (2009). "The use of genomics in microbial vaccine
development." Drug Discov Today 14(5-6): 252-260.
Barrette, W. C., Jr., D. M. Hannum, W. D. Wheeler and J. K. Hurst (1989).
"General mechanism for the bacterial toxicity of hypochlorous acid: abolition
of ATP production." Biochemistry 28(23): 9172-9178.
Bassoe, C. F., I. Smith, S. Sornes, A. Halstensen and A. K. Lehmann (2000).
"Concurrent measurement of antigen- and antibody-dependent oxidative
burst and phagocytosis in monocytes and neutrophils" Methods 21(3): 203-
220.
Batard, P., M. N. Monier, N. Fortunel, K. Ducos, P. Sansilvestri-Morel, T. Phan, A.
Hatzfeld and J. A. Hatzfeld (2000). "TGF-(beta)1 maintains hematopoietic
immaturity by a reversible negative control of cell cycle and induces CD34
antigen up-modulation." J Cell Sci 113 ( Pt 3): 383-390.
Beernink, P. T., J. Shaughnessy, E. M. Braga, Q. Liu. P. A. Rice. S. Ram and D.
M. Granoff (2011). "A meningococcal factor H binding protein mutant that
eliminates factor H binding enhances protective antibody responses to
vaccination." J ImmunoI186(6): 3606-3614.
Belmusto-Worn, V. E., J. L. Sanchez, K. McCarthy. R Nichols. C. T. Bautista, A. J.
Magill, G. Pastor-Cauna. C Echevarria. V A. Laguna-Torres, B. K.
Samame, M. E. Baldeon. J P Burans. J GOlson. P Bedford, S_
Kitchener and T. P. Monath (2005) "Randomized. double-blind, phase III.
pivotal field trial of the comparative immunogenicity. safety. and tolerability
of two yellow fever 170 vaccines (Arilvax and YF-VAX) in healthy infants
and children in Peru" Am J Trop Med Hyg 72(2) 189-197
288
Ben Nasr, A. and G. R. Klirnpel (2008). "Subversion of complement activation at
the bacterial surface promotes serum resistance and opsonophagocytosis
of Francisella tularensis." J Leukoc Bioi 84(1): 77-85.
Bhakdi, 5., R. Kaflein, T. S. Halstensen, F. Hugo, K. T. Preissner and T. E.
Mollnes (1988). "Complement S-protein (vitronectin) is associated with
cytolytic membrane-bound C5b-9 complexes." Clin Exp Immunol 74(3):
459-464.
Biolchi, A, L. Fagnocchi, E. Pigozzi, B. Brunella, G. Boccadifuoco, J. Donnelly, R.
Rappuoli, M. Pizza, M. Giuliani and I. Delany (2011). "In vitro level of NadA
expression may underestimate the potential effectiveness of immune
responses against NadA in vivo" EMGM 2011 Poster presentation.
Birnie, G. D. (1988). "The HL60 cell line: a model system for studying human
myeloid cell differentiation." Br J Cancer Suppl9: 41-45.
Birtles, A., N. McCarthy, C. L. Sheppard, H. Rutter, M. Guiver, E. Haworth and R.
C. George (2005). "Multilocus sequence typing directly on DNA from clinical
samples and a cultured isolate to investigate linked fatal pneumococcal
disease in residents of a shelter for homeless men." J Clin Microbial 43(4):
2004-2008.
Bjorkholm, B., M. Bottiger, B. Christenson and L. Hagberg (1986). "Antitoxin
antibody levels and the outcome of illness during an outbreak of diphtheria
among alcoholics" Scand J Infect Dis 18(3): 235-239.
Bjune, G., O. Closs, L. O. Froholm, J. K. Gronnesby, E. A. Hoiby and H. Nokleby
(1991). "Design of clinical trials with an outer membrane vesicle vaccine
against systemic serogroup B meningococcal disease in Norway." NIPH
Ann 14(2): 81-91; discussion 91-83.
289
Blackmore, T. K., J. Hellwage, T. A. Sadlon, N. Higgs, P. F. Zipfel, H. M. Ward and
D. L. Gordon (1998). "Identification of the second heparin-binding domain in
human complement factor H." J ImmunoI160(7): 3342-3348.
Blackmore, T. K., T. A. Sadlon, H. M. Ward, D. M. Lublin and D. L. Gordon (1996).
"Identification of a heparin binding domain in the seventh short consensus
repeat of complement factor H." J ImmunoI157(12): 5422-5427.
Borass, P., Van de Poel, K., Leusen, J., Van der winkel,J. (2008). "Fe Receptors."
Retrieved 9.09.11, from http://www.els.netlWileyCDAlElsArticle/refld-
a0000916.html.
Borrow, R, I. S. Aaberge, G. F. Santos, T. L. Eudey, P. Oster, A. Glennie, J.
Findlow, E. A. Hoiby, E. Rosenqvist, P. Balmer and D. Martin (2005).
"Interlaboratory standardization of the measurement of serum bactericidal
activity by using human complement against meningococcal seragroup b,
strain 44/76-SL, before and after vaccination with the Norwegian MenBvac
outer membrane vesicle vaccine." Clin Diagn Lab ImmunoI12(8): 970-976.
Boslego, J., J. Garcia, C. Cruz, W. Zollinger, B. Brandt, S. Ruiz, M. Martinez, J.
Arthur, P. Underwood, W. Silva and et al. (1995). "Efficacy, safety, and
immunogenicity of a meningococcal group B (15:P1.3) outer membrane
protein vaccine in Iquique, Chile. Chilean National Committee for
Meningococcal Disease." Vaccine 13(9): 821-829.
Brechard, S., J. L. Bueb and E. J. Tschirhart (2005). "lnterleukin-8 primes
oxidative burst in neutrophil-like HL-60 through changes in cytosolic
calcium." Cell Calcium 37(6): 531-540.
Bredius, R G., B. H. Derkx, C. A. Fijen, T. P. de Wit, M. de Haas, R S. Weening,
J. G. van de Winkel and T. A. Out (1994). "Fc gamma receptor lIa (CD32)
polymorphism in fulminant meningococcal septic shock in children." J Infect
Dis 170(4): 848-853.
290
Brown, J. S., T. Hussell, S. M. Gilliland, D. W. Holden, J. C. Paton, M. R.
Ehrenstein, M. J. Walport and M. Botto (2002). "The classical pathway is
the dominant complement pathway required for innate immunity to
Streptococcus pneumoniae infection in mice." Proc Natl Acad Sci USA
99(26): 16969-16974.
Bruge, J., N. Bouveret-Le Cam, B. Danve, G. Rougon and D. Schulz (2004).
"Clinical evaluation of a group B meningococcal N-propionylated
polysaccharide conjugate vaccine in adult, male volunteers." Vaccine 22(9-
10): 1087-1096.
Capecchi, B., J. Adu-Bobie, F. Di Marcello, L. Ciucchi, V. Masignani, A. Taddei, R.
Rappuoli, M. Pizza and B. Arico (2005). "Neisseria meningitidis NadA is a
new invasin which promotes bacterial adhesion to and penetration into
human epithelial cells." Mol MicrobioI55(3): 687-698.
Carbonnelle, E., D. J. Hill, P. Morand, N. J. Griffiths, S. Bourdoulous, I. Murillo, X.
Nassif and M. Virji (2009). "Meningococcal interactions with the host."
Vaccine 27 Suppl 2: B78-89.
Cartwright, K. (1995). "Meningococcal Carriage and Disease. Meningococcal
Disease .. " John Wiley & Sons: 115-146.
Cartwright, K. A. and D. A. Ala'Aldeen (1997). "Neisseria meningitidis: clinical
aspects." J Infect 34(1): 15-19.
Cartwright, K. A., J. M. Stuart, D. M. Jones and N. D. Noah (1987). "The
Stonehouse survey: nasopharyngeal carriage of meningococci and
Neisseria lactamica." Epidemiollnfect 99(3): 591-601.
Caugant, D. A., K. Bovre, P. Gaustad, K. Bryn, E. Holten, E. A. Hoiby and L. O.
Froholm (1986). "Multilocus genotypes determined by enzyme
electrophoresis of Neisseria meningitidis isolated from patients with
291
systemic disease and from healthy carriers" J Gen MicrobioI132(3): 641-
652.
Chen, R. T., L. E. Markowitz, P. Albrecht, J. A. Stewart. L. M. Mofenson, S. R.
Preblud and W. A. Orenstein (1990). "Measles antibody: reevaluation of
protective titers." J Infect Dis 162(5): 1036-1042.
Christensen, H., M. May, L. Bowen, M. Hickman and C L. Trotter (2010).
"Meningococcal carriage by age a systematic review and meta-analysis."
Lancet Infect Dis 10(12): 853-861.
Ciruela, F. (2008). "Fluorescence-based methods in the study of protein-protein
interactions in living celis." Current Opinion in Biotechnology 19(4): 338-
343.
Claus, H., M. C. Maiden, R. Maag, M. Frosch and U. Vogel (2002). "Many carried
meningococci lack the genes required for capsule synthesis and transport."
Microbiology 148(Pt 6): 1813-1819.
Comanducci, M., S. Bambini, B. Brunelli, J. Adu-Bobie, B. Arico, B. Capecchi, M.
M. Giuliani, V. Masignani, L. Santini, S. Savino, D. M. Granoff, D. A.
Caugant, M. Pizza, R. Rappuoli and M. Mora (2002) "NadA, a novel
vaccine candidate of Neisseria meningitidis." J Exp Med 195( 11): 1445-
1454.
de Moraes, J. C., B. A. Perkins, M. C. Camargo, N T Hidalgo. H. A. Barbosa, C.
T. Sacchi, I. M. Landgraf, V L. Gattas. G. Vasconcelos Hde and et al.
(1992). "Protective efficacy of a serogroup B meningococcal vaccine in Sao
Paulo, Brazil." Lancet 340(8827) 1074-1078
Deghmane, A. E., D. Giorgini, M Larribe, J M. Alonso and M. K. Taha (2002).
"Down-regulation of pili and capsule of Neisseria meningilidis upon contact
with epithelial cells is mediated by CrgA regulatory protein" Mol Microbial
43(6): 1555-1564.
292
Domingo, P., E. Muniz-Diaz. M. A. Baraldes. M. Arilla. N. Barquet, R. Pericas, C.
Juarez, P. Madoz and G. Vazquez (2002). "Associations between Fc
gamma receptor IIA polymorphisms and the risk and prognosis of
meningococcal disease." Am J Med 112(1): 19-25.
Donnelly, J., D. Medini, G. Boccadifuoco. A. Biolchi, J. Ward, C. Frasch, E. R.
Moxon, M. Stella. M. Comanducci. S. Bambini, A. Muzzi, W. Andrews, J.
Chen, G. Santos, L. Santini. P Boucher, D. Serruto, M. Pizza, R. Rappuoli
and M. M. Giuliani (2010). "Qualitative and quantitative assessment of
meningococcal antigens to evaluate the potential strain coverage of protein-
based vaccines." Proc Natl Acad Sci USA 107(45): 19490-19495.
Drabick, J. J., B. L Brandt, E. E. Moran, N. B. Saunders, D. R. Shoemaker and W.
D. Zollinger (1999). "Safety and immunogenicity testing of an intranasal
group B meningococcal native outer membrane vesicle vaccine in healthy
volunteers." Vaccine 18(1-2): 160-172.
Drogari-Apiranthitou, M., E. J. Kuijper, N. Dekker and J. Dankert (2002).
"Complement activation and formation of the membrane attack complex on
serogroup B Neisseria meningitidis in the presence or absence of serum
bactericidal activity." Infect Immun 70(7): 3752-3758.
Dunkelberger, J. R. and W. C. Song (2010). "Complement and its role in innate
and adaptive immune responses." Cell Res 20(1): 34-50.
Dunn, K. L., M. Virji and E. R. Moxon (1995). "Investigations into the molecular
basis of meningococcal toxicity for human endothelial and epithelial cells:
the synergistic effect of LPS and pili." Microb Pathog 18(2): 81-96.
Dyet, K. and J. Moir (2006). "Effect of combined oxidative and nitrosative stress on
Neisseria meningitidis" Biochem Soc Trans 34(Pt 1): 197-199.
Ehlenberger, A. G. and V. Nussenzweig (1977). "The role of membrane receptors
for C3b and C3d in phagocytosis." J Exp Med 145(2): 357-371.
293
Elbim, C., S. Bailly, S. Chollet-Martin, J. Hakim and M. A. Gougerot-Pocidalo
(1994). "Differential priming effects of proinflammatory cytokines on human
neutrophil oxidative burst in response to bacterial N-formyl peptides." Infect
Immun 62(6): 2195-2201.
Ellis, T. N. and B. L. Beaman (2004). "Interferon-gamma activation of
polymorphonuclear neutrophil function." Immunology 112(1): 2-12.
Ellison, R. T., 3rd, P. F. Kohler, J. G. Curd, F. N. Judson and L. B. Reller (1983).
"Prevalence of congenital or acquired complement deficiency in patients
with sporadic meningocococcal disease." N Engl J Med 308(16): 913-916.
Evans, C. M., C. B. Pratt, M. Matheson, T. E. Vaughan, J. Findlow, R. Borrow, A.
R. Gorringe and R. C. Read (2011). "Nasopharyngeal colonization by
Neisseria lactamica and induction of protective immunity against Neisseria
meningitidis." Clin Infect Dis 52(1): 70-77.
Fernandez, S., L. Arreaza, I. Santiago, A. Malvar, S. Berron, J. A. Vazquez, X.
Hervada and J. J. Gestal (1999). "Carriage of a new epidemic strain of
Neisseria meningitidis and its relationship with the incidence of
meningococcal disease in Galicia, Spain." Epidemiollnfect 123(3): 349-357.
Ferrante, A., E. J. Bates and M. Nandoskar (1988). "Neutrophil stimulating activity
released by Staphylococcus-stimulated mononuclear leukocyte conditioned
medium. Further characterization and partial purification." J Chromatogr
440: 105-118.
Figueroa, J. E. and P. Densen (1991). "Infectious diseases associated with
complement deficiencies." Clin Microbiol Rev 4(3): 359-395.
Fijen, C. A., E. J. Kuijper, M. Drogari-Apiranthitou, Y. Van Leeuwen, M. R. Daha
and J. Dankert (1998). "Protection against meningococcal serogroup ACYW
disease in complement-deficient individuals vaccinated with the tetravalent
294
meningococcal capsular polysaccharide vaccine." Clin Exp ImmunoI114(3):
362-369.
Fijen, C. A., E. J. Kuijper, A. J. Hannema, A. G. Sjoholm and J. P. van Putten
(1989). "Complement deficiencies in patients over ten years old with
meningococcal disease due to uncommon serogroups." Lancet 2(8663):
585-588.
Findlow, H., B. D. Plikaytis. A. Aase. M. C. Bash. H. Chadha, C. Elie, G. Laher. J.
Martinez, T. Herstad, E. Newton. S. Viviani. C. Papaspyridis, P. Kulkarni, M.
Wilding, M. P. Preziosi, E. Marchetti, M. Hassan-King, F. M. La Force, G.
Carlone and R. Borrow (2009). "Investigation of different group A
immunoassays following one dose of meningococcal group A conjugate
vaccine or AlC polysaccharide vaccine in adults." Clin Vaccine Immunol
16(7): 969-977.
Findlow, J., R. Borrow, M. D. Snape, T. Dawson, A. Holland, T. M. John, A. Evans,
K. L. Telford, E. Ypma, D. Toneatto, P. Oster, E. Miller and A. J. Pollard
(2010). "Multicenter, open-label, randomized phase" controlled trial of an
investigational recombinant Meningococcal serogroup B vaccine with and
without outer membrane vesicles, administered in infancy." Clin Infect Dis
51(10): 1127-1137.
Findlow, J., Gilchrist. S., Thompson. D.. Stella.M .. Frosi.G., Borrow, R. (2011).
"Potential coverage of english and welsh group B isolates by an
investigational meningococcal group B vaccine." EMGM 2011.
Findlow, J., A. Holland. D. Martin. P. Oster. P. Balmer and R. Borrow (2007).
"Inadequacy of colominic acid as an absorbent intended to facilitate use of
complement-preserved baby rabbit serum in the Neisseria meningitidis
serogroup B serum bactericidal antibody assay." Clin Vaccine Immunol
14(5): 556-561.
295
Findlow, J., S. Taylor, A. Aase, R. Horton, R. Heyderman, J. Southern, N.
Andrews, R. Barchha, E. Harrison, A. Lowe, E. Boxer, C. Heaton, P.
Balmer, E. Kaczmarski, P. Oster, A. Gorringe, R. Borrow and E. Miller
(2006). "Comparison and correlation of neisseria meningitidis serogroup B
immunologic assay results and human antibody responses following three
doses of the Norwegian meningococcal outer membrane vesicle vaccine
MenBvac." Infect Immun 74(8): 4557-4565.
Finne, J., D. Bitter-Suermann, C. Goridis and U. Finne (1987). "An IgG monoclonal
antibody to group B meningococci cross-reacts with developmentally
regulated polysialic acid units of glycoproteins in neural and extraneural
tissues." J ImmunoI138(12): 4402-4407.
Finney, M., T. Vaughan, S. Taylor, M. J. Hudson, C. Pratt, J. X. Wheeler, C.
Vipond, I. Feavers, C. Jones, J. Findlow, R. Borrow and A. Gorringe (2008).
"Characterization of the key antigenic components and pre-clinical immune
responses to a meningococcal disease vaccine based on Neisseria
lactamica outer membrane vesicles." Hum Vaccin 4(1): 23-30.
Fletcher, L. D., L. Bernfield, V. Barniak, J. E. Farley, A. Howell, M. Knauf, P. Ooi,
R. P. Smith, P. Weise, M. Wetherell, X. Xie, R. Zagursky, Y. Zhang and G.
W. Zlotnick (2004). "Vaccine potential of the Neisseria meningitidis 2086
lipoprotein." Infect Immun 72(4): 2088-2100.
Flexner, S. (1913). "The Results of the Serum Treatment in Thirteen Hundred
Cases of Epidemic Meningitis." J Exp Med 17(5): 553-576.
Fonkoua, M. C. (2002). "Meningococcal meningitis in Africa." Am J Nurs 102(12):
17.
Frasch, C. E., R. Borrow and J. Donnelly (2009). "Bactericidal antibody is the
immunologic surrogate of protection against meningococcal disease."
Vaccine 27 Suppl2: B112-116.
296
Frasch, C. E., W. D. Zollinger and J. T. Poolman (1985). "Serotype antigens of
Neisseria meningitidis and a proposed scheme for designation of
serotypes." Rev Infect Dis 7(4): 504-510.
Fraser, S. E. (1996). "Iontophoretic dye labeling of embryonic cells." Methods Cell
Bioi 51: 147-160.
Freitas, M., G. Porto, J. L. Lima and E. Fernandes (2009). "Optimization of
experimental settings for the analysis of human neutrophils oxidative burst
in vitro." Talanta 78(4-5): 1476-1483.
Gallagher, R, S. Collins, J. Trujillo, K. McCredie, M. Ahearn, S. Tsai, R Metzgar,
G. Aulakh, R Ting, F. Ruscetti and R Gallo (1979). "Characterization of the
continuous, differentiating myeloid cell line (HL-60) from a patient with acute
promyelocytic leukemia." Blood 54(3): 713-733.
Geoffroy, M. C., S. Floquet, A. Metais, X. Nassif and V. Pelicic (2003). "Large-
scale analysis of the meningococcus genome by gene disruption:
resistance to complement-mediated lysis." Genome Res 13(3): 391-398.
Gill, C. J., S. Ram, J. A. Welsch, L. DeTora and A. Anemona (2011). "Correlation
between serum bactericidal activity against Neisseria meningitidis
serogroups A, C, W-135 and Y measured using human versus rabbit serum
as the complement source." Vaccine 30(1): 29-34.
Giuliani, M. M., J. Adu-Bobie, M. Comanducci, B. Arico, S. Savino, L. Santini, B.
Brunelli, S. Bambini, A. Biolchi, B. Capecchi, E. Cartocci, L. Ciucchi, F. Di
Marcello, F. Ferlicca, B. Galli, E. Luzzi, V. Masignani, D. Serruto, D. Veggi,
M. Contorni, M. Morandi, A. Bartalesi, V. Cinotti, D. Mannucci, F. Titta, E.
Ovidi, J. A. Welsch, D. Granoff, R. Rappuoli and M. Pizza (2006). "A
universal vaccine for serogroup B meningococcus." Proc Natl Acad Sci U S
A 103(29): 10834-10839.
297
Givan, A. L., J. L. Fisher, M. Waugh, M. S. Ernstoff and P. K. Wallace (1999). "A
flow cytometric method to estimate the precursor frequencies of cells
proliferating in response to specific antigens." J Immunol Methods 230(1-2):
99-112.
Glitza, I. C., I. Ehrhard, B. Muller-Pebody, R. Reintjes, T. Breuer, A. Ammon and
H. G. Sonntag (2008). "Longitudinal study of meningococcal carrier rates in
teenagers." Int J Hyg Environ Health 211(3-4): 263-272.
Gold, R., I. Goldschneider, M. L. Lepow, T. F. Draper and M. Randolph (1978).
"Carriage of Neisseria meningitidis and Neisseria lactamica in infants and
children." J Infect Dis 137(2): 112-121.
Goldblatt, D., J. Southern, L. Ashton, N. Andrews, S. Woodgate, P. Burbidge, P.
Waight and E. Miller (2010). "Immunogenicity of a reduced schedule of
pneumococcal conjugate vaccine in healthy infants and correlates of
protection for serotype 6B in the United Kingdom." Pediatr Infect Dis J
29(5): 401-405.
Goldschneider, I., E. C. Gotschlich and M. S. Artenstein (1969). "Human immunity
to the meningococcus. I. The role of humoral antibodies." J Exp Med
129(6): 1307-1326.
Goldschneider, I., E. C. Gotschlich and M. S. Artenstein (1969). "Human immunity
to the meningococcus. II. Development of natural immunity." J Exp Med
129(6): 1327-1348.
Gomes, A., E. Fernandes and J. L. Lima (2005). "Fluorescence probes used for
detection of reactive oxygen species." J Biochem Biophys Methods 65(2-3):
45-80.
Gorringe, A. R., K. M. Reddin, P. Voet and J. T. Poolman (2001). "Animal models
for meningococcal disease." Methods Mol Med 66: 241-254.
298
Gorringe, A. R, S. Taylor, C. Brookes, M. Matheson, M. Finney, M. Kerr, M.
Hudson, J. Findlow, R Borrow, N. Andrews, G. Kafatos, C. M. Evans and
R C. Read (2009). "Phase I safety and immunogenicity study of a
candidate meningococcal disease vaccine based on Neisseria lactamica
outer membrane vesicles." Clin Vaccine ImmunoI16(8): 1113-1120.
Gotschlich, E. C., I. Goldschneider and M. S. Artenstein (1969). "Human immunity
to the meningococcus. V. The effect of immunization with meningococcal
group C polysaccharide on the carrier state." J Exp Med 129(6): 1385-1395.
Granoff, D. M. (2009). "Relative importance of complement-mediated bactericidal
and opsonic activity for protection against meningococcal disease." Vaccine
27 Suppl 2: B117-125.
Granoff, D. M., S. E. Maslanka, G. M. Carlone, B. D. Plikaytis, G. F. Santos, A.
Mokatrin and H. V. Raff (1998). "A modified enzyme-linked immunosorbent
assay for measurement of antibody responses to meningococcal C
polysaccharide that correlate with bactericidal responses." Clin Diagn Lab
lmmunol 5(4): 479-485.
Granoff, D. M., J. A. Welsch and S. Ram (2009). "Binding of complement factor H
(fH) to Neisseria meningitidis is specific for human fH and inhibits
complement activation by rat and rabbit sera." Infect Immun 77(2): 764-769.
GraY-Owen, S. D., C. Dehio, A. Haude, F. Grunert and T. F. Meyer (1997). "C066
carcinoembryonic antigens mediate interactions between Opa-expressing
Neisseria gonorrhoeae and human polymorphonuclear phagocytes." Embo
J 16(12): 3435-3445.
Gray, S. J., H. Campbell, W. J. Marsh, A. D. Carr, L. S. Newbold, R H. Mallard, M.
Guiver, R. Borrow, M. Ramsey and E. B. Kaczmarski (2011). "The
epidemiology and surveillance of meningococcal disease in England and
Wales." EMGM 2011.
299
Guttormsen, H. K., Y. Liu and L. C. Paoletti (2008). "Functional activity of Antisera
to Group B Streptococcal Conjugate Vaccines measured with an
Opsonophagocytosis Assay and HL-60 Effector cells." Hum Vaccin 4(5).
Halperin, S. A., J. M. Langley, B. Smith, P. Wunderli, L. Kaufman, A. Kimura and
D. Martin (2007). "Phase 1 first-in-human studies of the reactogenicity and
immunogenicity of a recombinant meningococcal NspA vaccine in healthy
adults." Vaccine 25(3): 450-457.
Halstensen, A, H. Sjursen, S. E. Vollset, L. O. Froholm, A Naess, R. Matre and
C. O. Solberg (1989). "Serum opsonins to serogroup B meningococci in
meningococcal disease." Scand J Infect Dis 21(3): 267-276.
Hampton, M. B., A. J. Kettle and C. C. Winterbourn (1996). "Involvement of
superoxide and myeloperoxidase in oxygen-dependent killing of
Staphylococcus aureus by neutrophils." Infect Immun 64(9): 3512-3517.
Hampton, M. B., A J. Kettle and C. C. Winterbourn (1998). "Inside the neutrophil
phagosome: oxidants, myeloperoxidase, and bacterial killing." Blood 92(9):
3007-3017.
Haralambous, E, S. O. Dolly, M. L. Hibberd, D. J. Litt, I. A Udalova, C. O'Dwyer,
P. R. Langford, J. Simon Kroll and M. Levin (2006). "Factor H, a regulator of
complement activity, is a major determinant of meningococcal disease
susceptibility in UK Caucasian patients." Scand J Infect Dis 38(9): 764-771.
Haralambous, E, H. A Weiss, A. Radalowicz, M. L. Hibberd, R. Booy and M.
Levin (2003). "Sibling familial risk ratio of meningococcal disease in UK
Caucasians." Epidemiollnfect 130(3): 413-418.
Harrison, L. H., C. L. Trotter and M. E Ramsay (2009). "Global epidemiology of
meningococcal disease." Vaccine 27 Suppl 2: B51-63.
Hellerud, B. C., A Aase, T. K. Herstad, L. M. Naess, L. H. Kristiansen, A. M.
Troseid, M. Harboe, K. T. Lappegard, P. Brandtzaeg, E. A. Hoiby and T. E.
300
Mollnes (2010). "Critical roles of complement and antibodies in host
defense mechanisms against Neisseria meningitidis as revealed by human
complement genetic deficiencies." Infect Immun 78(2): 802-809.
Hellwig, S. M., W. L. Hazenbos, J. G. van de Winkel and F. R. Mooi (1999).
"Evidence for an intracellular niche for Bordetel/a pertussis in broncho-
alveolar lavage cells of mice." FEMS Immunol Med Microbial 26(3-4): 203-
207.
Henckaerts, I., N. Durant, D. De Grave. L. Schuerman and J. Poolman (2006).
"Validation of a routine opsonophagocytosis assay to predict invasive
pneumococcal disease efficacy of conjugate vaccine in children." Vaccine.
Hill, D. J., N. J. Griffiths, E. Borodina and M. Virji (2010). "Cellular and molecular
biology of Neisseria meningitidis colonization and invasive disease." Clin
Sci (Land) 118(9): 547-564.
Hobbs, J. R, R D. Milner and P. J. Watt (1967). "Gamma-M deficiency
predisposing to meningococcal septicaemia." Br Med J 4(5579): 583-586.
Hoek, M. R, H. Christensen, W. Hellenbrand. P. Stefanoff, M. Howitz and J. M.
Stuart (2008). "Effectiveness of vaccinating household contacts in addition
to chemoprophylaxis after a case of meningococcal disease: a systematic
review." Epidemiollnfect 136(11): 1441-1447.
Holbein, B. E. (1981). "Enhancement of Neisseria meningitidis infection in mice by
addition of iron bound to transferrin." Infect Immun 34(1): 120-125.
Holmes, E. C., R Urwin and M. C. Maiden (1999). "The influence of recombination
on the population structure and evolution of the human pathogen Neisseria
meningitidis." Mol Bioi EvoI16(6): 741-749.
Holst, J., B. Feiring, L. M. Naess, G. Norheim, P. Kristiansen, E. A. Hoiby, K. Bryn,
P. Oster, P. Costantino, M. K. Taha, J. M. Alonso, D. A. Caugant, E.
Wedege, I. S. Aaberge. R Rappuoli and E. Rosenqvist (2005). "The
301
concept of "tailor-made", protein-based, outer membrane vesicle vaccines
against meningococcal disease." Vaccine 23(17-18): 2202-2205.
Hombach, J., T. Solomon, I. Kurane, J. Jacobson and D. Wood (2005). "Report on
a WHO consultation on immunological endpoints for evaluation of new
Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004."
Vaccine 23(45): 5205-5211.
Huo, Z., R. Sinha, E. A. McNeela, R. Borrow, R. Giemza, C. Cosgrove, P. T.
Heath, K. H. Mills, R. Rappuoli, G. E. Griffin and D. J. Lewis (2005).
"Induction of protective serum meningococcal bactericidal and diphtheria-
neutralizing antibodies and mucosal immunoglobulin A in volunteers by
nasal insufflations of the Neisseria meningitidis serogroup C
polysaccharide-CRM197 conjugate vaccine mixed with chitosan." Infect
Immun 73(12): 8256-8265.
Hyams, C., E. Camberlein, J. M. Cohen, K. Bax and J. S. Brown (2010). "The
Streptococcus pneumoniae capsule inhibits complement activity and
neutrophil phagocytosis by multiple mechanisms." Infect Immun 78(2): 704-
715.
Ison, C. A., N. Anwar, M. J. Cole, R. Galassini, R. S. Heyderman, N. J. Klein, J.
West, A. J. Pollard, S. Morley, Levin and R. the Meningococcal (1999).
"Assessment of immune response to meningococcal disease: comparison
of a whole-blood assay and the serum bactericidal assay." Microb Pathog
27(4): 207-214.
Ison, C. A., R. S. Heyderman, N. J. Klein, M. Peakman and M. Levin (1995).
"Whole blood model of meningococcal bacteraemia--a method for exploring
host-bacterial interactions." Microb Pathog 18(2): 97-107.
Jacobsson, S., P. Moiling, S. Thulin Heberg, m. Unemo, H. Fredlund and P. Olcen
(2011). "Invasive meningococcal disease in Sweden 2010." EMGM 2011.
302
James, K. (1982). "Complement: activation, consequences, and control." Am J
Med Technol48(9}: 735-742.
Jarva, H., S. Ram, U. Vogel, A. M. Blom and S. Meri (2005). "Binding of the
complement inhibitor C4bp to serogroup B Neisseria meningitidis." J
ImmunoI174(10): 6299-6307.
Jennings, H. J., A. Gamian and F. E. Ashton (1987). "N-propionylated group B
meningococcal polysaccharide mimics a unique epitope on group B
Neisseria meningitidis." J Exp Med 165(4): 1207-1211.
Jiang, H. Q., S. K. Hoiseth, S. L. Harris, L. K. McNeil, D. Zhu, C. Tan, A. A. Scott,
K. Alexander, K. Mason, L. Miller, I. DaSilva, M. Mack, X. J. Zhao, M. W.
Pride, L. Andrew, E. Murphy, M. Hagen, R. French, A. Arora, T. R. Jones,
K. U. Jansen, G. W. Zlotnick and A. S. Anderson (2010). "Broad vaccine
coverage predicted for a bivalent recombinant factor H binding protein
based vaccine to prevent serogroup B meningococcal disease." Vaccine
28(37): 6086-6093.
Johansson, L., A. Rytkonen, H. Wan, P. Bergman, L. Plant, B. Agerberth, T.
Hokfelt and A. B. Jonsson (2005). "Human-like immune responses in CD46
transgenic mice." J ImmunoI175(1): 433-440.
Jolley, K. A., L. Appleby, J. C. Wright, M. Christodoulides and J. E. Heckels
(2001). "Immunization with recombinant Opc outer membrane protein from
Neisseria meningitidis: influence of sequence variation and levels of
expression on the bactericidal immune response against meningococci."
Infect Immun 69(6): 3809-3816.
Kallstrom, H., M. S. Islam, P. O. Berggren and A. B. Jonsson (1998). "Cell
Signaling by the type IV pili of pathogenic Neisseria." J Bioi Chem 273(34):
21777 -21782.
303
Katial, R K., B. L. Brandt, E. E. Moran, S. Marks, V. Agnello and W. D. Zollinger
(2002). "Immunogenicity and safety testing of a group B intranasal
meningococcal native outer membrane vesicle vaccine." Infect Immun
70(2): 702-707.
Kayhty, H., V. Karanko, H. Peltola, S. Sarna and P. H. Makela (1980). "Serum
antibodies to capsular polysaccharide vaccine of group A Neissera
meningitidis followed for three years in infants and children." J Infect Dis
142(6): 861-868.
Keiser, P. B., S. Biggs-Cicatelli, E. E. Moran, D. H. Schmiel, V. B. Pinto, R E.
Burden, L. B. Miller, J. E. Moon, R. A. Bowden, J. F. Cummings and W. D.
Zollinger (2011). "A phase 1 study of a meningococcal native outer
membrane vesicle vaccine made from a group B strain with deleted IpxL1
and synX, over-expressed factor H binding protein, two ParAs and
stabilized OpcA expression." Vaccine 29(7): 1413-1420.
Kemper, C., L. M. Mitchell, L. Zhang and D. E. Hourcade (2008). "The complement
protein properdin binds apoptotic T cells and promotes complement
activation and phagocytosis." Proc Natl Acad Sci USA 105(26): 9023-
9028.
Kenedy, M. R, S. R. Vuppala, C. Siegel, P. Kraiczy and D. R Akins (2009).
"CspA-mediated binding of human factor H inhibits complement deposition
and confers serum resistance in Borrelia burgdorferi." Infect Immun 77(7):
2773-2782.
Keyserling, H., T. Papa, K. Koranyi, R Ryall, E. Bassily, M. J. Bybel, K. Sullivan,
G. Gilmet and A. Reinhardt (2005). "Safety, immunogenicity, and immune
memory of a novel meningococcal (groups A, C, Y, and W-135)
polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy
adolescents." Arch Pediatr Adolesc Med 159(10): 907-913.
304
Khatami, A and A J. Pollard (2010). "The epidemiology of meningococcal disease
and the impact of vaccines." Expert Rev Vaccines 9(3): 285-298.
Khwaja, A, J. E. Carver and D. C. Linch (1992). "Interactions of granulocyte-
macrophage colony-stimulating factor (CSF), granulocyte CSF, and tumor
necrosis factor alpha in the priming of the neutrophil respiratory burst."
Blood 79(3): 745-753.
Kirimanjeswara, G. S., L. M. Agosto, M. J. Kennett, O. N. Bjornstad and E. T.
Harvill (2005). "Pertussis toxin inhibits neutrophil recruitment to delay
antibody-mediated clearance of Bordetella pertussis." J Clin Invest 115(12}:
3594-3601.
Koeffler, H. P. and D. W. Golde (1980). "Human myeloid leukemia cell lines: a
review." Blood 56(3): 344-350.
Kolb, W. P., L. M. Kolb and E. R. Podack (1979). "C1q: isolation from human
serum in high yield by affinity chromatography and development of a highly
sensitive hemolytic assay." J ImmunoI122(5): 2103-2111.
Kolmer, J., Toyama, I., Matsunami, T. (1918). "The influence of active normal
serum (complement) upon meningococci: I.
The opsonic activity of fresh normal serum alone and in comdination with
antimeningitis serum for meningococci." The journal of immunology. 3: 157-
175.
Kshirsagar, N., N. Mur, U. Thatte, N. Gogtay, S. Viviani, M. P. Preziosi, C. Elie, H.
Findlow, G. Carlone, R. Borrow, V. Parulekar, B. Plikaytis, P. Kulkarni, N.
Imbault and F. M. LaForce (2007). "Safety, immunogenicity, and antibody
persistence of a new meningococcal group A conjugate vaccine in healthy
Indian adults." Vaccine 25 Suppl1: A101-107.
305
Kugelberg, E., B. Gollan and C. M. Tang (2008). "Mechanisms in Neisseria
meningitidis for resistance against complement-mediated killing." Vaccine
26 Suppl 8: 134-39.
Ladhani, S., M. P. Slack, M. Heys, J. White and M. E. Ramsay (2008). "Fall in
Haemophilus influenzae serotype b (Hib) disease following implementation
of a booster campaign." Arch Dis Child 93(8): 665-669.
Lehmann, A. K., A. R. Gorringe, K. M. Reddin, K. West, I. Smith and A.
Halstensen (1999). "Human opsonins induced during meningococcal
disease recognize transferrin binding protein complexes." Infect Immun
67(12): 6526-6532.
Lehmann, A. K., A. Halstensen, I. S. Aaberge, J. Holst, T. E. Michaelsen, S.
Sornes, L. M. Wetzler and H. Guttormsen (1999). "Human opsonins
induced during meningococcal disease recognize outer membrane proteins
PorA and PorB." Infect Immun 67(5): 2552-2560.
Lehmann, A. K., A. Halstensen and C. F. Bassoe (1998). "Flow cytometric
quantitation of human opsonin-dependent phagocytosis and oxidative burst
responses to meningococcal antigens." Cytometry 33(4): 406-413.
Lehner, P. J., K. A. Davies, M. J. Walport, A. P. Cope, R. Wurzner, A. Orren, B. P.
Morgan and J. Cohen (1992). "Meningococcal septicaemia in a C6-deficient
patient and effects of plasma transfusion on lipopolysaccharide release."
Lancet 340(8832): 1379-1381.
Leimkugel, J., A. Hodgson, A. A. Forgor, V. Pfluger, J. P. Dangy, T. Smith, M.
Achtman, S. Gagneux and G. Pluschke (2007). "Clonal waves of Neisseria
colonisation and disease in the African meningitis belt: eight- year
longitudinal study in northern Ghana." PLoS Med 4(3): e101.
Lewis, L. A., J. Ngampasutadol, R. Wallace, J. E. Reid, U. Vogel and S. Ram
(2010). "The meningococcal vaccine candidate neisserial surface protein A
306
(NspA) binds to factor H and enhances meningococcal resistance to
complement." PloS Pathog 6(7): e1001027.
Livorsi, D. J., M. Eaton and J. Glass (2010). "Generalized tetanus despite prior
vaccination and a protective level of anti-tetanus antibodies." Am J Med Sci
339(2): 200-201.
lucidarme, J., M. Comanducci, J. Findlow, S. J. Gray, E. B. Kaczmarski, M.
Guiver, E. Kugelberg, P. J. Vallely, P. Oster, M. Pizza, S. Bambini, A.
Muzzi, C. M. Tang and R. Borrow (2009). "Characterization of fHbp, nhba
(gna2132), nadA, porA, sequence type (ST), and genomic presence of
IS1301 in group B meningococcal ST269 clonal complex isolates from
England and Wales." J Clin MicrobioI47(11): 3577-3585.
luijkx, T., H. van Dijken, C. van Eis and G. van den Dobbelsteen (2006).
"Heterologous prime-boost strategy to overcome weak immunogenicity of
two serosubtypes in hexavalent Neisseria meningitidis outer membrane
vesicle vaccine." Vaccine 24(10): 1569-1577.
Maclennan, C. A., E. N. Gondwe, C. L. Msefula, R. A. Kingsley, N. R. Thomson,
S. A. White, M. Goodall, D. J. Pickard, S. M. Graham, G. Dougan, C. A.
Hart, M. E. Molyneux and M. T. Drayson (2008). "The neglected role of
antibody in protection against bacteremia caused by nontyphoidal strains of
Salmonella in African children." J Clin Invest 118(4): 1553-1562.
Maiden, M. C., J. A. Bygraves, E. Feil, G. Morelli, J. E. Russell, R. Urwin, Q.
Zhang, J. Zhou, K. Zurth, D. A. Caugant, I. M. Feavers, M. Achtman and B.
G. Spratt (1998). "Multilocus sequence typing: a portable approach to the
identification of clones within populations of pathogenic microorganisms."
Proc Natl Acad Sci USA 95(6): 3140-3145.
Maiden, M. C., A. B. Ibarz-Pavon, R. Urwin, S. J. Gray, N. J. Andrews, S. C.
Clarke, A. M. Walker, M. R. Evans, J. S. Kroll, K. R. Neal, D. A. Ala'aldeen,
307
D. W. Crook, K. Cann, S. Harrison, R. Cunningham, D. Baxter, E.
Kaczmarski, J. Maclennan, J. C. Cameron and J. M. Stuart (2008). "Impact
of meningococcal serogroup C conjugate vaccines on carriage and herd
immunity." J Infect Dis 197(5): 737-743.
Maiden, M. C. and J. M. Stuart (2002). "Carriage of serogroup C meningococci 1
year after meningococcal C conjugate polysaccharide vaccination." Lancet
359(9320): 1829-1831.
Maiden, M. C., J. Suker, A. J. McKenna, J. A. Bygraves and I. M. Feavers (1991).
"Comparison of the class 1 outer membrane proteins of eight serological
reference strains of Neisseria meningitidis." Mol Microbial 5(3): 727-736.
Mandrell, R. E., F. H. Azmi and D. M. Granoff (1995). "Complement-mediated
bactericidal activity of human antibodies to poly alpha 2-->8 N-
acetylneuraminic acid, the capsular polysaccharide of Neisseria
meningitidis serogroup B." J Infect Dis 172(5): 1279-1289.
Martin, D., L. McCallum, A. Glennie, N. Ruijne, P. Blatchford, J. O'Hallahan and P.
Oster (2005). "Validation of the serum bactericidal assay for measurement
of functional antibodies against group B meningococci associated with
vaccine trials." Vaccine 23(17-18): 2218-2221.
Martinez, J., T. Pilishvili, S. Barnard, J. Caba, W. Spear, S. Romero-Steiner and
G. M. Carlone (2002). "Opsonophagocytosis of fluorescent polystyrene
beads coupled to Neisseria meningitidis serogroup A, C, Y, or W135
polysaccharide correlates with serum bactericidal activity." Clin Diagn Lab
Immunol 9(2): 485-488.
Martinez, J. E., S. Romero-Steiner, T. Pilishvili, S. Barnard, J. Schinsky, D.
Goldblatt and G. M. Carlone (1999). "A flow cytometric opsonophagocytic
assay for measurement of functional antibodies elicited after vaccination
308
with the 23-valent pneumococcal polysaccharide vaccine." Clin Diagn Lab
ImmunoI6(4}: 581-586.
Martino, A, C. Magagnoli, G. De Conciliis, S. D'Ascenzi, M. J. Forster, L. Allen, C.
Brookes, S. Taylor, X. Bai, J. Findlow, I. M. Feavers, A Rodger and B.
Bolgiano (2011). "Structural characterisation, stability and antibody
recognition of chimeric NHBA-GNA 1030: An investigational vaccine
component against Neisseria meningitidis." Vaccine.
Marzoa, J., S. Sanchez, L. Costoya, E. Dieguez-Casal, P. Freixeiro, C. Brookes, L.
Allen, S. Taylor, A R. Gorringe, C. M. Ferreiros and M. T. Criado (2011).
"Induction of immune responses by purified outer membrane protein
complexes from Neisseria meningitidis." Vaccine.
Masignani, V., M. Comanducci, M. M. Giuliani, S. Bambini, J. Adu-Bobie, B. Arico,
B. Brunelli, A Pieri, L. Santini, S. Savino, D. Serruto, D. Litt, S. Kroll, J. A
Welsch, D. M. Granoff, R. Rappuoli and M. Pizza (2003). "Vaccination
against Neisseria meningitidis using three variants of the lipoprotein
GNA1870." J Exp Med 197(6}: 789-799.
Maslanka, S. E., L. L. Gheesling, D. E. Libutti, K. B. Donaldson, H. S. Harakeh, J.
K. Dykes, F. F. Arhin, S. J. Devi, C. E. Frasch, J. C. Huang, P. Kriz-
Kuzemenska, R. D. Lemmon, M. Lorange, C. C. Peeters, S. Quataert, J. Y.
Tai and G. M. Carlone (1997). "Standardization and a multilaboratory
comparison of Neisseria meningitidis serogroup A and C serum bactericidal
assays. The Multilaboratory Study Group." Clin Diagn Lab Immunol 4(2}:
156-167.
Mason, R. A, N. M. Tauraso, R. O. Spertzel and R. K. Ginn (1973). "Yellow fever
vaccine: direct challenge of monkeys given graded doses of 170 vaccine."
Appl Microbiol 25(4): 539-544.
309
Matsunami, T., Kolmer, J. (1918). "The influence of acitve normal serum
(complement) upon meningococci: II.
The bactericidal and protective value of fresh normal serum with antimeningitis
serum for meningococci." The journal of immunology. 3: 177-200.
McCloskey, P. S. and R. J. Salo (2000). "Flow cytometric analysis of group B
streptococci phagocytosis and oxidative burst in human neutrophils and
monocytes." FEMS Immunol Med Microbiol 27(1): 59-65.
McNeil, L. K., G. W. Zlotnick, E. Camposano, S. Logan, E. Novikova, X. Zhao, A.
Anderson, M. Pride and K. Jansen (2011). "Development of a
meningococcal antigen surface expression (MeASurE) assay for the
phenotypic characterisation of fHBP expression by Neisseria meningitidis."
EMGM 2011.
Menegazzi, R., R. Cramer, P. Patriarca, P. Scheurich and P. Dri (1994). "Evidence
that tumor necrosis factor alpha (TNF)-induced activation of neutrophil
respiratory burst on biologic surfaces is mediated by the p55 TNF receptor."
Blood 84(1): 287-293.
Michaelsen, T. E., A. Aase, J. Kolberg, E. Wedge and E. Rosenqvist (2001).
"PorB3 outer membrane protein on Neisseria meningitidis is poorly
accessible for antibody binding on live bacteria." Vaccine 19(11-12): 1526-
1533.
Milagres, L. G., S. R. Ramos, C. T. Sacchi, C. E. Melles, V. S. Vieira, H. Sato, G.
S. Brito, J. C. Moraes and C. E. Frasch (1994). "Immune response of
Brazilian children to a Neisseria meningitidis serogroup B outer membrane
protein vaccine: comparison with efficacy." Infect Immun 62(10): 4419-
4424.
Miller, E., D. Salisbury and M. Ramsay (2001). "Planning, registration, and
implementation of an immunisation campaign against meningococcal
310
serogroup C disease in the UK: a success story." Vaccine 20 Suppl1: S58-
67.
Mollnes, T. E.. O. L. Brekke, M. Fung. H. Fure. D. Christiansen, G. Bergseth, V.
Videm, K. T. Lappegard. J. Kohl and J. D. Lambris (2002). "Essential role of
the C5a receptor in E coli-induced oxidative burst and phagocytosis
revealed by a novel lepirudin-based human whole blood model of
inflammation." Blood 100(5}: 1869-1877.
Mollnes, T. E., W. C. Song and J. D. Lambris (2002). "Complement in
inflammatory tissue damage and disease." Trends Immunol 23(2}: 61-64.
Moore, P. S. (1992). "Meningococcal meningitis in sub-Saharan Africa: a model for
the epidemic process." Clin Infect Dis 14(2}: 515-525.
Morgan, B. P., K. J. Marchbank. M. P. Longhi, C. L. Harris and A. M. Gallimore
(2005). "Complement: central to innate immunity and bridging to adaptive
responses." Immunol Lett 97(2}: 171-179.
Mulks, M. H. and A. G. Plaut (1978). "lgA protease production as a characteristic
distinguishing pathogenic from harmless neisseriaceae." N Engl J Med
299(18}: 973-976.
Musher. D. M., A. J. Chapman. A. Goree, S. Jonsson, D. Briles and R. E. Baughn
(1986). "Natural and vaccine-related immunity to Streptococcus
pneumoniae." J Infect Dis 154(2}: 245-256.
Naess, L. M., T. Aarvak. A. Aase, F. Oftunq, E. A. Hoiby, R. Sandin and T. E.
Michaelsen (1999). "Human IgG subclass responses in relation to serum
bactericidal and opsonic activities after immunization with three doses of
the Norwegian serogroup B meningococcal outer membrane vesicle
vaccine" Vaccine 17(7-8}: 754-764.
Newcombe. J.. L. J. Eales-Reynolds. L. Wootton. A. R. Gorringe. S. G. Funnell. S.
C. Taylor and J. J. McFadden (2004). "Infection with an avirulent phoP
311
mutant of Neisseria meningitidis confers broad cross-reactive immunity."
Infect Immun 72(1): 338-344.
NICE. (2010). "CG102 Bacterial meningitis and meningococcal septicaemia: full
guideline." from
http://www.nice.org.uklnicemediallive/13027/49437/49437.pdf.
Nordenfelt, P., S. Bauer, P. Lonnbro and H. Tapper (2009). "Phagocytosis of
Streptococcus pyogenes by all-trans retinoic acid-differentiated HL-60 cells:
roles of azurophilic granules and NADPH oxidase." PLoS One 4(10):
e7363.
Oftung, F., M. Lovik, S. R Andersen, L. O. Froholm and G. Bjune (1999). "A
mouse model utilising human transferrin to study protection against
Neisseria meningitidis serogroup B induced by outer membrane vesicle
vaccination." FEMS Immunol Med Microbiol 26(1): 75-82.
Oliver, K. J., K. M. Reddin, P. Bracegirdle, M. J. Hudson, R Borrow, I. M. Feavers,
A. Robinson, K. Cartwright and A. R Gorringe (2002). "Neisseria lactamica
protects against experimental meningococcal infection." Infect Immun 70(7):
3621-3626.
Olsen, S. F., B. Djurhuus, K. Rasmussen, H. D. Joensen, S. O. Larsen, H.
Zoffman and I. Lind (1991). "Pharyngeal carriage of Neisseria meningitidis
and Neisseria lactamica in households with infants within areas with high
and low incidences of meningococcal disease." Epidemiollnfect 106(3):
445-457.
Pajon, R, D. Yero, O. Niebla, Y. Climent, G. Sardinas, D. Garcia, Y. Perera, A.
Llanes, M. Delgado, K. Cobas, E. Caballero, S. Taylor, C. Brookes and A.
Gorringe (2009). "Identification of new meningococcal serogroup B surface
antigens through a systematic analysis of neisserial genomes." Vaccine
28(2): 532-541.
312
Parent du Chatelet, I. and M. Taha (2011). "Invasive meningococcal disease in
France, 2009-2010." EMGM 2011.
Peltola, H., J. M. Kataja and P. H. Makela (1982). "Shift in the age-distribution of
meningococcal disease as predictor of an epidemic?" Lancet 2(8298): 595-
597.
Perkins, B. A., K. Jonsdottir, H. Briem, E. Griffiths, B. D. Plikaytis, E. A. Hoiby, E.
Rosenqvist, J. Holst, H. Nokleby, F. Sotolongo, G. Sierra, H. C. Campa, G.
M. Carlone, D. Williams, J. Dykes, D. Kapczynski, E. Tikhomirov, J. D.
Wenger and C. V. Broome (1998). "Immunogenicity of two efficacious outer
membrane protein-based serogroup B meningococcal vaccines among
young adults in Iceland." J Infect Dis 177(3): 683-691.
Perrin, A., X. Nassif and C. Tinsley (1999). "Identification of regions of the
chromosome of Neisseria meningitidis and Neisseria gonorrhoeae which
are specific to the pathogenic Neisseria species." Infect Immun 67(11):
6119-6129.
Perticarari, S., G. Presani, M. A. Mangiarotti and E. Banfi (1991). "Simultaneous
flow cytometric method to measure phagocytosis and oxidative products by
neutrophils." Cytometry 12(7): 687-693.
Phillips, W. A., M. Croatto and J. A. Hamilton (1990). "Priming the macrophage
respiratory burst with IL-4: enhancement with TNF-alpha but inhibition by
IFN-gamma." Immunology 70(4): 498-503.
Pizza, M., V. Scarlata, V. Masignani. M. M. Giuliani, B. Arico, M. Comanducci, G.
T. Jennings, L. Baldi, E. Bartolini, B. Capecchi, C. L. Galeotti, E. Luzzi, R.
Manetti, E. Marchetti, M. Mora, S. Nuti, G. Ratti, L. Santini, S. Savino, M.
Scarselli, E. Storni, P. Zuo, M. Broeker, E. Hundt, B. Knapp, E. Blair, T.
Mason, H. Tettelin, D. W. Hood, A. C. Jeffries, N. J. Saunders, D. M.
Granoff, J. C. Venter, E. R. Moxon, G. Grandi and R. Rappuoli (2000).
313
"Identification of vaccine candidates against serogroup B meningococcus
by whole-genome sequencing." Science 287(5459): 1816-1820.
Platonov, A. E., I. V. Vershinina, H. Kayhty, C. A. Fijen, R. Wurzner and E. J.
Kuijper (2003). "Antibody-dependent killing of meningococci by human
neutrophils in serum of late complement component-deficient patients." Int
Arch Allergy ImmunoI130(4): 314-321.
Platonov, A. E., I. V. Vershinina, E. J. Kuijper, R. Borrow and H. Kayhty (2003).
"Long term effects of vaccination of patients deficient in a late complement
component with a tetravalent meningococcal polysaccharide vaccine."
Vaccine 21(27-30): 4437-4447.
Plested, J. S. and D. M. Granoff (2008). "Vaccine-Induced Opsonophagocytic
Immunity to Neisseria meningitidis group B." Clin Vaccine Immunol.
Plested, J. S., J. A. Welsch and D. M. Granoff (2009). "Ex vivo model of
meningococcal bacteremia using human blood for measuring vaccine-
induced serum passive protective activity." Clin Vaccine ImmunoI16(6):
785-791.
Plotkin, S. A. (2010). "Correlates of protection induced by vaccination." Clin
Vaccine ImmunoI17(7): 1055-1065.
Pollard, A. J., R. Galassini, E. M. Rouppe van der Voort, M. Hibberd, R. Booy, P.
Langford, S. Nadel, C. Ison, J. S. Kroll, J. Poolman and M. Levin (1999).
"Cellular immune responses to Neisseria meningitidis in children." Infect
Immun 67(5): 2452-2463.
Poot, M., Y. Z. Zhang, J. A. Kramer, K. S. Wells, L. J. Jones, D. K. Hanzel, A. G.
Lugade, V. L. Singer and R. P. Haugland (1996). "Analysis of mitochondrial
morphology and function with novel fixable fluorescent stains." J Histochem
Cytochem 44(12): 1363-1372.
314
Purcell, B., S. Samuelsson, S. J. Hahne, I. Ehrhard, S. Heuberger, I. Camaroni, A.
Charlett and J. M. Stuart (2004). "Effectiveness of antibiotics in preventing
meningococcal disease after a case: systematic review." BMJ 328(7452):
1339.
Ramsay, M. E., N. J. Andrews, C. L. Trotter, E. B. Kaczmarski and E. Miller
(2003). "Herd immunity from meningococcal serogroup C conjugate
vaccination in England: database analysis." BMJ 326(7385): 365-366.
Reller, L. B., R. R. MacGregor and H. N. Beaty (1973). "Bactericidal antibody after
colonization with Neisseria meningitidis." J Infect Dis 127(1): 56-62.
Roilides, E., K. Uhlig, D. Venzon, P. A. Pizzo and T. J. Walsh (1993).
"Enhancement of oxidative response and damage caused by human
neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-
stimulating factor and gamma interferon." Infect Immun 61(4): 1185-1193.
Romero-Steiner, S., C. Frasch, N. Concepcion, D. Goldblatt, H. Kayhty, M.
Vakevainen, C. Laferriere, D. Wauters, M. H. Nahm, M. F. Schinsky, B. D.
Plikaytis and G. M. Carlone (2003). "Multilaboratory evaluation of a viability
assay for measurement of opsonophagocytic antibodies specific to the
capsular polysaccharides of Streptococcus pneumoniae." Clin Diagn Lab
ImmunoI10(6): 1019-1024.
Romero-Steiner, S., D. Libutti, L. B. Pais, J. Dykes, P. Anderson, J. C. Whitin, H.
L. Keyserling and G. M. Carlone (1997). "Standardization of an
opsonophagocytic assay for the measurement of functional antibody activity
against Streptococcus pneumoniae using differentiated HL-60 cells." Clin
Diagn Lab ImmunoI4(4): 415-422.
Romero-Steiner, S., D. M. Musher, M. S. Cetron, L. B. Pais, J. E. Groover, A. E.
Fiore, B. D. Plikaytis and G. M. Carlone (1999). "Reduction in functional
antibody activity against Streptococcus pneumoniae in vaccinated elderly
315
individuals highly correlates with decreased IgG antibody avidity." Clin
Infect Dis 29(2): 281-288.
Roos, A., L. H. Bouwman, D. J. van Gijlswijk-Janssen, M. C. Faber-Krol, G. L.
Stahl and M. R Daha (2001). "Human IgA activates the complement
system via the mannan-binding lectin pathway." J ImmunoI167(5): 2861-
2868.
Rosen, H., J. Orman, R M. Rakita, B. R Michel and D. R VanDevanter (1990).
"Loss of DNA-membrane interactions and cessation of DNA synthesis in
myeloperoxidase-treated Escherichia coli." Proc Natl Acad Sci USA
87 (24): 10048-10052.
Ross, S. C., P. J. Rosenthal, H. M. Berberich and P. Densen (1987). "Killing of
Neisseria meningitidis by human neutrophils: implications for normal and
complement-deficient individuals." J Infect Dis 155(6): 1266-1275.
Salit, I. E. (1981). "Meningococcemia caused by serogroup W135. Association
with hypogammaglobulinemia." Arch Intern Med 141(5): 664-665.
Santos, G. F., R R Deck, J. Donnelly, W. Blackwelder and D. M. Granoff (2001).
"Importance of complement source in measuring meningococcal
bactericidal titers." Clin Diagn Lab Immunol 8(3): 616-623.
Santos, G. F., Jimenez, M. , Goodman, R, Giuliani, M. , Pizza, .M., Rappuoli, R,
Donnelly, J., (2010). "Use of immunoglobulin depletion to develop a
universal complement source for use in the meningococcal serum
bactericidal assay." Poster presentation at IPNC 2010.
Sardinas, G., Y. Climent, Y. Rodriguez, S. Gonzalez, D. Garcia, K. Cobas, E.
Caballero, Y. Perez, C. Brookes, S. Taylor, A Gorringe, M. Delgado, R
Pajon and D. Yero (2009). "Assessment of vaccine potential of the
Neisseria-specific protein NMB0938." Vaccine 27(49): 6910-6917.
316
Sarkar, J. K., A. C. Mitra and M. K. Mukherjee (1975). "The minimum protective
level of antibodies in smallpox." Bull World Health Organ 52(3): 307-311.
Schlesinger, M., R. Greenberg, J. Levy, H. Kayhty and R. Levy (1994). "Killing of
meningococci by neutrophils: effect of vaccination on patients with
complement deficiency." J Infect Dis 170(2): 449-453.
Schneider, M. C., R. M. Exley, H. Chan, I. Feavers, Y. H. Kang, R. 8. Sim and C.
M. Tang (2006). "Functional significance of factor H binding to Neisseria
meningifidis." J ImmunoI176(12): 7566-7575.
Schneider, M. C., R. M. Exley, S. Ram, R. B. Sim and C. M. Tang (2007).
"Interactions between Neisseria meningifidis and the complement system."
Trends Microbiol 15(5): 233-240.
Selander, R. K., D. A. Caugant, H. Ochman, J. M. Musser, M. N. Gilmour and T. S.
Whittam (1986). "Methods of multilocus enzyme electrophoresis for
bacterial population genetics and systematics." Appl Environ Microbiol
51(5): 873-884.
Serruto, D., R. Rappuoli, M. Scarselli, P. Gros and J. A. van Strijp (2010).
"Molecular mechanisms of complement evasion: learning from
staphylococci and meningococci." Nat Rev Microbiol 8(6): 393-399.
Siber, G. R., I. Chang, S. Baker, P. Fernsten, K. L. O'Brien, M. Santosham, K. P.
Klugman, S. A. Madhi, P. Paradiso and R. Kohberger (2007). "Estimating
the protective concentration of anti-pneumococcal capsular polysaccharide
antibodies." Vaccine 25(19): 3816-3826.
Sierra, G. V., H. C. Campa, N. M. Varcacel, I. L. Garcia, P. L. Izquierdo, P. F.
Sotolongo, G. V. Casanueva, C. O. Rico, C. R. Rodriguez and M. H. Terry
(1991). "Vaccine against group B Neisseria meningifidis: protection trial and
mass vaccination results in Cuba." NIPH Ann 14(2): 195-207; discussion
208-110.
317
Sjolinder, H., J. Eriksson, L. Maudsdotter, H. Aro and A. B. Jonsson (2008).
"Meningococcal outer membrane protein NhhA is essential for colonization
and disease by preventing phagocytosis and complement attack." Infect
Immun 76(11): 5412-5420.
Snape, M. D., T. Dawson, P. Oster, A. Evans, T. M. John, B. Ohene-Kena, J.
Findlow, L. M. Vu, R. Borrow, E. Ypma, D. Toneatto and A. J. Pollard
(2010). "Immunogenicity of two investigational serogroup B meningococcal
vaccines in the first year of life: a randomized comparative trial." Pediatr
Infect Dis J 29(11): e71-79.
Spitzer, D., L. M. Mitchell, J. P. Atkinson and D. E. Hourcade (2007). "Properdin
can initiate complement activation by binding specific target surfaces and
providing a platform for de novo convertase assembly." J ImmunoI179(4):
2600-2608.
Storsaeter, J., H. O. Hallander, L. Gustafsson and P. Olin (1998). "Levels of anti-
pertussis antibodies related to protection after household exposure to
Bordetella pertussis." Vaccine 16(20): 1907-1916.
Szollosi, J., S. Damjanovich and L. Matyus (1998). "Application of fluorescence
resonance energy transfer in the clinical laboratory: routine and research."
Cytometry 34(4): 159-179.
Taha, M. K., I. Parent Du Chatelet, M. Schlumberger, I. Sanou, S. Djibo, F. de
Chabalier and J. M. Alonso (2002). "Neisseria meningitidis serogroups
W135 and A were equally prevalent among meningitis cases occurring at
the end of the 2001 epidemics in Burkina Faso and Niger." J Clin Microbiol
40(3): 1083-1084.
Tappero, J. W., R. Lagos, A. M. Ballesteros, B. Plikaytis, D. Williams, J. Dykes, L.
L. Gheesling, G. M. Carlone, E. A. Hoiby, J. Holst, H. Nokleby, E.
Rosenqvist, G. Sierra, C. Campa, F. Sotolongo, J. Vega, J. Garcia, P.
318
Herrera, J. T. Poolman and B. A. Perkins (1999). "Immunogenicity of 2
serogroup B outer-membrane protein meningococcal vaccines: a
randomized controlled trial in Chile." JAMA 281(16): 1520-1527.
Taylor, S. (2010). "Development of predictors of protection from meningococcal
disease.".
Teufelhofer, 0., R. M. Weiss, W. Parzefall, R. Schulte-Hermann, M. Micksche, W.
Berger and L. Elbling (2003). "Promyelocytic HL60 cells express NADPH
oxidase and are excellent targets in a rapid spectrophotometric microplate
assay for extracellular superoxide." Toxicol Sci 76(2): 376-383.
Thompson, E. A., I. M. Feavers and M. C. Maiden (2003). "Antigenic diversity of
meningococcal enterobactin receptor FetA, a vaccine component."
Microbiology 149(Pt 7): 1849-1858.
Toneatto, D., P. Oster, A. C. Deboer, A. Emerson, G. F. Santos, E. Ypma, L.
Detora, M. Pizza, A. Kimura and P. Dull (2011). "Early clinical experience
with a candidate meningococcal B recombinant vaccine (rMenB) in healthy
adults." Hum Vaccin 7(7).
Toropainen, M., H. Kayhty, L. Saarinen, E. Rosenqvist, E. A. Hoiby, E. Wedege, T.
Michaelsen and P. H. Makela (1999). "The infant rat model adapted to
evaluate human sera for protective immunity to group B meningococci."
Vaccine 17(20-21): 2677-2689.
Toropainen, M., L. Saarinen, P. van der Ley, B. Kuipers and H. Kayhty (2001).
"Murine monoclonal antibodies to ParA of Neisseria meningifidis show
reduced protective activity in vivo against B:15:P1.7,16 subtype variants in
an infant rat infection model." Microb Pathog 30(3): 139-148.
Toropainen, M., L. Saarinen, G. Vidarsson and H. Kayhty (2006). "Protection by
meningococcal outer membrane protein ParA-specific antibodies and a
319
serogroup B capsular polysaccharide-specific antibody in complement-
sufficient and C6-deficient infant rats." Infect Immun 74(5): 2803-2808.
Toropainen, M., A. Vainio, M. Saarinen, H. Kuusi, H. Kayhty and A. Virolainen
(2011). "Epidemiology of invasive meningococcal disease in Findland,
1995-2010." EMGM 2011.
Trotter, C., R. Borrow, N. Andrews and E. Miller (2003). "Seroprevalence of
meningococcal serogroup C bactericidal antibody in England and Wales in
the pre-vaccination era." Vaccine 21(11-12): 1094-1098.
Trotter, C., J. Findlow, P. Balmer, A. Holland, R. Barchha, N. Hamer, N. Andrews,
E. Miller and R. Borrow (2007). "Seroprevalence of bactericidal and anti-
outer membrane vesicle antibody to Neisseria meningitidis group B in
England." Clin Vaccine Immunol.
Vermont, C. and G. van den Dobbelsteen (2002). "Neisseria meningitidis
serogroup B: laboratory correlates of protection." FEMS Immunol Med
Microbiol 34(2): 89-96.
Vermont, C. L., H. H. van Dijken, C. J. van Limpt, R. de Groot, L. van Alphen and
G. P. van Den Dobbelsteen (2002). "Antibody avidity and immunoglobulin G
isotype distribution following immunization with a monovalent
meningococcal B outer membrane vesicle vaccine." Infect Immun 70(2):
584-590.
Vidarsson, G., W. L. van Der Pol, J. M. van Den Elsen, H. Vile, M. Jansen, J.
Duijs, H. C. Morton, E. Boel, M. R. Daha, B. Corthesy and J. G. van De
Winkel (2001). "Activity of human IgG and IgA subclasses in immune
defense against Neisseria meningitidis serogroup B." J ImmunoI166(10):
6250-6256.
320
Vu, D. M., T. T. Wong and D. M. Granoff (2011). "Cooperative serum bactericidal
activity between human antibodies to meningococcal factor H binding
protein and Neisserial heparin binding antigen." Vaccine 29(10): 1968-1973.
Walker, E. M., Jr. and S. M. Walker (2000). "Effects of iron overload on the
immune system." Ann Clin Lab Sci 30(4): 354-365.
Walport, M. J. (2001). "Complement. First of two parts." N Engl J Med 344(14):
1058-1066.
Walrand, S., S. Valeix, C. Rodriguez, P. Ligot. J. Chassagne and M. P. Vasson
(2003). "Flow cytometry study of polymorphonuclear neutrophil oxidative
burst: a comparison of three fluorescent probes." Clin Chim Acta 331(1-2):
103-110.
Welsch, J. A. and D. Granoff (2004). "Naturally acquired passive protective activity
against Neisseria meningitidis Group C in the absence of serum bactericidal
activity." Infect Immun 72(10): 5903-5909.
Welsch, J. A. and D. Granoff (2007). "Immunity to Neisseria meningitidis group 8
in adults despite lack of serum bactericidal antibody." Clin Vaccine Immunol
14(12): 1596-1602.
Welsch, J. A., G. R. Moe, R. Rossi, J. Adu-8obie, R. Rappuoli and D. M. Granoff
(2003). "Antibody to genome-derived neisserial antigen 2132, a Neisseria
meningitidis candidate vaccine, confers protection against bacteremia in the
absence of complement-mediated bactericidal activity." J Infect Dis 188(11):
1730-1740.
West, D., K. Reddin, M. Matheson, R. Heath, S. Funnell, M. Hudson, A. Robinson
and A. Gorringe (2001). "Recombinant Neisseria meningitidis transferrin
binding protein A protects against experimental meningococcal infection."
Infect Immun 69(3): 1561-1567.
321
www.HPA.org.uk. (2011). "Meningococcal Reference Unit isolates of Neisseria
meningitidis: England and Wales, by serogroup & epidemiological year,
1998/99-2009/10*." Retrieved September 2011,2011.
Yero, D., R Pajon, Y. Perez, M. Farinas, K. Cobas, D. Diaz, R L. Solis, A. Acosta,
C. Brookes, S. Taylor and A. Gorringe (2007). "Identification by genomic
immunization of a pool of DNA vaccine candidates that confer protective
immunity in mice against Neisseria meningitidis serogroup B." Vaccine
25(28): 5175-5188.
Yuste, J., S. Ali, S. Sriskandan, C. Hyams, M. Botto and J. S. Brown (2006).
"Roles of the alternative complement pathway and C1q during innate
immunity to Streptococcus pyogenes." J ImmunoI176(10): 6112-6120.
Zarantonelli, M. L., M. Szatanik, D. Giorgini, E. Hong, M. Huerre, F. Guillou, J. M.
Alonso and M. K. Taha (2007). "Transgenic mice expressing human
transferrin as a model for meningococcal infection." Infect Immun 75(12):
5609-5614.
Zollinger, W. D., M. A. Donets, D. H. Schmiel, V. B. Pinto, J. Labrie, E. E. Moran,
B. L. Brandt, B. lonin, R Marques, M. Wu, P. Chen, M. B. Stoddard and P.
B. Keiser (2010). "Design and evaluation in mice of a broadly protective
meningococcal group B native outer membrane vesicle vaccine." Vaccine.
Zollinger, W. D. and R E. Mandrell (1983). "Importance of complement source in
bactericidal activity of human antibody and murine monoclonal antibody to
meningococcal group B polysaccharide." Infect Immun 40(1): 257-264.
Zolopa, A. R, C. A. Kemper, S. Shiboski, J. R Hamilton, A. R Moss and S. C.
Deresinski (1994). "Progressive immunodeficiency due to infection with
human immunodeficiency virus does not lead to waning immunity to
measles in a cohort of homosexual men." Clin Infect Dis 18(4): 636-638.
322
PAGES NOT SCANNED AT THE
REQUEST OF THE UNIVERSITY
SEE ORIGINAL COpy OF THE THESIS
FOR THIS MATERIAL
